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Abstract 
Background: Analgesic medication is widely used in care homes but little is known 
about how often this medication is prescribed or administered, or what factors 
influence its use. 
Aim: To describe the prescription and administration of regular and PRN analgesic 
medication in care homes; to investigate whether individual or care home differences 
are associated with analgesic use; and to compare analgesic prescribing in English 
care homes to international prescriptions. 
Methods: This study is embedded in a longitudinal study of 86 care homes in England. 
Data were collected at 0-, 4-, and 12-months. Residents were eligible if they had 
diagnosed or probable dementia. Analgesic prescriptions are presented by drug and 
class. Administration of PRN analgesics is described. Individual differences 
(sociodemographic; agitation [Cohen-Mansfield Agitation Inventory]; dementia 
severity [Clinical Dementia Rating]; psychotropic drug prescriptions) and care home 
differences (type; ownership; number of beds; dementia-registered/specialist; CQC 
rating) are explored using multilevel models.  
Results: Data were available for 1483 residents. Around 70% of residents were 
prescribed analgesics at all study visits, predominantly PRN paracetamol. Overall, 
PRN analgesics were not administered frequently. There were differences between 
care homes in administration but these differences were not accounted for by the 
modelled care home-level variables. Residents with more severe dementia, and 
males, appear to be more at risk of untreated pain. 
Conclusion: This is the largest study to date exploring analgesic administration in care 
homes. Prescription levels of regular analgesics are lower in England compared to 
other countries, however it is unclear why. Pain management in care homes is largely 
reliant on PRN paracetamol that is frequently prescribed but infrequently 
administered. Care homes differ in how often they administer PRN analgesics and 
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this is likely due to internal factors. Therefore care home residents are likely to have 
untreated pain, and some groups are more at risk than others.  
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Outline of research and statement of personal contribution 
This thesis has two overarching aims: first, to comprehensively understand how 
analgesic medications are used in care homes; second, to explore factors associated 
with medication use. I was enabled to do this through the MARQUE (Managing 
Agitation and Raising QUality of LifE in dementia) programme, a longitudinal cohort 
study exploring, among other areas, symptoms and health resource use including 
medication, in English care home residents with dementia. I started working full-time 
for MARQUE as a research assistant in August 2014 and commenced a part-time PhD 
(one day per week) in November 2014.  
Prescription data was already being collected as part of MARQUE, and I amended the 
case report forms to include data on ‘as required’ medication, which I had identified 
as a gap in current knowledge through literature review. These data were collected 
by myself and a team of researchers based in UCL and clinical research networks 
across England. Of the 86 care homes included, I personally recruited and collected 
data from 16 care homes. The systematic review and data analysis was conducted 
independently of the MARQUE study programme. Throughout this thesis I will be 
explicit about my contribution.  
The first part of the thesis (chapters 1–3) introduces existing knowledge of 
medication use and behavioural symptoms in care home residents, and comprises a 
systematic review summarising temporal trends in analgesics. The main body of the 
thesis (chapters 4–8) describes an empirical study (embedded in the MARQUE 
programme) observing the prescribing patterns and administration of medication in 
English care home residents. Throughout the thesis I will refer to the care home 
participants as residents. Medication use is analysed with regards to resident factors, 
such as agitation and dementia severity, and care home factors. The thesis concludes 
(chapters 9-10) with a discussion of the findings in relation to previous literature, a 
critical appraisal of the research, an exploration of the clinical and policy implications, 
and directions for future research. 
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Chapter 1 Introduction  
1.1 Summary 
This chapter will explore the context for my empirical work. I will describe the setting 
(care homes), the population (cognitively impaired residents) and the main focus of 
the thesis (analgesics). I will discuss pain and pain management in the context of 
these three areas, and factors that may influence pain assessment and treatment.  
1.2 Ageing population and dementia 
People are now living longer than they have ever done and as a result the age 
structure of the current population has changed, with over 65s the fastest growing 
demographic group (Office for National Statistics, 2017). Although advances in 
medical research, safety, public health, and life expectancy are to be celebrated, age 
remains the greatest risk factor for developing dementia. 
Dementia is a syndrome that includes problems with memory, thinking, 
communication, changes in behaviour, emotions, and activities of daily living (ADLs) 
(World Health Organization, 1992). Dementia is used as an umbrella term for 
different diseases that cause changes in the structure and chemistry of the brain. The 
most common types of dementia are Alzheimer’s disease, vascular dementia, and 
Lewy body dementia, all of which cause the degeneration of brain cells. The rate of 
progression and the brain areas affected depends on the type of dementia and the 
individual. It is estimated that over 700,000 people in England have dementia 
(Dowrick and Southern, 2014).  
1.3 Care homes 
There are approximately 405,000 people aged 65 years and over living in care homes 
in the United Kingdom (UK) (Laing and Buisson, 2014) because they are unable to live 
independently. A care home is an institution providing accommodation, meals, and 
24 hour staffing. They range in size from a few beds to larger facilities with different 
units. There are two types of care home in the UK: residential homes, also known as 
care homes without nursing, where people live and can be assisted with personal 
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care, for example washing, dressing, and eating; nursing homes, also known as care 
homes with nursing, which are similar to residential homes but also employ 
registered nurses to provide round-the-clock care for those with a higher level of 
health needs. Both residential and nursing homes employ care assistants (CAs), also 
known as nursing assistants, to provide frontline care.  
All care home residents should be registered with a GP, and GPs are often central to 
the care, care co-ordination, and prescribing, for a resident. Some care homes will be 
served by multiple GPs whereas others may be served by a single GP on a block 
contract. There are often financial incentives in place for local GP practices, including 
the capacity to organise private arrangements for providing extra administrative 
services. Care homes will have different agreements in place regarding level of 
contact. Thus, models of clinical and multidisciplinary input to care homes can vary 
across the country and between homes, including pharmacy input (NHS England, 
2015, Gordon et al., 2018). There is a drive to increase the number of pharmacists 
involved in care homes, and local projects that have increased pharmacy input have 
led to more optimised prescriptions, reductions in hospital admissions, and financial 
savings (Royal Pharmaceutical Company, 2016). 
A survey conducted by the Alzheimer’s Society explored the reasons behind care 
home admission for UK residents with dementia, and found that the main reasons 
were a lack of community support, and carers being unable to look after the person 
with dementia (Quince, 2011). Many care home admissions occur following a crisis, 
such as a hospital admission (Stillwell and Kerslake, 2004). Another common cause 
for care home admission is agitation (Yaffe et al., 2002, Balestreri et al., 2000), which 
will be discussed in further detail in 1.4.5. 
Care homes come under the remit of social care (as opposed to the health system), 
because the support provided for the person with dementia is often assistance with 
ADLs, which is considered to be a social problem. The health care provision for care 
home residents is different and community medical services are often inadequate 
compared to people who live outside of care homes (Gordon et al., 2013, Sampson 
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et al., 2018). Medical care for UK care home residents is provided and co-ordinated 
by GPs. Normally medication is prescribed by the GP and administered by care home 
staff.  
1.4 Pain and analgesics 
1.4.1 Definition of pain, and treatment options 
Pain is defined as “an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage, or described in terms of such damage” (Merskey 
and Bogduk, 1994). Pain is considered chronic if it lasts three months or longer, 
whereas acute pain has sudden onset and is provoked and limited by an underlying 
cause. Pain can be nociceptive, resulting from damage to tissue, or neuropathic, 
caused by nerve damage. The two types of pain cause different sensations and are 
treated with different types of painkillers (analgesics). Analgesics can be divided into 
non-opioids, opioids, compound analgesics, and adjuvants. 
Nociceptive pain is often described as a sharp, aching or throbbing, for example tissue 
damage, and is treated with non-opioids or opioids.  
Non-opioid drugs (some of which are available over the counter) are the most 
common class, and include paracetamol and nonsteroidal anti-inflammatory drugs 
(NSAIDS) like ibuprofen. Paracetamol is indicated as first-line therapy for mild to 
moderate pain in older adults. It has few side effects, but over-dosage can cause 
hepatic damage; there is also concern over the long-term use of the maximum 
dosage especially when given to malnourished patients (Abdulla et al., 2013, AGS 
Panel, 2009). NSAIDs have both analgesic and anti-inflammatory properties, are 
effective in relieving musculoskeletal pain, and are more appropriate than 
paracetamol in inflammatory arthritis (Bradley et al., 1991). However, NSAIDs should 
be used with caution in older adults due to risks including gastrointestinal bleeding 
and effects on the renal system, and have been implicated in cases of hospitalisations 
resulting from adverse drug reactions (Franceschi et al., 2008). Of the NSAIDs tested 
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in this population, ibuprofen is preferred as it has the lowest risk of serious side 
effects (Ong et al., 2007). Ibuprofen has both analgesic and inflammatory properties, 
and is indicated for use in mild to moderate pain in migraine, dental pain, and 
rheumatic disease (Joint Formulary Committee, 2016). Topical NSAIDs have also been 
shown to be efficacious in the treatment of musculoskeletal pain (Mason et al., 2004). 
NSAIDs can also be bought over the counter.  
Opioids are the strongest class of analgesic, and most are prescription only. Opioids 
are used to treat moderate to severe pain, particularly visceral pain (Joint Formulary 
Committee, 2016), and have shown efficacy in controlled trials in providing relief for 
persistent nociceptive and neuropathic pain (Dworkin et al., 2007). NICE (National 
Institute for Health and Care Excellence) recommend that, when oral opioids are 
appropriate (and oral drugs should always be prescribed if possible), the first-line 
maintenance treatment should be morphine, with immediate-release morphine 
prescribed ‘as required’ (pro re nata; PRN) in case of breakthrough pain (National 
Institute for Health and Clinical Excellence, 2012a). Adverse effects of opioids include 
gastrointestinal effects, constipation, headache, somnolence, lethargy, urinary 
complications, and respiratory depression (Noble et al., 2008, AGS Panel, 2009). 
Opioids are often used long-term to treat chronic musculoskeletal pain, however 
there are questions around the efficacy of opioids versus non-opioids, especially 
considering the risk of harm from opioids (Krebs et al., 2018, Chou et al., 2015). 
Compound analgesics are a combination of drugs, typically an opioid and a non-
opioid (for example codeine and paracetamol), and weaker combinations can be 
bought over the counter. 
Neuropathic pain is usually described as shooting, tingling or burning, for example 
diabetic neuropathy, and is often treated with medication primarily associated with 
remedying other conditions (adjuvant drugs) like antidepressants.  
Although adjuvant analgesics are used for treating this type of pain, there are no 
primary studies relating to their use in pain management in older adults (Abdulla et 
al., 2013). Anticonvulsants, such as gabapentin and pregabalin, and antidepressants, 
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such as amitriptyline or duloxetine, have demonstrated efficacy, but have been 
associated with adverse effects. Anticonvulsants can cause drowsiness and sedation, 
and their excretion is affected by renal function. Antidepressants can cause urinary 
retention, cardiovascular effects, and postural hypotension. 
1.4.2 Pain management 
Drugs can be prescribed on a regular basis or PRN, which means that they are only 
given when necessary. PRN prescriptions are widely used in care homes and reflect 
how analgesics are typically used by the general population for episodic, acute pain 
(such as headaches). In chronic pain it is best, generally, for analgesics to be 
prescribed regularly.  
There are no specific pain management guidelines for people with cognitive 
impairment or care home residents. Current guidelines that could be applied to this 
population include STOPP/START criteria, British Geriatrics Society/British Pain 
Society guidelines for older people, national palliative care guidelines, or guidelines 
specific to NHS trusts (O'Mahony et al., 2015, Abdulla et al., 2013, National Institute 
for Health and Clinical Excellence, 2012b, Denison Davies et al., 2011, Department of 
Health, 2001, AGS Panel, 2009). Existing guidelines recommend that analgesics 
should be titrated from low starting doses (Abdulla et al., 2013, Scherder and Plooij, 
2012, AGS Panel, 2009), and a stepwise approach to prescribing pain relief is 
recommended, balancing adequate pain management and potential adverse effects 
(Abdulla et al., 2013, Corbett et al., 2012, AGS Panel, 2009, National Institute for 
Health and Care Excellence, 2018b). The World Health Organisation (WHO) 
developed a tool (see Figure 1) called the WHO pain relief ladder that was originally 
intended for use in prescribing analgesics to adults with cancer pain (World Health 
Organization, 1987). Clinicians are advised to start at the first step with non-opioid 
analgesics for mild to moderate pain. If this proves insufficient (i.e. the patient has 
moderate to severe pain) weak opioids can be added and adjuvant therapy can be 
considered. The third step introduces the prescription of strong opioids for severe 
pain. The WHO pain relief ladder is a useful and valid tool, and adaptations have been 
 23 
suggested for use in acute pain, and persistent non-cancer pain (Schaffer, 2010). It 
has been suggested that people with dementia may benefit from a higher dose of 
analgesic medication due to diminished placebo effect (Achterberg et al., 2013). 
The SHELTER study, a large-scale study in European care homes, found that 47.7% of 
residents were prescribed analgesics at WHO step 1, 5.9% at WHO step 2, and 7.4% 
at WHO step 3. Combination therapy (step 1, and 2 or 3) was prescribed to 15.3% of 
care home residents (Lukas et al., 2013a). 
 
Figure 1. Adaptation of WHO pain relief ladder  
1.4.3 Pain prevalence 
The most common morbidities within the care home population are reported to be 
dementia, musculoskeletal disorders, diabetes, cerebrovascular disease, and 
depression (Gordon et al., 2013, Jensen-Dahm, 2013). These conditions are often 
painful, for example osteoarthritis (from musculoskeletal disorders) or diabetic 
neuropathy (Hunter et al., 2008, Davies et al., 2006). It can be difficult to determine 
the absolute prevalence of pain due to differences in reporting or study 
methodology, such as different definitions of pain or assessment tools. A recent study 
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in Europe reported that 48.4% of nursing home residents experienced pain, where a 
diagnosis of pain was given based on resident interview, observation, or if the 
resident was receiving a prescription of analgesic medication (Lukas et al., 2013b). 
Pain was reported as highest in Finland (73.0%) and lowest in Israel (19.8%). In the 
Netherlands, from a longitudinal care home study, 18-25% of residents experienced 
pain rarely, 12-25% experienced pain sometimes, 3-10% experienced pain often, and 
7-17% experienced pain almost daily (Hendriks et al., 2015). 
In England, pain prevalence was reported to be 54.5%, with 8.1% of all residents in 
constant pain (comparatively low against other European countries), 57.4% 
experiencing intermittent pain, 6.2% who had experienced a single episode of pain, 
and 10.9% who had experienced breakthrough pain. Interestingly, England had the 
highest levels of residents with most or total dependence on assistance with ADLs 
(Lukas et al., 2013b). Of those in pain, 53.8% received regular analgesic medication 
only, 16.3% were prescribed PRN analgesics only, and 4.3% received regular and PRN 
(Lukas et al., 2013a). A study based in Greater London (England) used an 
observational scale and found that 11% of residents with severe dementia were in 
pain at rest and 61% were in pain at movement, and prevalence was largely 
unchanged 9 months later (Sampson et al., 2018). The WHELD study was also 
conducted in and near London and found that 35.3% of residents with dementia (of 
any severity) had clinically relevant pain, predominantly mild chronic pain. WHELD 
authors acknowledged that the lower prevalence of pain compared to other studies 
could have been related to the use of analgesics in 39.0% of their population which 
may have reduced pain behaviours. There was still evidence of under-treatment of 
pain, as 41.9% of residents with pain were not prescribed regular analgesics 
(Rajkumar et al., 2017). 
A literature review conducted in 2010 reported that approximately 40-60% care 
home residents were in pain currently or had experienced pain in the last three 
months (Takai et al., 2010). Takai and colleagues found that the prevalence was 
dependent upon the methods and time frame used to detect pain. Prevalence was 
highest when based on interviews with residents, compared to those whose pain was 
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assessed using observation or chart review. However figures obtained from interview 
data may not be representative of the care home population as most residents able 
to complete interviews had mild or no cognitive impairment (and were presumably 
more able to remember and communicate their pain than residents with moderate 
or severe dementia) and higher levels of ADL (whereas nursing patients may be in 
more pain from physical difficulties that require nursing care). Chart review (which 
assumes that all residents in pain are receiving analgesia) and use of Minimum Data 
Set (MDS) reported lower levels (Takai et al., 2010). The limitations of observational 
assessment tools are discussed in 1.4.4.1. 
Between the years of 2001 and 2011, there has been an 11% growth in UK citizens 
aged 65 years and over. However there has only been an increase of 0.3% in care 
home beds, and higher levels of community support. As a result there has been a 
change in the health profile of care home residents; they are older and have 
increased levels of dependency and morbidity (Office for National Statistics, 2014, 
Pitkala et al., 2015, Robbins et al., 2013) therefore it can be assumed that pain 
prevalence in care homes will remain high and is likely to increase. 
1.4.4 Barriers to recognising and treating pain 
Barriers and challenges in identifying and appropriately treating pain include pain 
assessment, personal beliefs of residents, clinicians, and carers, and institutional 
barriers relating to care homes.  
1.4.4.1 Pain assessment in dementia 
Pain has been described as “whatever the experiencing person says it is, existing 
whenever the experiencing person says it does” (McCaffery, 1968). However, this 
definition assumes that the patient is able to self-report, and for many residents this 
is impossible due to physical or cognitive impairment.  
It is estimated that around 80% of care home residents have some form of dementia 
or severe memory problem (Quince, 2013, Selbæk et al., 2016). In England this 
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equates to around 322,000 people, with roughly 91,000 of these residents cared for 
in registered ‘dementia’ beds (Quince, 2013). Dementia is often underdiagnosed and 
prevalence rates of dementia diagnoses tend to give a more conservative figure 
(Gordon et al., 2013, Lukas et al., 2013b); an Irish hospital study found that 22.9% of 
patients admitted from nursing homes did not have a clinical diagnosis but did have 
dementia (Walsh et al., 2016). If dementia is underdiagnosed and not recognised by 
care home staff then they may not consider impaired cognition or communication 
when assessing pain or discussing pain with residents.  
Self-reporting pain can be difficult for people with dementia for a number of reasons. 
First, they may not be able to understand or remember the question. Second, the 
person needs both a semantic understanding of the construct of pain, and the 
episodic memory of the pain, for the abstract thinking required to report an episode 
of pain (Oosterman et al., 2014, Herr, 2011, Ferrell et al., 1995). Third, the person 
must also be able to translate a subjective experience of pain and communicate this 
to the carer. Fourth, pain assessment tools often ask that the patient quantifies their 
pain in terms of severity or frequency which requires further skills that may be 
impaired as a result of dementia (Gagliese et al., 2017). As self-report can be complex, 
and because the ability of each person with dementia can be compromised in a 
different way and can fluctuate, it can be very difficult for carers to assess pain in this 
way. In a study comparing the correlation between staff proxy and resident pain 
reports for residents without dementia compared to residents with dementia, the 
correlations were, respectively, 0.88 and 0.41 (Lövheim, 2008).  
Conversely, the presence of a dementia diagnosis may lead nurses to assume that 
these residents are unable to report their own pain and therefore staff may not 
routinely ask them. A study in a single care home found that, despite being able to 
verbally communicate, residents with mild or moderate dementia were significantly 
less likely to have an opioid prescription, and reported greater pain intensity, than 
residents without dementia (Monroe et al., 2014).  
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In place of self-report, observational tools are widely (but not necessarily 
consistently) used in care homes. These tools consider pain indicators such as facial 
expression and distress behaviours. They are reliant on the ability of the carer to 
appropriately recognise pain, as well as have adequate training and time to complete 
the observation, interpret the results, and take further appropriate action (Sawyer et 
al., 2007, Kaasalainen et al., 2010, Zwakhalen et al., 2018). There is evidence to 
suggest that judgements of observed pain may be influenced by resident factors (to 
be discussed in 1.6) and observer factors. For example, observers with higher levels 
of empathy and who are female tend to rate pain more frequently (Green et al., 2009, 
Robinson and Wise, 2003).  
Another concern is that pain behaviours may not have enough discriminant validity 
to distinguish from other behaviours typically seen in older age, for example, 
difficulty moving may be related to frailty and not arthritic pain, and care home staff 
may become desensitised to this, especially in chronic pain where a resident’s 
behaviour is not vastly, or at all, different from their baseline (Weiner et al., 1999). 
However there is also a risk of false positives, whereby pain is mistakenly identified 
using observational scales, but the behaviours are actually caused by other reasons 
such as psychosocial distress (Jordan et al., 2010).  
1.4.4.2 Personal beliefs 
It has been questioned whether people with dementia experience pain in the same 
way as people without dementia, which may lead to under-treatment of pain. There 
does not appear to be a difference in number or type of painful conditions between 
people with Alzheimer’s disease and people without dementia (Pickering et al., 
2006). As verbal self-report becomes more difficult for the person with dementia, 
researchers have investigated response to pain using a variety of assessment tools 
including facial response, motor reflexes, neuroimaging, and autonomic responses. 
The differences, and direction of difference, is dependent upon the type of 
assessment (Scherder et al., 2009, Kunz et al., 2009), but in summary, it appears that 
pain processing is not reduced for those with cognitive impairment, nor pain 
threshold (the lowest level of stimuli perceived as painful), but there may be an 
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increase in pain tolerance (the greatest acceptable stimulation of pain) (Achterberg 
et al., 2013, Defrin et al., 2015, Gagliese et al., 2017). A limitation of the literature is 
that the majority of experimental research in this field has focused on Alzheimer’s 
disease over other dementias (Achterberg et al., 2013). However current evidence 
suggests that there is no difference in pain prevalence between dementia subtypes 
(Gagliese et al., 2017).  
Residents may be reluctant to report their own pain for a number of reasons. First, 
there can be an inclination to believe that pain is a natural part of ageing (de Souto 
Barreto et al., 2013, Vaismoradi et al., 2016). Second, residents may be stoical about 
their pain and not report it for a number of reasons: because they do not want to 
bother staff, they do not want to be labelled as a ‘complainer’, they do not have any 
hope of relief, or they lack confidence in their own value (Achterberg, 2016, Mentes 
et al., 2004, Kaasalainen et al., 2010, Vaismoradi et al., 2016). Third, pain may signify 
their own frailty including impending death or loss of independence so they may be 
reluctant to admit or publicise their pain (Kaasalainen et al., 2010). Fourth, residents 
may become desensitised to their own chronic pain (Weiner et al., 1999). 
Clinicians also have differing perceptions about opioids, and may refrain from 
prescribing opioids due to fears regarding addiction or side effects, occasionally 
referred to as ‘opiophobia’. Family members and nurses may also be reluctant to 
agree to the use of stronger pain medication for this reason (Kaasalainen et al., 2010). 
However these concerns may be unfounded (Noble et al., 2008, Rainov et al., 2001, 
Morley-Forster et al., 2003), and nonetheless are less risky for care home residents 
who do not have autonomy over their medication.  
1.4.4.3 Institutional barriers and communication 
Medical care and prescribing is typically managed by a resident’s GP. This can be a 
resident’s own GP but is often a GP associated with the care home, and so prescribing 
practice in a home may be subject to their own clinical preference. Care homes need 
a close relationship with primary care (Corbett et al., 2016) and GPs are often the 
‘gatekeepers’ to accessing secondary care services that could aid pain management 
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such as palliative care services or physiotherapy or more specialist hospital care. A 
study in Germany (where the primary clinician also tends to be a GP) found that the 
number of clinician contacts correlated with appropriateness of pain medication, but 
only when combining primary care clinician visits and specialist visits. The authors 
suggested that good pain management may be somewhat dependent on a 
multidisciplinary approach due to the complexity of this population. It is of interest 
that the positive correlation was identified only after combining visits, as the authors 
found low levels of input from specialists for care home residents, which could 
indicate a lack of training for primary care clinicians or poor quality visits, however 
evidence is sparse in this area (Flaig et al., 2016). Similarly, community medical 
service provision in England is low for nursing home residents (Sampson et al., 2018). 
Carers (with the exception of those with nursing qualifications) may not receive 
training in pain (Corbett et al., 2016) and do not necessarily relate the presence of a 
chronic painful diagnosis with the need for analgesia (Mezinskis et al., 2004). Pain 
assessment is variable between care homes. In some homes formal tools for pain 
assessment in dementia were used, and in others they relied on observations of body 
language (Care Quality Commission UK, 2014). Carers may already believe that the 
residents are receiving analgesia; care assistants may overestimate the total number 
of residents prescribed analgesics, or incorrectly believe that residents assessed as in 
pain are prescribed pain relief. In these cases CAs will be less likely to hand over 
concerns about pain and advocate for analgesia (Lövheim et al., 2006, Hemmingsson 
et al., 2017).  
Communication within care homes can also be lacking. First, shift work and 
handovers can hinder clear and consistent channels of communication, and residents 
are likely to see multiple carers in a day (Lukas et al., 2013a). Second, the main 
channel of communication between nurses and CAs tends to be unidirectional: CAs 
report pain to nurses, at which point they devolve responsibility. Gaps in 
responsibility for follow-up assessments have been described, as well as a lack of 
confidence from junior staff in taking a proactive role in pain management (Corbett 
et al., 2016). Therefore it may not be an issue of lack of understanding of pain 
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assessments but a lack of communication between front-line staff and those with 
responsibility for prescribing pain medication, for example GPs, or nurses who advise 
GPs (Mezinskis et al., 2004, Mentes et al., 2004, Lövheim et al., 2006). 
Similar factors were implicated in inadequate pain management in a large study of 
European care homes: heavy workload including staff shortages, team instability, 
professional staff mix, high staff turnover, and lack of time (Lukas et al., 2013a). These 
factors can undermine the motivated and well-trained workforce that is needed to 
implement evidence-based care (Corbett et al., 2016).  
Family members may be an under-utilised source of information; knowing residents 
well is often raised as a means of improving pain assessment and family members 
can increase this knowledge by relaying how the resident used to be, including 
behaviours (especially non-verbal) indicative of pain that can be particularly helpful 
when assessing residents with cognitive impairment (Mentes et al., 2004). However 
discussions with family carers can be challenging if relationships are not good, and 
miscommunication can lead to more confusion (Corbett et al., 2016). 
1.4.5 Pain and behavioural and psychological symptoms of dementia 
If pain is not recognised then residents are at risk of under-treatment which can, 
aside from discomfort, distress, and decreased quality of life, have more pervasive 
consequences for the resident, for instance pain can lead to the development of, or 
contribute to, existing behavioural and psychological symptoms of dementia (BPSD) 
(Corbett et al., 2014b, Algase et al., 1996, Katz, 2002). BPSD is an umbrella term used 
to describe a heterogeneous range of symptoms of disturbed behaviour, mood, 
thought content, or perception, that often occur in people with dementia of any type 
(Lawlor, 2002, Finkel and Burns, 2000, Cilag, 2002). Common BPSD include psychosis, 
depression, anxiety, and agitation behaviours (Cilag, 2002). Agitation and depression 
have been linked to pain (Sampson et al., 2015, Fishbain et al., 1997). 
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1.4.5.1 Agitation  
Agitated behaviour has been defined as behaviour that is socially inappropriate: 
abusive or aggressive; appropriate behaviour at an inappropriate frequency; 
inappropriate for the social situation (Cohen-Mansfield et al., 1989). A study 
conducted in England estimated that 79% of care home residents had clinically 
significant BPSD, and the most common symptoms were agitation, irritability, and 
aberrant motor behaviour (Margallo-Lana et al., 2001). This is similar to a Norwegian 
study that found 72% of nursing home residents with dementia had clinically 
significant BPSD, and furthermore, that frequency of symptoms increased with 
severity of dementia (Selbæk et al., 2007). A study exploring the association between 
agitation behaviours and dementia severity found that physically aggressive 
behaviours were more common in severe dementia and physically non-aggressive 
and verbally aggressive behaviours were more common in moderate dementia. The 
study also reported that female gender was associated with more verbally agitated 
behaviours and male gender with physically aggressive behaviours (Zuidema et al., 
2009). There is mixed evidence with regard to agitation prevalence and gender. Mega 
and colleagues found that agitation was more common in males (Mega et al., 1996). 
However the participants were community-dwelling and may present differently to 
care home populations. In contrast, a Norwegian care home study found that female 
residents had more severe symptoms of agitation (Helvik et al., 2016).  
There is an overlap between behaviours associated with pain and agitation (Sampson 
et al., 2015, Cipher and Clifford, 2004, Ahn and Horgas, 2013). Pain is associated with 
aggression, increased pacing, socially inappropriate behaviour and resistance to care 
(Herr et al., 2006, AGS Panel, 2009, Tosato et al., 2012). A US database study found 
that residents with more severe pain were more likely to display agitation behaviours 
that involved less movement (controlling for ADL impairment) and were less likely to 
have wandering behaviours (Ahn and Horgas, 2013). An inverse association between 
wandering and pain was also found in European care homes (Tosato et al., 2012). 
 32 
1.4.5.2 Antipsychotics and anxiolytics/hypnotics to treat BPSD 
Psychotropic drugs (drugs that affect the mind, behaviour, and mood), 
predominantly antipsychotics and anxiolytic/hypnotic drugs, are often used in care 
homes to treat BPSD (including agitation) and for their sedative effects. Currently 
risperidone and haloperidol are the only antipsychotics licensed in the UK to treat 
BPSD in dementia (National Institute for Health and Care Excellence, 2018b) however 
other antipsychotics are used ‘off-label’ for this purpose. In English care homes 
antipsychotic prevalence is 17.7% (Ballard et al., 2015). This is lower than other 
countries such as the US (25% in nursing homes), Canada (34%, atypical 
antipsychotics only), Finland (39-42%), and Australia (25.1%) (Szczepura et al., 2016, 
Vasudev et al., 2015). Overall, there is limited and conflicting evidence regarding the 
efficacy of antipsychotics, especially as the benefit may not justify the side effect 
profile that includes sedation, extrapyramidal symptoms, and associations with 
cardiovascular events (Banerjee, 2009, Medicines and Healthcare products 
Regulatory Agency, 2005, Ballard et al., 2014, Sink et al., 2005). 
Anxiolytics and hypnotics are drugs that are used to relieve anxiety, sedate, or as a 
sleep aid. NICE does not recommend the use of benzodiazepines or Z-drugs 
(zopiclone and zolpidem; drugs that aid sleep) in the older population due to higher 
risk of adverse effects (National Institute for Health and Care Excellence, 2018c) 
including falls, confusion, impaired balance, over-sedation, and because there is no 
indication for prolonged use (O'Mahony et al., 2015). Anxiolytics and hypnotics are 
frequently used in care homes for long periods of time to treat BPSD including 
agitation despite evidence that does not support routine use (Margallo-Lana et al., 
2001, Olsson et al., 2010, Tampi and Tampi, 2014). In England and Wales, care home 
residents are over twice as likely to be prescribed benzodiazepines than older people 
who live in the community (Shah et al., 2012) which may be due to a higher 
proportion of BPSD in care homes (Margallo-Lana et al., 2001, Sørensen et al., 2001). 
1.4.5.3 Depression and antidepressants 
Pain can also affect cognition and mood, and correlations have been found between 
pain and depression (Parmelee et al., 1991, Fishbain et al., 1997). One study found 
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that while pain did not directly affect ADL, it did influence depression and behavioural 
symptoms which in turn affected ADL (Cipher and Clifford, 2004). Pain and depression 
commonly occur together, and there is a body of evidence to suggest an interaction 
between symptoms of depression and pain, including exacerbating one another and 
overlapping symptoms. A literature review (including all settings) exploring this 
comorbidity found an association between depression and negative pain outcomes 
and worse prognosis, including increased pain complaints, pain that lasted longer, 
and pain that was more severe (Bair et al., 2003). A US study found that higher levels 
of self-reported pain of people with dementia predicted an increase in depression 
over the following four months but there is evidence that this relationship is 
multidirectional (Snow et al., 2009). An English study in care homes reported a 
prevalence of depression of 26.3% (Stewart et al., 2014). 
Antidepressants are another class of psychotropic drug. They are used to treat 
moderate to severe depression, have adjuvant uses that include treating neuropathic 
pain, and can have a sedating effect so may be prescribed for insomnia or agitation 
rather than depression. A study from 2010 reported that 37.5% of care home 
residents in England and Wales were prescribed antidepressants (Shah et al., 2012). 
Treating pain can improve symptoms of depression (Husebø et al., 2014a). In a care 
home study conducted by Mezinskis et al. (2004) where antidepressants were the 
most commonly prescribed type of regular medication, it was posited that care home 
staff were missing the link between chronic pain and depression. 
1.5 BPSD and analgesics 
Pain may be falsely identified as distress or agitation, and it can be impossible to 
confidently assess concordance between dyads (person with dementia and proxy 
reporter), so staff cannot definitively know whether their assessment was accurate 
(Gagliese et al., 2017). In clinical practice there is no standard guidance to accurately 
distinguish agitation caused by pain from other causes. Some studies have explored 
whether treating agitation with a trial of analgesic medication can result in an 
improvement in symptoms. When assessing the effect of paracetamol in a 
randomised placebo-controlled cross-over trial, during treatment there was no effect 
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on agitation or PRN psychotropic use, but there was increased activity through social 
interaction, engagement with media, and work-like activities (Chibnall et al., 2005). 
Husebø and colleagues tested the efficacy of analgesia for treating agitation using a 
systematic stepwise protocol, and found significant improvements in agitation 
(particularly verbal) and aggression and severity of neuropsychiatric symptoms, but 
no difference in ADL or cognition (Husebø et al., 2011, Husebø et al., 2014b). From 
these results it was inferred that pain relief could contribute to a reduction in 
agitation.  
As previously mentioned, there is also a risk of falsely identifying pain through 
observational pain assessments. However in one study where this was the case, the 
identification of psychosocial distress via the pain assessment tool led to carers 
developing strategies to reduce the distress (Jordan et al., 2010). 
Dementia costs the UK economy £26.3 billion per year and the average cost of a 
person with dementia living in a care home is £36,738 (Prince et al., 2014). Agitation 
has been implicated in increasing costs for care home residents. A cross-sectional 
study using data from eight European countries found that care home residents who 
were agitated used more healthcare resources; primarily through increased 
outpatient visits but also inpatient admissions and medication, and on average cost 
€261 more per month than residents that were not agitated (Costa et al., 2015). 
Therefore, besides the distress that untreated agitation can cause (for the person 
with dementia, family members, and paid carers), there is an economic imperative 
to reduce these symptoms too. 
1.6 Individual differences in analgesic prescribing in care home residents 
There is limited research exploring whether analgesic prescriptions and 
administration are associated with individual differences in care home residents, 
however several studies have highlighted influencing factors. These include age, 
gender, dementia diagnosis, and dementia severity. 
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1.6.1 Age 
There is no evidence to suggest that pain lessens with age (Rajkumar et al., 2017, 
Hemmingsson et al., 2017) but differences have been found in analgesic prescribing. 
A Danish population study reported that prescriptions of opioids increased with age, 
although this was less pronounced for care home residents than those living in the 
community (Jensen-Dahm et al., 2015). Age as an influencing factor is supported in a 
Norwegian study as care home residents above the age of 81 years received 
significantly more analgesics than residents younger than 80 years (Sandvik et al., 
2016). On the contrary, other studies have found no association between analgesic 
prescribing or administration and age (Stokes et al., 2004, Rigler et al., 2007).  
1.6.2 Gender 
Gender differences with regards to both pain and pain relief have been identified in 
several studies. In the community, females were more likely to use analgesics 
(prescription and non-prescription) (Kung et al., 1999, Jacob and Kostev, 2018), and 
this association was also found in European care homes (Lukas et al., 2013a, Sandvik 
et al., 2016). In a recent study female care home residents were more likely to receive 
a prescription of paracetamol than men (Sandvik et al., 2016), and a US study found 
higher use of opioids in female residents compared to males, however this study 
excluded residents with moderate to severe dementia and is therefore less 
generalisable to most care home populations (Won et al., 2004). Conversely, several 
studies have found no gender difference in analgesic prescribing or administration 
(Hemmingsson et al., 2017, Stokes et al., 2004, Rigler et al., 2007). The gender 
difference may be explained by results from clinical studies that indicate that females 
are at increased risk of painful conditions, but are also likely to report pain more 
frequently, have higher pain intensity levels, and have a greater amount of painful 
body areas than males (Fillingim et al., 2009, Racine et al., 2012). 
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1.6.3 Diagnosis of dementia 
Many researchers have investigated whether care home residents with dementia are 
at risk of under-detected and under-treated pain. Earlier studies (data collected pre-
2000) exploring the risk of under-treatment of pain consistently reported that people 
with dementia were less likely to receive analgesic medication (Horgas and Tsai, 
1998, Mantyselka et al., 2004, Won et al., 2004). In one study, despite non-verbal 
cues (for example increased irritability, change in behaviours, not moving a body part, 
grimacing, crying) that were interpreted by care assistants and nurses as pain, nurses 
were still not administering pain medication to the majority of cognitively impaired 
patients (Mezinskis et al., 2004).  
Recent findings, predominantly from the Nordic countries, present a mixed picture. 
Several studies show that people with dementia are more likely to receive 
paracetamol than people without dementia (Lövheim et al., 2008, Haasum et al., 
2011). Care home residents with dementia appear less likely to receive opioid 
medication than residents without dementia (Jensen-Dahm et al., 2015). These 
results are supported by the findings of a recent international systematic review: 
Griffioen et al. (2017b) reported that opioid use ranged from 4-41% and that people 
without cognitive impairment were prescribed the same amount or more opioids 
than cognitively impaired residents. A recent Norwegian study investigating trends 
over time found that in 2000, 2004, and 2009, care home residents with dementia 
received significantly fewer opioids (and analgesics) than care home residents 
without dementia, but in 2011 there was no significant difference (Sandvik et al., 
2016), which was also found in 2013 in Sweden (Hemmingsson et al., 2017). This 
review also found that care home residents were prescribed more opioids than those 
living in the community. 
1.6.4 Dementia severity 
A US study using the MDS found that people with moderate or severe cognitive 
impairment experienced less pain but, even accounting for that, cognitive 
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impairment was found to be strongly associated with untreated pain (Hunnicutt et 
al., 2017). In a study of Norwegian care home residents with severe dementia, 38.4% 
of residents who were in pain were not prescribed analgesics (Griffioen et al., 2017a). 
A recent study in England found a positive association between pain and dementia 
severity; 37.1% of people with severe dementia had mild pain compared to 26.1% 
residents with mild dementia, and at follow-up residents with severe dementia were 
more likely to still be experiencing mild pain compared to those with mild dementia 
(29.5% versus [vs] 7.7%) (Rajkumar et al., 2017).  
Considering analgesic use, a UK study reported that as dementia severity increased, 
prescription and administration decreased, despite no differences in pain scores 
across the levels of severity (Closs et al., 2004). Several studies have found that 
residents with greater communication impairments were prescribed fewer regular 
analgesics, or administered less PRN analgesia, thus supporting the idea that those 
less able to communicate are less able to report their own pain and advocate for their 
own pain relief (Mezinskis et al., 2004, Bauer et al., 2016, Stokes et al., 2004). 
Disorientation, withdrawal, functional impairment, and needing help to eat (and thus 
find taking medication more difficult) have also been identified as predictors of 
whether analgesics were administered, with more cognitively impaired residents 
given fewer analgesics (Horgas and Tsai, 1998, Stokes et al., 2004). A Dutch study 
found under-treatment for those people with dementia in pain but no difference in 
treatment when looking at dementia severity (Plooij et al., 2012), however another 
Dutch study found that residents with high cognitive performance were administered 
more analgesics than residents with low cognitive performance (60.9% received 
medication versus 55.8%) (Achterberg et al., 2007).  
Overall it appears that analgesic prescribing is improving in care homes, and fewer 
residents are at risk of under-treatment for their pain. However while individual 
studies provide a snapshot of analgesic prescribing, it would be useful to have a global 
picture of prescribing prevalence in care homes, and furthermore, if and how 
prescribing has changed in this population. I conducted a systematic review to 
answer these questions. Due to under-diagnosis of dementia in care homes I did not 
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conduct separate analyses comparing residents diagnosed with dementia versus 
those without a diagnosis. 
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 Temporal trends in analgesic use in care 
homes: a systematic review of international prescribing 
The following systematic review is an edited version of a published paper:  
 
LA FRENAIS, F. L., BEDDER, R., VICKERSTAFF, V., STONE, P. & SAMPSON, E. L. 2017. 
Temporal Trends in Analgesic Use in Long‐Term Care Facilities: A Systematic 
Review of International Prescribing. Journal of the American Geriatrics 
Society. 
Please see Appendix 1 for the full article. 
2.1 Review aims  
The aim of this systematic review was to investigate whether, and how, international 
prescribing patterns of analgesic medication for care home residents have changed 
over time. Specific objectives were to explore changes in the prescription of analgesic 
drugs, explore changes in prescribing of opioids and paracetamol; and examine 
changes in regular medications and regular plus as-needed (pro re nata (PRN)) 
medications.  
2.2 Methods 
2.2.1 Search Strategy  
A three-step search strategy was used. To refine the search terms, an initial limited 
search of PubMed was run, followed by analysis of the text words and Medical 
Subject Heading terms contained in the title, abstract, and index of identified papers. 
Then a search was run using identified key words and index terms (for long-term care 
facilities and analgesics; see Appendix 2) across included databases (PubMed 
(including Medline, 1966–present), EMBASE (1947–present), CINAHL (1937–
present), International Pharmaceutical Abstracts (1970–present), PsycINFO (1880s–
present), Cochrane (1898–present), Web of Science (1900–present) and Google 
Scholar). There were no restrictions on country. Finally, references of included 
articles were hand searched. The original (published) search was run until December 
2016. The updated search (analgesics only) was run in May 2018. 
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2.2.2 Eligibility Criteria  
Original research articles reporting prescribing of analgesics in care homes were 
included. Single case studies and studies not published in English were excluded.  
2.2.3 Setting  
Care homes (residential homes (institution with board, meals, 24-hour staffing), 
nursing homes (as before plus 24-hour nurse coverage), and group dwellings (if 
deemed suitable based on description)) were included. Assisted living 
accommodations, sheltered accommodations, retirement apartments, and hospitals, 
were excluded.  
2.2.4 Study population  
Included participants were residents in an eligible setting where the majority of 
residents were aged 55 and older in studies that did not focus on a specific illness or 
condition. A study population was ineligible if it consisted of newly admitted 
(admission <3 months) residents; those diagnosed with a specific illness, those 
receiving palliative care, individuals who were included only if they were deemed to 
be in pain; individuals who were included only because of polypharmacy; incidence 
of adverse drug event; incidence of fall or recent hospital admission; if dementia or 
cognitive impairment were excluded; mild cognitive impairment or severe cognitive 
impairment only; or where residents with severe impairment were excluded, and the 
number of residents in the excluded population exceeded the number of included 
residents. 
2.2.5 Data 
One reviewer (FL) independently screened titles, abstracts, and full-text articles and 
extracted the number or percentage of residents prescribed analgesics (including 
analgesic-antipyretics), opioids, or paracetamol; the total number of residents; if 
available the number of care homes; and year and country of data collection. Data 
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were ineligible if prescriptions included drugs that were potentially not for analgesia 
or analgesics combined with other medications, such as disease modifying 
antirheumatic products; only PRN data were available; medication was recorded only 
if the drug was administered within a specific time window (unless daily, when it was 
counted as regular only); or only weighted percentages were given. If authors 
indicated that they had collected relevant but unpublished information, they were 
contacted. There was no restriction on study design. Randomized controlled trials 
were included if baseline data were published. For longitudinal studies, data were 
analysed from the first time point that was at least 3 months after admission to the 
care home to avoid confounding variables associated with newly admitted residents.  
2.2.6 Data extraction and quality checking (original search only) 
Two researchers independently extracted and reviewed data (FL, RB). Eligible studies 
were assessed for methodological validity using a 5-point scale (Appendix 3) adapted 
from the Newcastle-Ottawa scale (Wells et al., 2000) and Boyle scale (Boyle, 1998). 
Studies were deemed strong, moderate, or weak (adapted from (Boyle, 1998)) by 
rating representativeness of the target cohort, adequacy and standardization of data 
collection tools, participation rate, and inclusion of cluster sampling in analysis. If a 
study did not account for cluster sampling, it was demoted by 1 quality rating. If 
answers were unclear, the authors were contacted. If they could not be reached, 
lowest score for that item was used. Final scores were resolved through discussion 
and with a third independent author (ELS). 
2.2.7 Analysis 
The percentage of residents prescribed analgesics was calculated to one decimal 
place. Data were specified as regular drugs only or regular plus PRN; if not explicitly 
mentioned, they were deemed to be regular plus PRN. Articles that included regular 
medications and regular plus PRN medications or published data from 2 time points 
were divided into “cohorts” for separate analysis. Analgesic medications were coded 
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using the Anatomical Therapeutic Chemical classification system (World Health 
Organization, 2015) (Appendix 4).  
Study heterogeneity was quantified (I2 > 75% is considerable heterogeneity) (original 
search only). If the data were statistically viable it would be meta-analysed, but if that 
was not possible, then correlation coefficients would be generated using the Pearson 
correlation. The Pearson correlation is sensitive to outliers. Extreme outliers would 
be identified from the scatter plot, and if there was sufficient clinical justification to 
do so based on the original article’s discussion, would be excluded from the analysis. 
Stata version 14 (StataCorp, 2015) was used.  
2.3 Results 
In the original search 14,323 citations were reviewed, and 40 studies were included 
(Figure 2). From the 40 studies, 50 cohorts were eligible. Appendix 5 describes study 
characteristics and quality ratings. The updated search added four new studies.  
 43 
 
Figure 2. Flow diagram of study selection. 
Data were divided according to prescription type: regular only (n = 17) or regular plus 
PRN (n = 37). For regular only, the median number of residents per study was 705 
(range 215–1,387,405). For regular plus PRN prescriptions, the median was 818 
(range 13–16,126). Data were available from 17 countries. One study included data 
from across Europe (excluding Italy). The countries with the most cohorts were 
Australia (n = 8), Norway (n = 10), and the United States (n = 7). All other cohorts 
were from Europe, North America, and Australia. It was not possible to meta-analyse 
the data because of heterogeneity (prescriptions of regular analgesics, I2 = 99.1, 
regular plus PRN analgesics, I2 = 99.8). 
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2.3.1 Quality Rating  
Six cohorts were scored as being of strong quality, 20 as moderate, and 24 as weak. 
The main reasons for low scores were authors not using cluster sampling and lack of 
detail about data collection methods.  
2.3.2 Analgesics 
2.3.2.1 Temporal changes in prescriptions of regular analgesics 
There were 17 cohorts eligible (Table 1) (data drawn from 1,406,006 residents and at 
least 555 care homes in 8 countries). Two studies (Veal et al., 2014, Lövheim et al., 
2008) accounting for 1,394,950 residents, did not provide the number of included 
care homes. Figure 3 suggests that, between 1996 and 2015, analgesic prescribing 
increased in care homes. Data from Norwegian studies show that 23% of residents 
were prescribed regular analgesics in 1996, compared with 57.6% in 2011 (Nygaard 
and Naik, 1999, Sandvik et al., 2016) and 47.8% in 2015 (Erdal et al., 2017). Two 
studies, both from Germany, reported lower levels: one (Hoffmann and Schmiemann, 
2016) reported that 33.7% of residents were prescribed regular analgesics in 2014, 
and another (Kölzsch et al., 2012) reported a 32% prescription rate in 2010. In the 
original review the correlation between prescription prevalence and final year of data 
collection was 0.59, showing a moderate positive trend. In the updated review, the 
correlation was 0.54. 
2.3.2.2 Temporal changes in prescriptions of regular opioids and paracetamol 
Ten studies included data on opioid prescriptions (correlation coefficients (Rs) = 
0.94), and eight on paracetamol prescriptions (Rs = 0.93, excluding one outlier that 
reported very low paracetamol use (2.5%)). The number of regular prescriptions of 
opioids and paracetamol has increased over time (see Figure 4).  
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Table 1. Cohorts included in analysis of regular analgesic prescribing rates 
1 Opioid data available 
2 Paracetamol data available 
Study 
Year data 
collection 
ended Country 
% of residents 
prescribed 
regular analgesics  
Erdal et al. (2017) 2015 Norway 47.8 
Hoffmann and Schmiemann (2016) 2 2015 Germany 33.7 
Tan et al. (2015) 1,2 2014 Australia 75.2 
Bauer et al. (2016) 1 2012 Austria 52 
(Hunnicutt et al., 2017) 2012 US 39.7 
Veal et al. (2014) 1 2012 Australia 62.8 
Sandvik et al. (2016) 1,2 2011 Norway 57.6 
Kölzsch et al. (2012) 2010 Germany 32 
Krüger et al. (2012) 1 2008 Norway 54.8 
Lövheim et al. (2008) 1,2 2006 
Sweden, 
Finland 60.6 
Reynolds et al. (2008) 2004 US 32 
Sandvik et al. (2016) 1,2 2004 Norway 45 
Decker et al. (2009) 2003 US 45.6 
Smalbrugge et al. (2007) 1,2 2001 Netherlands 45.9 
Sandvik et al. (2016) 1,2 2000 Norway 34.9 
Nygaard et al. (2003) 1,2 1997 Norway 29.9 
Nygaard and Naik (1999) 1996 Norway 23 
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Figure 3. Percentage of residents prescribed regular analgesics over time 
 
 Figure 4. Percentage of residents prescribed regular opioids and paracetamol over 
time 
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2.3.2.3 Temporal changes in prescriptions of regular plus PRN analgesics 
There were 33 eligible cohorts (87,450 residents, at least 590 care homes in 17 
countries plus Europe, excluding Italy; see Table 2). There were 11 cohorts, 
accounting for 57,898 residents, which did not provide the number of care homes 
included. Because the scatter plot did not suggest a trend, it was not appropriate to 
run a correlation. Regular plus PRN prescriptions have not changed since 1984. 
Several studies (Lövheim et al., 2008, Jervis et al., 2007, Kaasalainen et al., 1998) 
show very high prescribing rates (>90%). One of the most recent studies (from 2013) 
reported the lowest prescribing rate (16%) (Onder et al., 2014). Of the four U.S. 
studies, the earliest (1990) reported that 38.3% of residents were prescribed 
analgesics (Williams et al., 1999), compared with 68.6% in 2004 (Reynolds et al., 
2008).  
Table 2. Cohorts Included in analysis of regular plus PRN analgesic prescribing rates 
Study  
Year data 
collection 
ended Country 
% of residents 
prescribed 
regular plus 
PRN analgesics  
Hoffmann and Schmiemann 
(2016) 2 2015 Germany 73.8 
Hemmingsson et al. (2017) 1,2 2013 Sweden 66.6 
Atramont et al. (2018) 2013 France 61.2 
Onder et al. (2014) 1 2013 
Europe not 
including Italy 28 
Onder et al. (2014) 1 2013 Italy 16 
Bauer et al. (2016) 2012 Austria 83 
Kaasalainen et al. (2016) 2012 Canada 90 
Veal et al. (2014) 2012 Australia 90.8 
Blytt et al. (2018) 2011 Norway 55 
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Study  
Year data 
collection 
ended Country 
% of residents 
prescribed 
regular plus 
PRN analgesics  
Taxis et al. (2016)1 2009 
Australia, 
Netherlands 80.8 
Boerlage et al. (2013)1 2008 Netherlands 45.8 
Hemmingsson et al. (2017) 1,2 2007 Sweden 62.8 
Stafford et al. (2011) 2007 Australia 56.8 
Torvik et al. (2009)1 2006 Norway 54.7 
Carey et al. (2008) 2005 UK 60.6 
Elseviers et al. (2010) 2005 Belgium 41.5 
Roughead et al. (2008) 2 2005 Australia 53.8 
Reynolds et al. (2008) 2004 US 68.6 
Bergman et al. (2007)1 2003 Sweden 61.5 
Snowdon et al. (2006) 2003 Australia 63.6 
Jervis et al. (2007) 2002 US 95 
Smalbrugge et al. (2007) 2001 Netherlands 54.5 
Jyrkka et al. (2006) 1998 Finland 54 
King (2003) 1,2 1997 Australia 74 
O'Grady and Weedle (1997) 1997 Ireland 20 
Kaasalainen et al. (1998) 1996 Canada 95 
Neutel et al. (2002) 1996 Canada 33.5 
van Dijk et al. (2000)1 1995 Netherlands 53 
King (2003) 1,2 1994 Australia 60.9 
Ferrell et al. (1990) 1990 US 78 
Vander Stichele et al. (1992) 1990 Belgium 26 
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Study  
Year data 
collection 
ended Country 
% of residents 
prescribed 
regular plus 
PRN analgesics  
Williams et al. (1999) 1990 US 38.3 
Passmore et al. (1995) 1989 N. Ireland 24.8 
Hatton (1990) 1987 England 43 
Nolan and O'Malley (1989) 1987 Ireland 27 
Yakabowich et al. (1994) 1987 Canada 58.5 
Primrose et al. (1987) 1984 Scotland 32 
1Opioid data available 
2 Paracetamol data available 
 
2.3.2.4 Temporal changes in prescriptions of regular plus PRN opioids and 
paracetamol 
For regular plus PRN prescriptions for opioids and paracetamol over time, there was 
a positive linear trend for opioids over time, with a moderate correlation coefficient 
(0.48). It appears that regular prescriptions for opioids have increased. Opioids were 
prescribed less frequently than paracetamol.  
2.4 Discussion 
2.4.1 Prescribing Patterns  
There is a multinational trend of increased prescription of regular analgesics, with 
corroborative findings for paracetamol and opioids. Intra-country longitudinal 
studies (e.g., increases in Norway between 2000 and 2011) and intercountry 
comparisons (in 2000–01, 34.9% of Norwegian residents and 45.9% of Dutch 
residents were prescribed analgesics, and in 2011–12, 57.6% of Norwegian residents 
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and 62.8% Australian residents were prescribed analgesics) support this finding 
(Sandvik et al., 2016, Veal et al., 2014, Smalbrugge et al., 2007).  
There does not appear to be a temporal trend for regular plus PRN prescribing. This 
may be because there is no explicit guidance regarding assessment before giving PRN 
medication (Barry et al., 2014) and individual clinical preference continues to 
influence prescribing.  
As expected, paracetamol remained the most commonly prescribed analgesic (Lukas 
et al., 2013a, Veal et al., 2014, Miu and Chan, 2014), and prescriptions have 
increased. The exception is Germany, probably because of the frequent use of 
dipyrone, a drug banned in several other countries because of risk of agranulocytosis 
(Hoffmann and Schmiemann, 2016).  
Several factors may have influenced increases in opioid prescriptions. Clinicians are 
more cautious about nonsteroidal anti-inflammatory drugs (NSAIDS) and may 
prescribe opioids as an alternative. A Finnish study saw a reduction in NSAID use in 
care homes from 13.0% in 2003 to 2.6% in 2011 (Pitkala et al., 2015), as did a 
Norwegian study (6.8% in 2000 to 3.2% in 2011), alongside increases in opioids and 
paracetamol (Sandvik et al., 2016). Concerns have been expressed that opioids are 
used for their sedative effect, not just pain (Jensen-Dahm et al., 2015, Pitkala et al., 
2015). Another concern is that opioids may be wrongly prescribed for neuropathic 
pain, for which an adjuvant drug may be more effective; the prevalence of adjuvant 
drugs does not match the prevalence of neuropathic pain (Pitkala et al., 2015, Sandvik 
et al., 2016).  
More detailed studies have identified that strong opioids are used more than weak 
opioids (Sandvik et al., 2016, Lukas et al., 2013a, Ruscitto et al., 2015). The 
introduction of buprenorphine and fentanyl patches may have contributed to use of 
strong opioids (Achterberg, 2016). A Danish study reported that nursing home 
residents were more likely to receive transdermal opioids (Jensen-Dahm et al., 2015). 
Their use may be appealing because of ease of administration (Vadivelu and Hines, 
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2008), but U.S. and U.K. guidelines advise that extended-release opioids should not 
be the first choice because of negative side effects (Vadivelu and Hines, 2008, Abdulla 
et al., 2013, National Institute for Health and Clinical Excellence, 2012a, Dowell et al., 
2016).  
2.4.2 Quality Rating  
The ranges of prescribing prevalence were similar for high and low-quality studies. It 
is troubling that there were so few high-quality studies (6 out of 50 cohorts). There 
was no clear indication that higher-quality studies produced mutually consistent 
results in terms of prescribing prevalence, which may be because of the 
heterogeneity of samples and settings.  
2.4.3 Systemic and organisational factors  
Several studies found a low prevalence of analgesic use. In Italy, 24% of residents 
reporting pain did not receive analgesics, and authors commented that medication 
was neither appropriately nor effectively managing pain (Onder et al., 2014). A Dutch 
study reported that 38% of residents in “substantial” pain received no analgesics, 
noting that pain was not included in national nursing home performance indicators 
(Boerlage et al., 2013). Another study reported remarkably low analgesic use in 
Poland. Only 28.8% of residents received analgesics, and only 21.4% of these received 
regular pain relief. Authors commented that pain is not routinely assessed in nursing 
homes (Neumann-Podczaska et al., 2016). Where low analgesic use is reported, 
authors often describe a climate that does not prioritize pain assessment. In Italy, 
where low rates of analgesic prescriptions are reported, nonpharmacological 
analgesia is used more frequently, as it is in Finland (Lukas et al., 2013a). Long-term 
care is organised differently between countries, and is impacted by healthcare 
systems, the economy, care service provision from the state, and sociocultural 
factors. These factors can influence analgesic prescribing, and lead to variability in 
resident factors. For example, there are differences between countries in family 
responsibilities towards care, place of death for older adults, organisational access to 
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multidisciplinary and dementia care, and medical training for clinicians in this sector 
(Van den Block et al., 2016, Verbeek et al., 2015, Froggatt et al., 2010). 
2.4.4 Limitations  
In this review, findings from different countries were compiled and analysed over 
time. However studies from different countries were not evenly spread over time. 
For example, data from Australia (Veal et al., 2014, Tan et al., 2015) which is a 
particularly high prescribing country, appears towards the end. Further, an increase 
in analgesic prescribing is not always seen within countries, such as the US and 
Germany where prescribing prevalence is largely static. Therefore increases seen 
may be a reflection of different practices between countries instead of a universal 
increase. Future studies should consider controlling for the effect of country.  
The cohorts included in this review are heterogeneous. Sample sizes varied greatly, 
from primary data collection studies involving one care home to databases of 
thousands. One doctor or practice typically manages care home prescribing, which is 
thus subject to individual preferences. Data from a small number of facilities may 
indicate less typical prescribing patterns than a larger sample and contribute to the 
high levels of observed heterogeneity. Conversely, it can be more difficult to ensure 
reliability of database records because they depend on accurate input from the care 
home (Lix et al., 2015). While authors did their best to ensure that the cohorts 
included in the review were drawn from care home populations that were as 
homogenous as possible, the long-term care sector does vary between countries. 
There are likely to be factors, such as medical and pharmacist input into care homes, 
that influence prescribing rates, and these are not measured. There were no studies 
from South America, Africa, or Asia, and conclusions are not generalizable outside 
Western Europe, North America, and Australia. Lastly, it has been suggested that 
neuropathic pain, estimated to be present in 8% to 11% of elderly and nursing home 
populations (Kollenburg et al., 2012, Torrance et al., 2006) is often treated 
inappropriately. This review has not explored prescriptions of neuropathic analgesics 
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because they may be prescribed for other conditions, and most studies do not collect 
information on prescribing indications.  
2.4.5 Clinical and policy implications  
Many countries have shifted from NSAID use, and in their place other analgesics may 
be prescribed. In Australia, 2005 national prescribing guidelines, which highlighted 
good practice in pain management in residential care (Veal et al., 2014, The 
Australian Pain Society, 2005) may be influencing increasing analgesic use, and a UK 
increase in fentanyl use may have occurred after its licensing for non-cancer pain in 
2002. There has been growing interest in pain in individuals with dementia and care 
homes highlighting under-treatment (Lukas et al., 2013b, Barry et al., 2014), leading 
to greater use of assessment tools and treatment guidelines (AGS Panel, 2009, 
Abdulla et al., 2013, Corbett et al., 2014a). Furthermore, there has been more 
research into behavioural and psychological symptoms of dementia and pain 
(Sampson et al., 2015, Tosato et al., 2012). These studies, combined with policy 
pressure to limit use of psychotropics, such as the Omnibus Budget Reconciliation Act 
of 1987, may have contributed to the increase in analgesic prescriptions, particularly 
opioids (Banerjee, 2009, Hawes et al., 1997).  
2.4.6 Future research needed  
An increase in analgesic prescribing does not necessarily mean that residents are 
receiving the most appropriate treatment (Ruscitto et al., 2015), and more frequent 
pain assessment does not necessarily equate to more analgesia (Petyaeva et al., 
2018). Medication is often prescribed as needed, and administration depends upon 
staff and their ability to assess pain accurately. This is particularly relevant for 
cognitively impaired residents who cannot communicate their pain; regular 
prescriptions may ensure that this population is at less risk of under-treatment (Veal 
et al., 2015). Research into using clinical decision-making algorithms (with stepped 
treatment approaches), greater collaboration between professionals such as 
pharmacists and palliative care nurses, and developing interventions to empower 
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and engage the whole care team involved in regularly assessing pain and evaluating 
pain management strategies could address the disconnect between recognizing and 
treating pain (Achterberg, 2016).  
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 Review conclusion and future directions 
This is the first systematic review to investigate temporal changes in prescribing 
patterns of analgesics in the international care home population. We included data 
from all studies reporting analgesic use and demonstrated that increases in 
prescribing seen in smaller studies are representative of an international upward 
trend, providing a context for current prescribing practices in care homes and insight 
into the influence of research focus and policy changes.  
This upward trend may be attributed to improvements in pain recognition and pain 
management in care homes since early studies focused on under-treatment of 
people with dementia (for example, Ferrell et al. (1995), Horgas and Tsai (1998)), 
which is undoubtedly in part thanks to the priority that this field has been given 
within the international research community, and new and improved pain 
management guidelines. Increases may also be a result of changes in the care home 
population, namely an older and frailer group of residents with more painful 
conditions (Pitkala et al., 2015). It is important to note that the analysis included data 
from different countries and there is variability between care home populations and 
analgesic prescribing that is not accounted for this in this review. Therefore the 
conclusions drawn may not be universally representative. 
We have not yet achieved a consistent approach to analgesic prescribing, even where 
pain is recognised (de Souto Barreto et al., 2013), and this was seen very clearly when 
analysing regular and PRN prescriptions. The findings from the review further 
reinforce that there is a huge gap in our knowledge of the use of PRN medication. A 
commercially-funded report (Napp Pharmaceuticals Limited, 2014) recommended a 
national study to be initiated into the administration of analgesics (as opposed to 
prescribing prevalence) and many studies have reiterated the need for data regarding 
PRN use (Achterberg, 2016, Dörks et al., 2016, Hoffmann and Schmiemann, 2016, 
Bauer et al., 2016).  
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Care home residents with dementia are a vulnerable population, with limited or no 
autonomy concerning their own medication use. They are largely unable to advocate 
for themselves and are entirely reliant on the medical care services provided by the 
home that they reside in. Analgesics are often prescribed as PRN, but currently there 
are no large-scale studies that report how PRN drugs are used in care homes. 
Fortunately the MARQUE programme (detailed on page 57) had access to a large 
number of care homes with the benefit of detailed data that previously has only been 
achievable in small-scale studies. MARQUE offers a large dataset to test the 
association between resident factors but also care home factors. Little work has been 
conducted analysing care home characteristics and analgesic use; a positive 
association has been found between nursing home size and PRN prescribing (but not 
administration) (Stokes et al., 2004). 
Pain treatment estimates may be misleading if the presence of PRN analgesia is 
treated with equal weight compared to regular analgesia and influencing factors may 
be missed. Analgesics prescribed on a PRN basis may lead to under-treatment, even 
when patients do not have cognitive impairment and are able to self-report pain 
(Short et al., 1990). There is evidence of under-treatment with PRN analgesics in care 
homes. Despite significant pain, nearly 21% of residents did not receive any 
analgesics (Lukas et al., 2013a). In a study where the majority of cognitively impaired 
residents had a prescription for PRN analgesia, less than a third received any, despite 
the presence of chronic painful diagnoses (Mezinskis et al., 2004). Pickering et al. 
(2006) found that residents with Alzheimer’s disease were administered significantly 
fewer dosages for chronic pain compared to residents without dementia. A French 
study found that, of the residents who complained of pain, 65.8% of those with 
diagnosed dementia were administered an analgesic in the prior week compared to 
77.0% of residents without dementia (de Souto Barreto et al., 2013). Given the 
relationships that exist between pain, analgesics, BPSD, and psychotropics, it is vital 
that we understand how often these drugs are used. These data will also increase our 
ability to interpret previous studies where PRN prescriptions are reported without 
administration data. 
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 The MARQUE programme and my 
contribution 
The MARQUE (Managing Agitation and Raising QUality of LifE in dementia) 
programme consists of six work streams exploring dementia and agitation. It is 
funded by the Economic and Social Research Council (ESRC) and National Institute of 
Health Research (NIHR), as part of their Improving Dementia Care initiative. The data 
used in this study were collected as part of work stream 2 (WS2): A Naturalistic Two-
Year Cohort study of Agitation and Quality of Life in Care Homes. Stream 2 was a 
longitudinal study that recruited residents, relatives, and staff members from care 
homes across England. Research assistants interviewed residents and relatives about 
the resident’s quality of life, and interviewed staff members about residents’ quality 
of life, health, BPSD, and health resource use. Staff were also able to complete 
questionnaires about their own levels of coping and stress.  
The MARQUE programme commenced in March 2014, and recruitment for Stream 2 
started in April 2014. The Chief Investigator of MARQUE is Professor Gill Livingston 
and Principal Investigator for Stream 2 was Dr Claudia Cooper, both based in the 
Division of Psychiatry at UCL.  
I have been working as a MARQUE research assistant full-time since August 2014 and 
completing my PhD part-time since November 2014. My primary responsibilities 
were recruiting participants and collecting data, and as such where I write ‘research 
assistants’ or ‘we’, I refer to the team of research assistants, within which I had an 
active role. The London-based team of eight research assistants collected data in 
London, Cambridge, Kent, and Sussex, and NHS researchers collected the data 
elsewhere. 
Table 3 details the data collected as part of the MARQUE study analysis and additional 
data collected for the purpose of my PhD. 
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Table 3. Measures collected and whether it was relevant for the MARQUE Stream 2 
study only, PhD only (in bold), or both (in bold) 
 Name of measure Subject Analysis 
Home 
measures 
Home census Home demographics PhD + 
MARQUE 
TESS-NH/RC (Therapeutic Environment 
Screening Survey for Nursing Homes 
and Residential Care) (Lawton et al., 
2000) 
Physical environment MARQUE 
only 
Staff 
measures 
Brief COPE (Coping Orientations to 
Problems Experienced) (Burgess et al., 
2010) 
Coping MARQUE 
only 
MBI (Maslach Burnout Inventory) 
(Maslach and Jackson, 1981) 
Burnout MARQUE 
only 
MCTS (Modified Conflicts Tactics Scale) 
(Beach et al., 2005) (adapted for use in 
care homes, as it was in a previous UCL 
study: SILQ IRAS ID 84034) 
Possible abusive 
behaviour 
MARQUE 
only 
Resident 
measures  
DEMQOL (Dementia quality of life) 
(Smith et al., 2007)  
Quality of life MARQUE 
only 
EQ-5D (EuroQoL Five Dimensions) 
(Brooks and Group, 1996) 
Health status MARQUE 
only 
CMAI (Cohen-Mansfield Agitation 
Inventory) (Cohen-Mansfield and Billig, 
1986) 
Agitation PhD + 
MARQUE 
NPI (Neuropsychiatric Inventory) 
(Cummings et al., 1994) 
Neuropsychiatric 
symptoms 
MARQUE 
only 
CDR (Clinical Dementia Rating) 
(Hughes et al., 1982) 
Dementia severity PhD + 
MARQUE 
CSRI (Client Service Receipt Inventory) 
(Beecham and Knapp, 2001) 
Use of health and social 
care resources 
MARQUE 
only 
Medication – prescriptions (preceding 
30 days) 
Drug, dosage, frequency, 
length of prescription 
PhD + 
MARQUE 
Medication – PRN administration 
(preceding 14 days) 
Route; indication; how 
many times the drug was 
offered/administered 
PhD only 
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The additional data for PRN medication were solely collected for the purpose of my 
PhD. To improve the quality of data collection I provided further training to research 
assistants (face-to-face and telephone), and wrote and disseminated detailed 
instructions (see Appendix 6). Furthermore, I was the named contact for queries 
relating to the PRN data and more often than not, all medication queries that were 
sent to the London team. 
4.1 Ethical approval 
The Principal Investigator submitted the application for ethical approval of this study 
on 2nd December 2012 to Harrow Research Ethics Committee. Ethical approval was 
granted on 6th March 2014 (REC reference 14/LO/0034; see Appendix 7). No further 
ethical approval was required for my PhD data. 
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 Research aims and objectives  
5.1 Aims 
The primary aim of my thesis was to describe prescribing patterns and administration 
of analgesics for residents with dementia in a representative sample of English care 
homes. 
The secondary aim was to explore associations between analgesic medication use 
and care home factors and resident factors, including psychotropic use. 
5.2 Primary objective 
1. To describe at three study visits (baseline; four-month; twelve-month) the 
prescription of analgesic medication (overall, and analgesic drug classes [non-
opioids, opioids], and prescription type [regular or PRN]) 
2. To describe at three study visits the administration of PRN analgesic 
medication. 
5.3 Secondary objectives: analgesics  
1. To identify whether care home factors (care provision; ownership; 
dementia registered; dementia specialist; number of beds; overall CQC 
rating) are associated with the prescription and/or PRN administration of 
analgesic medication. 
2. To identify differences in prescribing and PRN administration of analgesic 
medication according to different resident factors, specifically age, 
gender, and dementia severity. 
3. To identify associations between agitation (as measured on the CMAI) 
and the prescription and PRN administration of analgesic medication, and 
specifically the associations with clinically significant agitation, and with 
agitation subtypes. 
4. To compare analgesic prescribing in this cohort to international prescribing 
prevalence. 
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5.4 Secondary objectives: psychotropics and analgesics 
1. To describe at three study visits (baseline; four-month; twelve-month) the 
prescription of psychotropic medication. 
2. To identify whether there is an association between the number of analgesic 
prescriptions and the number of psychotropic prescriptions prescribed to a 
resident. 
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 Methods 
6.1 Setting and Sampling 
MARQUE WS2 was an observational cohort study that collected data from care 
homes across England. Care homes were eligible for participation if they had 
residents with dementia. Recruitment of care homes was intended to be 
representative of care provision (nursing or residential), ownership (state, private, or 
third sector), and location (urban, suburban, or rural), to ensure external validity and 
generalisability.  
The sample size is based upon the multivariable logistic regressions exploring the 
prescribing rates. Various variables, including agitation and dementia severity, will be 
examined to explore the associations with prescribing rates. The regression with the 
most variables includes agitation subtypes (four groups), gender (two groups) and 
age (continuous), and thus has five covariates included in the model (number of 
groups minus 1 for each variable, where continuous equals 1 covariate).  
Consequently, using the rule of 10 events per variable, 50 events will be required.  We 
estimate that 8.1% of people with dementia will be prescribed opioids (Lukas et al., 
2013a), consequently 618 people with dementia will be required. Inflating for 
clustering effects, assuming 16 participants on average per care home (Whitaker et 
al., 2014) and an intra cluster correlation of 0.075 (Fossey et al., 2006), as used in the 
main WS2 study, the sample size needed for this PhD was calculated as 1313 
participants from 82 care homes. This was achieved. 
6.2 Procedures 
6.2.1 Care home consent 
Care homes were recruited through local clinicians, the NIHR (National Institute of 
Health Research) Clinical Research Network, study links in the private and voluntary 
sector, and cold calling. Study managers approached the care home manager (or 
most appropriate individual) for an initial meeting or phone call to introduce the 
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study. If they were interested in proceeding, a ‘set-up’ meeting was held, with a study 
manager and a research assistant, to explain the study procedures and complete 
consent. It was typical that in this meeting potential participants within the home 
were identified. 
6.2.2 Resident consent 
Care home residents were eligible for inclusion if they had a known dementia 
diagnosis, or screened positively using the Noticeable Problems Checklist (NPC) 
(Levin, 1989) (see Appendix 8), a checklist where scoring two or more out of five 
indicates probable dementia. This screening measure is completed by care home 
staff and so does not cause distress to the resident, it is independent of culture and 
education, and has been validated against clinical diagnosis (Moriarty and Webb, 
2000). Henceforth all eligible residents, whether identified through clinical diagnosis 
or NPC, will be referred to as having dementia.  
All residents with dementia were invited to take part. We worked in line with the 
Mental Capacity Act (Department of Health, 2005) to assess residents’ capacity and 
obtain consent. During the set-up meeting we asked staff if they thought that the 
resident would potentially have the capacity to consent themselves into the study. 
When it was indicated that the resident may have capacity, to gain informed consent 
from the resident. Where the resident did not have capacity, we sought consent from 
a personal consultee. If there was no appropriate personal consultee, we spoke to 
the care home manager and sought consent from a professional consultee: either a 
care home staff member who worked closely with the resident or a social worker. 
Appendices 9 to 12 comprise information sheets and consent forms used for 
residents and consultees.  
6.3 Care home measures 
We used a home census (Appendix 13) to record characteristics of each care home: 
number of beds; number of staff; whether it was residential or nursing; whether it 
was dementia–registered or dementia-specialist; staff turnover; current Care Quality 
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Commission rating (CQC) rating. A care home can receive one of four CQC ratings: 
‘Outstanding’, ‘Good’, ‘Requires improvement’, or ‘Inadequate’. 
6.4 Resident measures 
The MARQUE study collected data at baseline (0-month) and four further study visits 
(at 4-month, 8-month, 12-month, and 16-month). Due to time and resource 
constraints, this PhD used data from baseline, 4-month, and 12-month study visits. 
These data were collected from May 2014 – December 2016.  
At the baseline visit, demographics were recorded for each resident, comprising date 
of birth, gender, ethnicity, and whether English was their first language. At every 
study visit interviews were conducted with a care home staff member who knew the 
resident well, to collect data regarding medication, agitation, and dementia severity. 
Residents were eligible for inclusion in analysis for this PhD if both medication data 
and agitation data were available. 
6.4.1 Medication  
Prescriptions of all medication were taken from Medication Administration Records 
(MAR) and transcribed to study case report forms (CRF; see Appendix 14). These data 
were collected: drug; dosage; frequency; length of prescription (up to 28 days); 
whether it was regular or PRN. If the drug was prescribed PRN, additional data were 
collected from the previous two-week period (ending the day before the interview): 
how many times the drug was offered (if there were initials or a code recorded for 
the dose on the MAR); of the doses offered, how many days it was not given (it was 
not possible to accurately record reasons why it was not given due to a number of 
reasons, for example absence of reason, illegible, or unclear records); the indication 
(if available on the MAR). The two-week period was chosen to coincide with the 
agitation data.  
 65 
Analgesic and psychotropic drugs were considered relevant for this thesis (see 
Appendix 15 for list of relevant drugs), categorised as per the British National 
Formulary (BNF) (Joint Formulary Committee, 2016). 
Table 4. Drug categories relevant to this thesis 
Analgesics Psychotropics 
Simple non-opioids Anxiolytics and hypnotics 
Opioids Antidepressants 
NSAIDs (oral) Antipsychotics 
 
6.4.2 Agitation 
The Cohen-Mansfield Agitation Inventory (CMAI) (Cohen-Mansfield et al., 1989) is a 
29-item questionnaire measuring agitation in people with dementia retrospectively 
over a two-week period (see Appendix 16), assessing average frequency as: 1, 
‘Never’; 2, ‘Less than once a week’; 3, ‘Once or twice a week’; 4, ‘Several times a 
week’; 5, ‘Once or twice a day’; 6, ‘Several times a day’; 7, ‘Several times an hour’. 
CMAI data were collected during interview with a care home staff member who knew 
the resident well. The score range is 29-203, where 29 indicates no agitation. A total 
sum score of 45 and greater indicates clinically significant agitation (Cohen-Mansfield 
et al., 1989).  
There are four syndromes of agitation identified, described in Table 5 below: 
aggressive behaviour, physically nonaggressive behaviour, verbally agitated 
behaviour, and hiding/hoarding behaviour (Cohen-Mansfield et al., 1989, Schreiner 
et al., 2001, Choy et al., 2001, Jonghe and Kat, 1996). Some items are excluded due 
to low occurrence, or they did not load onto any factor. The CMAI and factor 
structure have demonstrated acceptable reliability and validity, including good 
construct validity and inter-rater and test-retest reliability (Husebø et al., 2014b, 
Rabinowitz et al., 2005, Zuidema et al., 2011).  
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Table 5. CMAI factor structure 
Factor Behaviours 
Aggressive behaviour Hitting, kicking, pushing, scratching, 
grabbing, cursing or verbal aggression, 
hurting self or other, biting, spitting, 
throwing things, tearing things or 
destroying property, screaming 
Physically nonaggressive behaviour Pacing or aimless wandering, inappropriate 
undressing or disrobing, performing 
repetitive mannerisms, trying to get to a 
different place, handling things 
inappropriately, general restlessness 
Verbally agitated behaviour Constant requests for attention, repetitive 
sentences or questions, complaining, 
negativism 
Hiding/hoarding Hiding, hoarding 
Excluded factors Low occurrence: intentional falling, verbal 
sexual advances, physical sexual advances 
Did not load: strange noises, eating or 
drinking inappropriate substances 
 
6.4.3 Dementia severity 
The Clinical Dementia Rating (CDR) (Hughes et al., 1982, Berg, 1988) is a measure that 
assesses dementia severity in six domains of cognition and function: memory; 
orientation; judgement; problem solving; community affairs; home and hobbies; 
personal care. Each domain is rated according to impairment: 0, ‘None’; 0.5, 
‘Questionable’; 1, ‘Mild’; 2, ‘Moderate’; 3, ‘Severe’. A global impairment score is 
generated via an algorithm (score range 0-3, also from None to Severe) (Baty and 
Morris, 2011). The CDR was completed during interview with a care home staff 
member who knew the resident well. The global score, and internal factors, are 
widely accepted as a valid and reliable assessment measure of dementia severity, 
including acceptable content and convergent validity, and inter-rater and test-retest 
reliability (Morris, 1997, Cedarbaum et al., 2013). An adapted version that did not 
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involve interviewing the resident (see Appendix 17) was used. For analysis purposes, 
residents with questionable dementia were subsumed into the mild dementia group. 
6.5 Data quality checking, input and cleaning 
I requested a random sample of one in ten MAR charts from each research assistant 
at each visit to audit against the case report form (CRF) regarding the transcription of 
relevant drugs. Where persistent errors were identified, I contacted the researcher 
to clarify data collection procedures.  
All data were entered by research assistants into an online database (‘MACRO’), with 
the exception of the additional PRN data as the MACRO database creation pre-dated 
my PhD.  
I initially intended to check ten per cent of all CRFs against the MACRO database. 
However due to the high levels of inaccuracy I decided to check every CRF against the 
MACRO entry for all relevant drugs. I did this at each study visit. 
The data sets required for my analysis were extracted from MACRO by the MARQUE 
statisticians at the request of the study manager. Two data sets were extracted per 
study visit; one for resident measures and one for care home measures. The 
extracted data sets were in Microsoft Excel 2013 version. I added the additional PRN 
data from the CRF, the number of days that PRN data were available (out of a possible 
14), and whether I had audited the CRF against the MAR chart.  
Regarding dementia diagnosis, demographic, agitation, and dementia severity data, 
study managers checked ten per cent of all CRFs against the MACRO entry.  
6.6 Data analysis 
I developed the analysis plan after discussion with my primary and secondary 
supervisor, and a statistician based in the Marie Curie Palliative Care Research 
Department, Division of Psychiatry at UCL. 
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I independently imported and merged datasets in StataSE 14 (StataCorp, 2015), 
generated new variables, and recoded missing variables. I conducted my analysis 
independently, however for more complex analyses I consulted the statistician 
before proceeding. 
6.6.1 Missing data 
All instances of missing data were described. Residents for whom we had no data 
were identified by selecting those without a caregiver interview date, and checked to 
confirm that there was no data available.  
In the case of missing items in the CMAI (and thus unable to generate a total sum 
score) I assessed the data to see whether missingness was random or not. If deemed 
random, I used person mean imputation, whereby the mean response of the 
available items is calculated and replaces the missing items (Shrive et al., 2006). This 
imputation method was only employed where less than 50% of the questionnaire 
was missing. 
6.7 Analysis plan  
6.7.1 Description of sample 
The study population was explored using descriptive analyses. For care homes I have 
described these characteristics at baseline: number of beds; whether it is residential 
or nursing; dementia registration; dementia specialism (if any); current CQC rating. 
For residents I have described these characteristics at baseline: age, gender, 
ethnicity, marital status, first language (English or other), dementia diagnosis, and 
dementia severity. 
Simple analyses are used to describe the variables of dementia severity and agitation, 
including the four subtypes: physically aggressive agitation; physically non-aggressive 
agitation; verbally agitated agitation; hiding/hoarding behaviour.  
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Mean and standard deviations are used for continuous, symmetric variables. 
Medians and inter-quartile ranges (IQR) are used for continuous, skewed variables. 
Frequencies and percentages are used for categorical variables. Descriptive statistics 
are presented as cross-sectional data from each study visit. 
6.7.2 Primary objective: analgesics  
1. The primary objective was to describe prescribing patterns and administration of 
analgesic drugs and analgesic classes. These data are presented as cross-sectional 
data from each study visit. 
Analgesics were categorised into five classes: simple non-opioids; weak opioids; 
strong opioids; compound drugs; oral NSAIDs. Compound drugs were divided into 
their constituent parts and incorporated into the relevant drug type, for instance co-
codamol was divided into paracetamol (simple non-opioid) and codeine (weak 
opioid).  
For each drug and class: the total number (n) and percentage (with 95% confidence 
intervals) of residents who were prescribed each drug at each study visit was 
recorded, and the total number (n) and percentage (with 95% confidence intervals) 
of residents who were prescribed a regular prescription, PRN prescription, or both. 
The median daily dose (and IQR) was recorded. The median number (and IQR) of 
study visits that residents were prescribed each drug was recorded, both including 
and excluding those who were withdrawn from the study (as inclusion would increase 
the number of false negatives of prescription cessation).  
Daily doses were calculated for each drug. Doses of non-oral non-morphine opioids 
were converted to an equianalgesic dose of oral morphine (cross-tolerance set at 
0%). The BNF was used for calculating opioid conversion ratios (BMJ Group and the 
Royal Pharmaceutical Society of Great Britain, 2017). The tables below describe 
conversion information. Total opioid daily doses were generated from oral and non-
oral opioid medications.   
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Table 6. Equivalent opioid doses (National Institute for Health and Care Excellence, 
2017) 
Analgesic (route) 
Reference: Morphine (oral) 
Dose (mg) 
Reference: 10mg 
Codeine (oral) 100 
Diamorphine (intramuscular, intravenous, subcutaneous) 3 
Morphine (intramuscular, intravenous, subcutaneous) 5 
Oxycodone (oral) 6.6 
Tramadol (oral) 100 
Buprenorphine 5mcg/hour (patch) 12 
Buprenorphine 10mcg/hour (patch) 24 
Buprenorphine 20mcg/hour (patch) 48 
Buprenorphine 35mcg/hour (patch) 84 
Buprenorphine 70mcg/hour (patch) 168 
Fentanyl 12mcg/hour (patch) 30 
Fentanyl 25mcg/hour (patch) 60 
Fentanyl 50mcg/hour (patch) 120 
Fentanyl 100mcg/hour (patch) 240 
 
For PRN prescriptions (where 14 days’ worth of PRN prescriptions were available) the 
median and IQR of the percentage of times the drug was offered and administered 
was recorded, and compared to the amount prescribed. A flowchart was created, for 
simple non-opioids, weak opioids, and strong opioids, to describe at each study visit 
the number of residents that were offered and administered a PRN analgesic, and 
the median and IQR of the number of doses offered and administered per week. A 
graph was generated to show the mean PRN administration across study visits for 
residents who were prescribed a PRN analgesic. 
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Analgesic levels were compared to the WHO pain ladder (World Health Organization, 
2015) and data are analysed with the whole cohort, and including only those who 
remained in the study for all three study visits, to examine attrition bias.  
6.7.3 Secondary objectives: analgesics 
A multi-level linear regression model was used to explore the effects of care home 
factors (demographics; CQC ratings) on prescribing patterns and administration of 
analgesics at baseline. Prior to this I conducted univariate analysis to identify 
potential confounders, which were included in the final model. If no care home 
factors had a relationship with prescribing or administration, then heterogeneity 
between care homes was quantified by calculating I2 (I2 > 75% is considerable 
heterogeneity) and forest plots were generated. 
Analgesic prescriptions and administration (as binary [yes/no] variables) were 
compared between different groups. Prior to running these tests, a sensitivity 
analysis was run to determine any differences in baseline factors between residents 
who had died compared to those who were still alive. To do this, a chi-square test 
was run for binary variables, or a t-test for continuous baseline factors, with 
missingness due to death at each study visit as an outcome. The distribution of the 
data was tested to determine the most appropriate test; Mann-Whitney U tests were 
used to analyse nonparametric data. If any baseline variables predicted missingness 
they were incorporated as independent variables in the models. Factors were also 
included in the model if there was a clinical reason to do so. The following regression 
models were run as longitudinal data, clustered at the study visit and care home level. 
A multi-level logistic regression model was used to explore the effects of age and 
gender on prescribing patterns and administration over the three study visits. When 
exploring age, data were analysed as a continuous variable and also as a binary 
variable, divided into two groups: 65-80 years; 81 years and over. Where appropriate, 
odds ratios were calculated. 
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A multi-level logistic regression model was used to explore whether residents with 
more severe dementia were prescribed and/or administered fewer doses of 
analgesic medication than those with mild dementia (using three levels of severity: 
mild; moderate; severe).  
To explore associations between agitation behaviours and the prescription of 
analgesic medication, subscales for the CMAI were generated (verbally agitated; 
verbally non-aggressive; physically aggressive; hiding/hoarding). Multi-level logistic 
regression models were run to explore associations between clinically significant 
agitation, total CMAI score, and agitation subtypes, and prescription and 
administration of analgesic medication.  
Analgesic prescribing prevalence in this cohort versus international prescribing 
prevalence were visually compared using a scatter plot, utilising the studies included 
in the systematic review.  
6.7.4 Secondary objective: psychotropics and analgesics 
A secondary objective was to describe prescribing patterns of psychotropic drugs.  
Psychotropics were categorised into three classes: anxiolytics and hypnotics; 
antidepressants; antipsychotics (see Appendix 15 for full list of relevant drugs). These 
categorisations are based on the first indication for these drugs according to the BNF 
(Joint Formulary Committee, 2016). 
For each drug and drug class: the total number (n) and percentage (with 95% 
confidence intervals) of residents who were prescribed each drug at each study visit 
was recorded, and the total number (n) and percentage (with 95% confidence 
intervals) of residents who were prescribed a regular prescription, PRN prescription, 
or both. The median number of study visits (and IQR) that residents were prescribed 
each drug was recorded, both including and excluding those who were withdrawn 
from the study (as inclusion would increase the number of false negatives of 
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prescription cessation). Median daily doses (and IQR) were also calculated for each 
drug. 
To explore the association between analgesic and psychotropic medication, a simple 
multi-level Poisson regression model was used to test by how many the number of 
psychotropic medication drug prescriptions increased or decreased for every 
increase in analgesic medication drug prescriptions. Multi-level logistic regression 
models were run to explore associations between analgesic prescriptions and 
prescriptions of each psychotropic class. The models were clustered at the care home 
and study visit level. 
6.7.5 Clustering 
Where appropriate, the analysis was clustered at two levels (see Table 7), at the level 
of study visit (baseline; 4-month; 12-month) to account for the longitudinal nature of 
the data, and at the care home level, so the model will recognise all residents who 
reside in the same care home. This is important because residents of the same care 
home may be more alike than residents chosen at random from the population, and 
unobserved variables that may result from this shared context can be accounted for 
within the analysis. Adjustments are made for standard errors and different degrees 
of freedom, and furthermore it allows you to explore cross-level interactions (Robson 
and Pevalin, 2015).  
Table 7. Hierarchical structure of my analysis 
Level 1 Care home 
Level 2 Resident 
Level 3 Study visit 1 Study visit 2 Study visit 3 
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 Results: Description of cohort and data 
7.1 Care homes 
Of the 114 care homes approached, 86 care homes participated (75.4%). Of those 
that did not participate, 21 were nursing homes and 7 were residential homes. Figure 
5 describes reasons for non-participation and Table 8 describes the recruited care 
homes. 
 
Figure 5. Flow diagram of care home participation 
A total of 3859 staff members worked across the recruited homes (median 30, IQR 
20, 48). Two care homes dropped out at the 4-month study visit (one private 
dementia-specific nursing home, and one voluntary residential home). A further two 
homes had withdrawn by the 12-month study visit (one private dementia-registered 
nursing home, and one private dementia-specific residential home). Figure 6 shows 
the spread of recruited care homes across England. 
The MARQUE study recruited a higher proportion of dementia-registered and 
dementia-specialist care homes compared to the national average. The study also 
recruited more homes with ‘Outstanding’ and ‘Good’ CQC ratings, and fewer homes 
with ‘Requires improvement’ and ‘Inadequate’ CQC ratings compared to national 
distribution.  
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Figure 6. Geographical spread of recruited care homes in MARQUE study (Robertson, 
2017) 
7.2 Residents 
At baseline, there were 4186 beds in the recruited care homes, and the median 
number of residents per care home was 44 (IQR 32, 62). We screened 3542 residents 
for eligibility. Of those, 3053 (86.2%) were identified as having dementia and 
therefore eligible for participation. We approached 2825 residents for consent and 
1489 (52.7%) participated in MARQUE. There were 300 residents (20.1%) who 
consented themselves, and for the remaining residents, consultee agreement was 
sought from next of kin, or care home staff members. The STROBE diagram below 
(Figure 7) describes reasons for non-participation and missing data.  
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Table 8. Type and provider of recruited care homes compared to national average 
Type N % National average1, % 
Nursing 50 58.1 26.01 
Residential 36 41.9 74.01 
Provider    
Charity/Voluntary 15 17.4 20.7 
Council/Local authority 2 2.3 4.0 
Independent/Private 68 79.1 75.0 
NHS 1 1.2 0.3 
Registration    
Dementia specialist 76 87.4 46.1 
Dementia registered 29 33.3 15.0 
CQC rating    
Outstanding 6 7.1 0.6 
Good 59 69.4 49.6 
Requires improvement 18 21.2 45.1 
Inadequate 2 2.4 4.8 
1(Care Quality Commission, 2016) 
The median number of participating residents per care home was 17. Baseline data 
were collected for 1483 residents. Of these, 1281 (86.4%) had a clinical diagnosis of 
dementia and the remaining 202 residents (13.6%) were identified as eligible using 
the Noticeable Problems Checklist (Levin, 1989). At baseline, there were staff proxy 
data available for 1465 residents, and 1425 residents had CMAI and medication data 
(and were therefore eligible for the analysis in my thesis). Of these 1425 residents, 
1231 (86.4%) had a diagnosis of dementia and 194 (13.6%) scored positively on the 
NPC. 
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Figure 7. STROBE diagram describing eligible residents at each study visit and number 
of residents with medication and agitation data, with reasons for withdrawal and 
missing data 
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At the 4-month study visit, 1244 residents were eligible, and proxy data including 
CMAI and medication data were available for 1215 residents. At the 12-month study 
visit there were 899 eligible residents, with proxy data available for 865 residents. 
CMAI and medication data were collected for 856 residents. Table 9 describes the 
resident characteristics at each study visit. 
Table 9. Resident characteristics at each study visit: baseline (n=1425), 4-month 
(n=1215), and 12-month (n=856) 
Characteristic  Study visit  N % 
Gender (baseline only) 
Female  985 69.1 
Male  440 30.9 
Marital status (baseline only) 
Single/unmarried  201 14.1 
Married  331 23.2 
Separated  10 0.7 
Divorced  3 5.1 
Widowed  769 53.7 
Common law couple  4 0.3 
Ethnicity (baseline only) 
White British  1251 87.8 
White Irish  43 3.0 
White Other  46 3.2 
Chinese  2 0.1 
Black or Black British 
Caribbean 
 22 1.5 
Black or Black British African  11 0.8 
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Characteristic  Study visit  N % 
Asian or Asian British: Indian  7 0.5 
Asian or Asian British: 
Pakistani 
 3 0.2 
Asian or Asian British: 
Bangladeshi 
 3 0.2 
Mixed: White and Black 
Caribbean 
 1 0.1 
Other  26 1.9 
Dementia diagnosis1 
Dementia diagnosis  1231 86.4 
NPC  194 13.6 
First language English (baseline only) 
Yes  1318 92.5 
No  67 4.7 
Dementia severity (based on Clinical Dementia Rating assessment) 
Very mild or Mild Baseline 419 29.4 
 4-month 289 23.8 
 12-month 160 18.7 
Moderate Baseline 464 32.6 
 4-month 358 29.5 
 12-month 264 30.8 
Severe Baseline 534 37.5 
 4-month 568 46.8 
 12-month 431 50.4 
1 Data only collected at baseline 
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Figure 8. Percentage of residents at each study visit with mild, moderate, and severe 
dementia 
Table 10. Missing demographic data at baseline 
Characteristic N % 
Gender 0 0 
Marital status 32 2.2 
Ethnicity 10 0.7 
Dementia diagnosis 0 0 
First language 40 2.8 
 
At baseline, the mean age of the group was 84.9 years (range 40-105 years, SD 8.6). 
The majority of residents (69.1%, n=985) were female. There were 889 females 
(87.8%) and 377 males (83.4%) with a diagnosis of dementia. More males than 
females (16.6% vs 12.2%) were deemed eligible via the NPC. Table 10 and Table 11 
describe the missing demographic and dementia rating data. Figure 8 describes the 
 81 
proportion of residents at each study visit with mild (and very mild), moderate, and 
severe dementia.  
Table 11. Missingness of CDR, by study visit 
Characteristic Study visit N % 
Dementia severity (CDR) Baseline 2 0.1 
 4-month 0 0 
 12-month 1 0.1 
 
7.3 Medication data 
At baseline, medication data were available for 1425 residents and a full 14 days’ 
worth of PRN data were available for 641 residents. At the 4-month study visit, 
medication data were available for 1215 residents. A full 14 days’ worth of PRN data 
were available for 587 residents. At 12-month, medication data were available for 
856 residents. A full 14 days’ worth of PRN data were available for 390 residents. At 
each study visit, there were four residents who were not prescribed any medication. 
One resident was not prescribed any medication for all three study visits, and one 
resident was not prescribed any medication for two study visits (4-month and 12-
month). 
7.4 Cohen-Mansfield Agitation Inventory  
At baseline, CMAI data were available for 1426 residents, but one resident did not 
have any medication data and was excluded from this analysis. Table 12 shows the 
spread of missing data of the CMAI across all three study visits.  
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Table 12. Missingness of CMAI by item, at each study visit 
CMAI item Missing items 
 Baseline 4-month 12-month 
Pacing and aimless wandering 0 0 2 
Inappropriate dressing or disrobing 1 0 0 
Spitting (including while feeding) 0 0 0 
Cursing or verbal aggression 1 0 0 
Constant unwarranted request for attention or help 1 0 0 
Repetitive sentences or questions 1 0 0 
Hitting (including self) 0 1 1 
Kicking 3 3 1 
Grabbing onto people or things inappropriately 0 0 0 
Pushing 0 3 3 
Throwing things 1 1 0 
Making strange noises 1 3 0 
Screaming 2 1 1 
Biting 3 0 0 
Scratching 3 1 1 
Trying to get to a different place 2 1 2 
Intentional falling 2 0 2 
Complaining 1 2 1 
Negativism 1 0 0 
Eating or drinking inappropriate substances 1 1 1 
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CMAI item Missing items 
 Baseline 4-month 12-month 
Hurting self or others 6 1 0 
Handling things inappropriately 4 1 0 
Hiding things 1 1 2 
Hoarding things 3 0 0 
Tearing things or destroying property 1 0 0 
Performing repetitive mannerisms 1 1 1 
Making verbal sexual advances 2 0 1 
Making physical sexual advances or exposing genitals 1 2 0 
General restlessness 3 1 0 
 
The range of missing data was 0-6. The item with the most missing responses 
(‘hurting self or others’) accounted for 0.4% of data. Given that the level of 
missingness was low, it was assumed to be random, and person mean imputation 
was used.  
At baseline, the median CMAI score was 41 (IQR 33, 55). It was reported that 574 
(40.0%) residents had clinically significant agitation (CMAI>45). 208 (14.6%) residents 
did not have any agitated behaviours on the CMAI. Table 13 describes how many 
residents displayed behaviours relating to different factors of the CMAI, including 
those who displayed clinically significant agitation in the previous two weeks. 
At the 4-month study visit, the median CMAI score was 40 (IQR 32, 55). It was 
reported that 190 (15.6%) residents had not been agitated in the two weeks prior to 
data collection. There were 474 (39.0%) residents with clinically significant agitation.  
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At the 12-month study visit, 329 (38.4%) residents had clinically significant agitation. 
The median CMAI score was 40 (IQR 32, 55) and 149 (17.4%) residents were not 
reported to have shown any agitated behaviours in the preceding 2 weeks. 
Table 13. Number of residents (all, and those with clinically significant agitation) who 
had agitated behaviours, relating to CMAI factors, and divided by gender 
 All residents (n, %) Residents with clinically significant 
agitation (n, %) 
 
CMAI factor 
Baseline 4-month 12-month Baseline 4-month 12-month 
Aggressive 
Females 
Males 
855 (60.0) 
564 (57.3) 
291 (66.1) 
714 (58.8) 
472 (55.6) 
242 (66.1) 
513 (59.9) 
351 (57.4) 
162 (66.4) 
528 (37.1) 
342 (34.7) 
184 (41.8) 
438 (36.0) 
298 (35.1) 
140 (38.3) 
304 (35.5) 
205 (33.5) 
99 (40.6) 
Physically non- 
aggressive 
Females 
Males 
894 (62.7) 
 
608 (61.7) 
286(65.0) 
737 (60.7) 
 
501 (59.0) 
236 (64.5) 
488 (57.0) 
 
346 (56.5) 
142 (58.2) 
527 (37.0) 
 
349(35.4) 
176 (40.0) 
441 (36.3) 
 
304 (35.8) 
137 (37.4) 
295 (34.5) 
 
202 (33.0) 
93 (38.1) 
Verbally 
agitated 
Females 
Males 
857 (60.1) 
 
609 (61.8) 
248 (56.4) 
691 (56.9) 
 
503 (59.2) 
188 (51.4) 
473 (55.3) 
 
348 (56.8) 
125 (51.2) 
481 (33.8) 
 
324 (32.9) 
155 (35.2) 
385 (31.7) 
 
274 (32.3) 
111 (30.3) 
268 (31.3) 
 
190 (31.0) 
78 (32.0) 
Hiding/ 
hoarding 
Females 
Males 
233 (16.6) 
 
168 (17.1) 
65 (14.8) 
195 (16.0) 
 
136 (16.0) 
59 (16.1) 
119 (13.9) 
 
87 (14.2) 
32 (13.1) 
169 (11.9) 
 
117 (11.9) 
52 (11.8) 
132 (10.9) 
 
91 (10.7) 
41 (11.2) 
84 (9.8) 
 
58 (9.4) 
26 (10.7) 
 
Table 13 describes the prevalence of agitation related to each of the CMAI factors. 
There was a similar prevalence between aggressive, physically non-aggressive, and 
verbally agitated behaviours; hiding/hoarding was the least prevalent. For each 
factor and overall, agitation prevalence appeared to remain stable with a small 
decline over the three study visits. 
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Prevalence was similar when comparing genders but males were more agitated than 
females on each factor except verbally agitated behaviours. The biggest difference 
was seen for aggressive behaviours (males, 66.1% vs females, 57.3%). This pattern 
was consistent when including only those with clinically significant agitation.  
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 Results: Aims and objectives 
8.1 Primary aim and objective: analgesics 
8.1.1 Description of the prescription of analgesic medication 
At baseline, 968 (67.9%) residents were prescribed analgesics, and at the final study 
visit, analgesics were prescribed to 70.4% of residents. More residents were 
prescribed analgesics as PRN (46.9-50.5% across study visits) rather than regular 
(29.9-28.3%), and at each study visit, 38.0-42.2% of residents were prescribed 
analgesia PRN only. 
Paracetamol was the most widely used analgesic drug, prescribed to 56.7-59.4% 
residents and as such, the most commonly prescribed class of analgesics were simple 
non-opioids (paracetamol or nefopam), received by 63.3-65.2% of residents. More 
non-opioids were prescribed as PRN rather than regular prescriptions, with 43.8-
48.1% of residents receiving PRN prescriptions compared to 17.7-20.5% of residents 
with regular prescriptions. There was a low prevalence of NSAID prescribing in this 
cohort, with around 1% of residents prescribed these drugs at each study visit. 
Ibuprofen was the most commonly prescribed NSAID. 
Opioids were prescribed to 22.8-23.6% of residents. At baseline more residents were 
prescribed weak opioids compared to strong opioids (13.4% vs 11.4%) however at 
the 12-month study visit, strong opioids were more prevalent (12.4% vs 14.1%). 
Residents were more likely to be prescribed regular strong opioids than PRN (9.8% vs 
2.8%). More weak opioids were prescribed as PRN rather than regular (7.8% vs 5.7%). 
Overall, opioids were more likely to be prescribed regularly than PRN (14.3-15.8% vs 
10.3-10.7%). Approximately 2% of residents were prescribed both regular and PRN 
opioids. Table 14 describes the prescribing prevalence of analgesic drugs and classes 
at each study visit. 
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Table 14. Prescribing prevalence of analgesic drugs and classes at baseline (n=1425), 4-month study visit (n=1215) and 12-month study visit 
(n=856), by prescription schedule 
 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
Analgesics Baseline 967 (67.9%) 
[65.4-70.2] 
298 (20.9%) 
[18.9-23.1] 
542 (38.0%) 
[35.5-40.6] 
128 (9.0%) 
[7.6-10.6] 
na 
4-month 851 (70.0%) 
[67.4-72.6] 
232 (19.1%) 
[17.0-21.4) 
513 (42.2%) 
[39.5-45.0] 
100 (8.2%) 
[6.8-9.9] 
na 
12-month 604 (70.6%) 
[67.4-73.5] 
172 (20.1%) 
[17.5-22.9] 
361 (42.2%) 
[38.9-45.5] 
71 (8.3%) 
[6.6-10.3] 
na 
 Median (IQR) study visits that drug is prescribed: 3 (2, 3) (inc. withdrawn residents), 3 (2, 3) (exc. withdrawn residents) 
Simple non-opioids1 Baseline 902 (63.3) 
[60.8-65.8] 
277 (19.4) 
[17.4-21.6] 
609 (42.7) 
[40.2-45.3] 
16 (1.1) 
[0.7-1.8] 
na 
4-month 793 (65.3%) 
[62.5-67.9] 
196 (16.1%) 
[14.2-18.3] 
559 (46.0%) 
[43.2-48.8] 
20 (1.6%) 
[1.1-2.5] 
na 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
12-month 558 (65.2%) 
[61.9-68.3] 
146 (17.1%) 
[14.7-19.7] 
405 (47.3%) 
[44.0-50.7] 
7 (0.8%) 
[0.4-1.7] 
na 
 Median (IQR) study visits that drug is prescribed: 3 (2, 3) (inc. withdrawn residents), 3 (2, 3) (exc. withdrawn residents) 
Paracetamol 
 
Baseline 809 (56.7%) 
[54.2-59.3] 
237 (16.6%) 
[14.8-18.7] 
566 (39.7%) 
[37.2-42.3] 
6 (0.4%) 
[0.2-0.9] 
3430.01 (975.7) 
500-5000 
4-month 722 (59.4%) 
[56.6-62.2] 
178 (14.7%) 
[12.8-16.8] 
538 (44.3%) 
[41.5-47.1] 
6 (0.5%) 
[0.2-1.1] 
3624.01 (833.2) 
500-4000 
12-month 504 (58.9%) 
[55.5-62.1] 
122 (14.3%) 
[12.1-16.8] 
378 (44.2%) 
[40.9-47.5] 
4 (0.5%) 
[0.2-1.2] 
3483.31 (920.9) 
500-4000 
 Median (IQR) study visits that drug is prescribed: 3 (2, 3) (inc. withdrawn residents), 3 (2, 3) (exc. withdrawn residents) 
Nefopam 
 
Baseline 4 (0.3%) 
[0.1-0.7] 
3 (0.2%) 
[0.1-0.7] 
1 (0.1%) 
[0.0-0.5] 
0 (0%) 
 
90.0 (0) 
 
4-month 2 (0.2%) 
[0.0-0.6] 
2 (0.2%) 
[0.0-0.6] 
0 (0%) 
 
0 (0%) 
 
135 (63.6) 
90-180 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
12-month 0 (0%) 0 (0%) 0 (0%) 0 (0%) na 
 Median (IQR) study visits that drug is prescribed: 2 (1.5, 2.5) (inc. withdrawn residents), 1.5 (1, 2) (exc. withdrawn residents) 
Opioids Baseline 332 (23.3%) 
[21.2-25.6] 
185 (13.0%) 
[11.3-14.8] 
121 (8.5%) 
[7.1-10.1] 
26 (1.8%) 
[1.2-2.7] 
7.52 (6.8) 
0-27 
4-month 277 (22.8%) 
[20.5-25.2] 
147 (12.1%) 
[10.4-14.1] 
103 (8.5%) 
[7.0-10.2] 
27 (2.2%) 
[1.5-3.2] 
7.02 (6.0) 
0-25 
12-month 202 (23.6%) 
[20.9-26.6] 
111 (13.0%) 
[10.9-15.4] 
67 (7.8%) 
[6.2-9.8] 
24 (2.8%) 
[1.9-4.2] 
9.12 (7.7) 
0-46 
 Median (IQR) study visits that drug is prescribed: 2 (1, 3) (inc. withdrawn residents), 2 (1, 3) (exc. withdrawn residents) 
Weak opioids1 Baseline 191 (13.4%) 
[11.7-15.3] 
80 (5.6%) 
[4.5-6.9] 
110 (7.7%) 
[6.4-9.2] 
1 (0.1%) 
[0.0-0.4] 
na 
4-month 153 (12.6%) 
[10.8-14.6] 
55 (4.5%) 
[3.5-5.9] 
97 (8.0%) 
[6.6-9.6] 
1 (0.1%) 
[0.0-0.6] 
na 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
12-month 106 (12.4%) 
[10.3-14.8] 
43 (5.0%) 
[3.7-6.7] 
62 (7.2%) 
[5.7-9.2] 
1 (0.1%) 
[0.0-0.8] 
na 
 Median (IQR) study visits that drug is prescribed: 3 (1, 3) (inc. withdrawn residents), 3 (1, 3) (exc. withdrawn residents) 
Codeine Baseline 77 (5.4%) 
[4.3-6.7] 
28 (2.0%) 
[1.4-2.8] 
49 (3.4%) 
[2.6-4.5] 
0 (0%) 
 
108.31 (75.1) 
15-480 
4-month 64 (5.3%) 
[4.1-6.7] 
24 (2.0%) 
[1.3-2.9] 
40 (3.3%) 
[2.4-4.5] 
0 (0%) 
 
100.81 (58.8) 
15-240 
12-month 40 (4.7%) 
[3.4-6.3] 
12 (1.4%) 
[0.8-2.5] 
27 (3.2%) 
[2.2-4.6] 
1 (0.1%) 
[0.0-0.6] 
101.91 (67.0) 
15-360 
 Median (IQR) study visits that drug is prescribed: 3 (1, 3) (inc. withdrawn residents), 2.8 (1, 3) (exc. withdrawn residents) 
Dihydrocodeine Baseline 7 (0.5%) 
[0.2-1.0] 
4 (0.3%) 
[0.1-0.7] 
3 (0.2%) 
[0.1-0.7] 
0 (0%) 
 
137.11 (45.4) 
120-240 
4-month 4 (0.3%) 
[0.1-0.8] 
1 (0.1%) 
[0.0-0.5] 
3 (0.2%) 
[0.1-0.7] 
0 (0%) 
 
901 (52.0) 
30-120 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
12-month 2 (0.2%) 
[0.1-0.9] 
1 (0.1%) 
[0.0-0.6] 
1 (0.1%) 
[0.0-0.6] 
0 (0%) 1801 (84.9) 
120-240 
 Median (IQR) study visits that drug is prescribed: 2 (1, 3) (inc. withdrawn residents), 2 (1, 3) (exc. withdrawn residents) 
Meptazinol Baseline 1 (0.1%) 
[0.0-0.5] 
0 (0%) 
 
1 (0.1%) 
[0.0-0.5] 
0 (0%) 
 
200 (0.0) 
4-month 0 (0%) 0 (0%) 0 (0%) 0 (0%) na 
12-month 0 (0%) 0 (0%) 0 (0%) 0 (0%) na 
 Median (IQR) study visits that drug is prescribed: 2 (N/A) (inc. withdrawn residents), 2 (N/A) (exc. withdrawn residents) 
Strong opioids Baseline 163 (11.4%) 
[9.9-13.2] 
125 (8.8%) 
[7.4-10.4] 
24 (1.7%) 
[1.1-2.5] 
14 (1.0%) 
[0.6-1.7] 
na 
4-month 147 (12.1%) 
[10.4-14.1] 
113 (9.3%) 
[7.8-11.1] 
23 (1.9%) 
[1.3-2.8] 
11 (0.9%) 
[0.5-1.6] 
na 
12-month 121 (14.1%) 88 (10.3%) 22 (2.6%) 11 (1.3%) na 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
[12.0-16.6] [8.4-12.5] [1.7-3.9] [0.7-2.3] 
 Median (IQR) study visits that drug is prescribed: 2 (1, 3) (inc. withdrawn residents), 2 (1, 3) (exc. withdrawn residents) 
Buprenorphine Baseline 100 (7.0%) 
[5.8-8.5] 
99 (6.9%) 
[5.7-8.4] 
1 (0.1%) 
[0.0-0.5] 
0 (0%) 
 
21.7 (19.9) 
12-1682 
4-month 93 (7.7%) 
[6.3-9.1] 
89 (7.3%) 
[6.0-8.9] 
4 (0.3%) 
[0.1-0.9] 
0 (0%) 
 
20.7 (19.3) 
12-1682 
12-month 71 (8.3%) 
[6.6-10.3] 
71 (8.3%) 
[6.6-10.3] 
0 (0%) 
 
0 (0%) 
 
21.9 (20.0) 
12-1682 
 Median (IQR) study visits that drug is prescribed: 1.5 (1, 2) (inc. withdrawn residents), 2 (1, 3) (exc. withdrawn residents) 
Diamorphine Baseline 7 (0.5%) 
[0.2-1.0] 
0 (0%) 
 
7 (0.5%) 
[0.2-1.0] 
0 (0%) 
 
25.0 (7.1) 
20-30 
4-month 8 (0.7%) 
[0.3-1.3] 
2 (0.2%) 
[0.0-0.8] 
6 (0.7%) 
[0.3-1.5] 
0 (0%) 
 
30.0 (0.0) 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
12-month 7 (0.8%) 
[0.4-1.7] 
1 (0.1%) 
[0.0-0.6] 
6 (0.7%) 
[0.3-1.5] 
0 (0%) 
 
30.0 (15.5) 
20-60 
 Median (IQR) study visits that drug is prescribed: 3 (1, 3) (inc. withdrawn residents), 2 (1, 3) (exc. withdrawn residents) 
Fentanyl Baseline 24 (1.7%) 
[1.1-2.5] 
22 (1.5%) 
[1.0-2.3] 
2 (0.1%) 
[0.0-0.6] 
0 (0%) 21.2 (19.2) 
4-79 
4-month 25 (2.1%) 
[1.4-3.0] 
25 (2.1%) 
[1.4-3.0] 
0 (0%) 0 (0%) 9.2 (5.9) 
4-24 
12-month 21 (2.5%) 
[1.6-3.7] 
21 (2.5%) 
[1.6-3.7] 
0 (0%) 0 (0%) 12.3 (8.1) 
4-33 
 Median (IQR) study visits that drug is prescribed: 2 (2, 3) (inc. withdrawn residents), 2 (2, 3) (exc. withdrawn residents) 
Morphine Baseline 32 (2.2) 
[1.6-3.2] 
10 (0.7) 
[0.4-1.3] 
22 (1.5%) 
[1.0-2.3] 
0 (0%) 39.81 (61.1) 
5-240 
4-month 21 (1.7%) 
[1.1-2.6] 
3 (0.2%) 
[0.1-0.8] 
15 (1.2%) 
[0.7-2.0] 
3 (0.2%) 
[0.1-0.8] 
48.61 (58.1) 
10-240 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
12-month 25 (2.9%) 
[2.0-4.3] 
5 (0.6%) 
[0.2-1.4] 
19 (2.2%) 
[1.4-3.5] 
1 (0.1%) 
[0.0-0.6] 
48.0 (51.2) 
10-200 
 Median (IQR) study visits that drug is prescribed: 3 (1, 3) (inc. withdrawn residents), 3 (1, 3) (exc. withdrawn residents) 
Oxycodone Baseline 6 (0.4) 
[0.2-0.9] 
2 (0.1%) 
[0.0-0.6] 
3 (0.2%) 
[0.1-0.7] 
1 (0.1%) 
[0.0-0.5] 
31 (24.3) 
4-60 
4-month 5 (0.4%) 
[0.2-1.0] 
2 (0.2%) 
[0.0-0.7] 
3 (0.2%) 
[0.1-0.8] 
0 (0%) 28.8 (21.0) 
15-60 
12-month 4 (0.5%) 
[0.2-1.2] 
3 (0.4%) 
[0.1-1.1] 
1 (0.1%) 
[0.0-0.6] 
0 (0%) 33.5 (21.5) 
10-60 
 Median (IQR) study visits that drug is prescribed: 3 (2, 3) (inc. withdrawn residents), 3 (1, 3) (exc. withdrawn residents) 
Tramadol Baseline 13 (0.9) 
[0.5-1.6] 
10 (0.7) 
[0.4-1.3] 
2 (0.1%) 
[0.0-0.6] 
1 (0.1%) 
[0.0-0.5] 
219.3 (117.8) 
100-400 
4-month 8 (0.7%) 
[0.3-1.3] 
4 (0.3%) 
[0.1-0.9] 
4 (0.3%) 
[0.1-0.9] 
0 (0%) 243.8 (134.8) 
100-400 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
12-month 7 (0.8%) 
[0.4-1.7] 
1 (0.1%) 
[0.0-0.6] 
6 (0.7%) 
[0.3-1.4] 
0 (0%) 233.3 (136.6) 
100-400 
 Median (IQR) study visits that drug is prescribed: 1 (1, 2) (inc. withdrawn residents), 2 (1, 3) (exc. withdrawn residents) 
Compound 
analgesics 
Baseline 108 (7.6) 
[6.3-9.1] 
49 (3.4) 
[2.6-4.5] 
58 (4.1) 
[3.2-5.2] 
1 (0.1) 
[0.0-0.4] 
na 
4-month 86 (7.1%) 
[5.8-8.7] 
31 (2.6%) 
[1.8-3.6] 
64 (5.3%) 
[4.1-6.7] 
0 (0%) na 
12-month 64 (7.5%) 
[5.9-9.4] 
30 (3.5%) 
[2.5-5.0] 
34 (4.0%) 
[2.8-5.5] 
0 (0%) na 
 Median (IQR) study visits that drug is prescribed: 3 (1, 3) (inc. withdrawn residents), 3 (1, 3) (exc. withdrawn residents) 
Co-codamol 
 
 
Baseline 
 
86 (6.0) 
[4.9-7.4] 
 
37 (2.6) 
[1.8-3.6] 
 
48 (3.4) 
[2.5-4.4] 
 
0 (0%) 
Paracetamol + codeine 
2613.3 + 87.8  
(1478.6) + (69.9) 
500-4000 + 16-24 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
4-month 71 (5.8%) 
[4.7-7.3] 
24 (2.0%) 
[1.3-2.9] 
47 (3.9%) 
[2.9-5.1] 
0 (0%) 2608.3 + 85.9 
(1476.1) + (64.9) 
500-1000 + 16-240 
12-month 55 (6.4%) 
[5.0-8.3] 
24 (2.8%) 
[1.9-4.2] 
31 (3.6%) 
[2.6-5.1] 
0 (0%) 2659.6 + 86.8 
(1496.8) + (73.6) 
500-4000 + 8-240 
 Median (IQR) study visits that drug is prescribed: 3 (1, 3) (inc. withdrawn residents), 3 (1, 3) (exc. withdrawn residents) 
Co-dydramol 
 
 
Baseline 
 
22 (1.5) 
[1.0-2.3] 
 
12 (0.8) 
[0.4-1.5] 
 
0 (0%) 
 
0 (0%) 
Paracetamol + dihydrocodeine 
3026.3 + 60.6 
(1060.3) + (21.8) 
1000-4000 + 20-80 
4-month 16 (1.3%) 
[0.8-2.1] 
7 (0.6%) 
[0.2-1.2] 
9 (0.7%) 
[0.3-1.4] 
0 (0%) 3033.3 + 62.3 
(1342.5) + (28.3) 
500-4000 + 10-80 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
12-month 9 (1.1%) 
0.5-2.0] 
6 (0.7%) 
[0.3-1.6] 
1 (0.1%) 
[0.0-0.6] 
0 (0%) 3111.1 + 62.5 
(928.0) + (19.8) 
2000-4000 + 40-80 
 Median (IQR) study visits that drug is prescribed: 2.5 (1, 3) (inc. withdrawn residents), 2.5 (1, 3) (exc. withdrawn residents) 
NSAIDs Baseline 15 (1.1) 
[0.7-1.8] 
10 (0.7) 
[0.4-1.3] 
5 (0.4) 
[0.1-0.8] 
0 (0.0) 
[0.0-0.0] 
na 
4-month 16 (1.3%) 
[0.8-2.1] 
11 (0.9%) 
[0.5-1.6] 
5 (0.4%) 
[0.2-1.0] 
0 (0%) na 
12-month 5 (0.6%) 
[0.2-1.4] 
5 (0.6%) 
[0.2-1.4] 
0 (0%) 0 (0%) na 
 Median (IQR) study visits that drug is prescribed: 1.5 (1, 3) (inc. withdrawn residents), 1 (1, 3) (exc. withdrawn residents) 
Aspirin (>75mg) Baseline 2 (0.1%) 
[0.0-0.6] 
2 (0.1%) 
[0.0-0.6] 
0 (0%) 0 (0%) 300 (0.0) 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
4-month 4 (0.3%) 
[0.1-0.9] 
4 (0.3%) 
[0.1-0.9] 
0 (0%) 0 (0%) 262.5 (75.0) 
150-300 
12-month 0 (0%) 0 (0%) 0 (0%) 0 (0%) na 
 Median (IQR) study visits that drug is prescribed: 1 (1, 2) (inc. withdrawn residents), 1 (1, 1) (exc. withdrawn residents) 
Ibuprofen Baseline 7 (0.5) 
[0.2-1.0] 
3 (0.2) 
[0.0-0.6] 
4 (0.3) 
[0.1-0.7] 
0 (0%) 885.7 (397.6) 
400-1200 
4-month 5 (0.4%) 
[0.1-1.0] 
2 (0.2%) 
[0.0-0.7] 
3 (0.2) 
[0.0-0.6] 
0 (0%) 940.0 (527.3) 
200-1500 
12-month 1 (0.1%) 
[0.0-0.8] 
1 (0.1%) 
[0.0-0.8] 
0 (0%) 0 (0%) 1200 (0.0) 
 Median (IQR) study visits that drug is prescribed: 1 (1, 3) (inc. withdrawn residents), 1 (1, 1) (exc. withdrawn residents) 
Meloxicam Baseline 2 (0.1%) 
[0.0-0.6] 
1 (0.1%) 
[0.0-0.5] 
1 (0.1%) 
[0.0-0.5] 
0 (0%) 15 (0.0) 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
4-month 1 (0.1%) 
[0.0-0.5] 
1 (0.1%) 
[0.0-0.5] 
0 (0%) 0 (0%) 15 (0.0) 
12-month 0 (0%) 0 (0%) 0 (0%) 0 (0%) na 
 Median (IQR) study visits that drug is prescribed: 2.5 (2, 3) (inc. withdrawn residents), 2.5 (2, 3) (exc. withdrawn residents) 
Naproxen Baseline 4 (0.3) 
[0.1-0.7] 
4 (0.3) 
[0.1-0.7] 
0 (0%) 0 (0%) 1187.5 (746.5) 
500-2250 
4-month 6 (0.5%) 
[0.1-1.1] 
4 (0.3%) 
[0.1-0.9] 
2 (0.1%) 
[0.0-0.6] 
0 (0%) 708.3 (245.8) 
500-1000 
12-month 4 (0.5%) 
[0.2-1.2] 
4 (0.5%) 
[0.2-1.2] 
0 (0%) 0 (0%) 583.3 (144.3) 
500-750 
 Median (IQR) study visits that drug is prescribed: 3 (2, 3) (inc. withdrawn residents), 3 (2, 3) (exc. withdrawn residents) 
1including compound analgesics  
2 Oral morphine equivalent 
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Table 14 identified several prescriptions that warranted further investigation. For 
example, some residents were prescribed both regular and PRN paracetamol. On 
closer inspection it was found that most residents had two concurrent prescriptions, 
for example a resident who was prescribed PRN paracetamol then received a 
prescription for regular paracetamol and the initial PRN prescription was ceased. A 
common prescribing error identified was that regular strong opioid prescriptions 
were not accompanied by PRN prescriptions (in case of breakthrough pain). There 
were also cases of residents with both regular and PRN opioid prescriptions, for 
example Tramadol and compound analgesics, and in these cases the regular 
prescription was for a dose lower than the BNF recommended maximum daily dose 
(Joint Formulary Committee, 2016).  
Analgesics and analgesic classes were typically prescribed for at least two study visits. 
The exception to this was NSAIDs, with a median prescription duration of one study 
visit (IQR 1, 3) (excluding those who had withdrawn from the study). 
8.1.1.1 WHO Ladder 
The WHO ladder (World Health Organization, 2015) corresponds to the level of 
analgesia prescribed. Step 1 is non-opioids or NSAIDs only, step 2 is weak opioids (+/- 
non-opioids or NSAIDs), and step 3 is strong opioids (+/- non-opioids or NSAIDs). 
Figure 9 shows the percentage of residents at each study visit who were prescribed 
analgesics, corresponding to the WHO ladder. The highest proportion of residents 
(44.6-47.2%) received step 1 analgesics. At baseline, slightly more residents were 
prescribed step 2 analgesics (11.9%) than step 3 (11.4%) but at 4- and 12-months, 
there are more residents prescribed step 3 analgesics (12.1% and 14.0%, 
respectively) than those on step 2 (10.7% and 9.4%). 
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Figure 9. Percentage of residents at each study visit prescribed analgesics according 
to WHO analgesic ladder  
 
Figure 10 shows the WHO ladder, but only includes residents who survived (or did 
not withdraw) until the 12-month study visit, thus eliminating attrition bias. The 
highest proportion of residents (43.7-53.0%) received step 1 analgesics. Overall 
prescribing prevalence does not differ largely between the whole cohort and the 
surviving cohort. Similar to above, at baseline, slightly more residents were 
prescribed step 2 analgesics (12.0%) than step 3 (10.0%) but at 4- and 12-months, 
there was a more marked difference in the surviving cohort, and more residents were 
prescribed step 3 analgesics (11.0% and 14.1%, respectively) than those on step 2 
(4.4% and 3.5%). 
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Figure 10. Percentage of residents at each study visit prescribed analgesics according 
to WHO analgesic ladder, excluding withdrawn residents 
8.1.2 Description of the administration of analgesic medication 
At baseline, there were 641 residents (44.9%) with 14 days’ worth of PRN prescription 
data. At 4-months, there were data for 587 residents (48.3%) and at 12-months there 
were data for 390 residents (45.6%). 
Figure 11 shows the percentage of pain relief, of the total amount prescribed, that 
was administered to the residents. Many residents did not receive any of their 
potential PRN analgesia: at baseline 32.8% of residents who were prescribed PRN 
analgesics were not administered any; at 4-months, 55.2%; at 12-months, 55.9%. 
Looking at all study visits, 41.9% residents did not receive any analgesic medication 
during the three two-week periods of data collection. One resident was prescribed 
500mg of paracetamol once daily, but (during the three study visits) was 
administered 2.5 times (250%) the dose prescribed. 
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Figure 11. Frequency graph of number of residents prescribed PRN analgesics and the 
mean percentage (across all study visits) of potential analgesic doses administered 
(range 0%-250%) 
8.1.2.1 Simple non-opioids 
At all study visits, the only non-opioid drug with 14 days’ worth of PRN records was 
paracetamol. At baseline, there were 500 residents with 14 days’ worth of PRN dose 
records for paracetamol.  
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Figure 12. Flow diagram of number of residents prescribed, offered, and 
administered PRN paracetamol at baseline, plus median (and interquartile range) of 
doses offered and received  
Figure 12 describes how many residents were offered and administered paracetamol, 
and the median number of doses offered and administered. For those residents who 
were not prescribed another type of analgesic (i.e. regular non-opioid, or regular or 
PRN opioid; N=302) 43.6% were offered paracetamol and 19.6% were administered 
paracetamol. In the previous 14 days: 157 (31.4%) residents were not offered any 
PRN paracetamol and 204 (40.8%) residents were not administered any PRN 
paracetamol.  
At 4-months (see Figure 13, below), there were 466 residents with 14 days’ worth of 
PRN dose records for paracetamol. In the previous 14 days: 127 (27.3%) residents 
were not offered any PRN paracetamol and 217 (46.6%) residents were not 
administered any PRN paracetamol. At 12-months, (Figure 14), 72 (23.4%) residents 
were not offered any PRN paracetamol and 142 (46.1%) residents were not 
administered any PRN paracetamol. 
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Figure 13. Flow diagram of number of residents prescribed, offered, and 
administered PRN paracetamol at 4-month study visit, plus median (and interquartile 
range) of doses offered and received 
 
 
Figure 14. Flow diagram of number of residents prescribed, offered, and 
administered PRN paracetamol at 12-month study visit, plus median (and 
interquartile range) of doses offered and received 
Looking at all three study visits, the mean number of residents who were offered 
paracetamol at least once was 72.6% and the mean percentage of residents who 
were given paracetamol at least once was 55.5%.  
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8.1.2.2 Weak opioids 
At baseline, there were 77 residents with 14 days’ worth of PRN dose records for 
weak opioids. In the previous 14 days: 46 (59.7%) residents were not offered any PRN 
weak opioids and 51 (72.7%) residents were not administered any PRN weak opioids. 
See Figure 15 for details. For residents whose only prescribed analgesic was a weak 
opioid (n=31), the median number of days that it was administered was 9 (IQR, 1, 12). 
 
Figure 15. Flow diagram of number of residents prescribed, offered, and 
administered PRN weak opioids at baseline, plus median (and interquartile range) of 
doses offered and received 
 
At 4-months, there were 69 residents with 14 days’ worth of PRN dose records for 
weak opioids. In the previous 14 days: 19 (27.5%) residents were not offered any PRN 
weak opioids and 28 (40.6%) residents were not administered any PRN weak opioids 
(see Figure 16). The median number of days that weak opioids were administered 
was 2 (IQR, 0, 11). For residents whose only prescribed analgesic was a weak opioid 
(n=31), the median number of days that it was administered was 0 (IQR, 0, 9). 
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Figure 16. Flow diagram of number of residents prescribed, offered, and 
administered PRN weak opioids at 4-month study visit, plus median (and interquartile 
range) of doses offered and received 
At 12-months, there were 40 residents with 14 days’ worth of PRN dose records for 
weak opioids. In the previous 14 days: 4 (10.0%) residents were not offered any PRN 
weak opioids and 13 (32.5%) residents were not administered any PRN weak opioids. 
See Figure 17 for details. 
 
Figure 17. Flow diagram of number of residents prescribed, offered, and 
administered PRN weak opioids at 12-month study visit, plus median (and 
interquartile range) of doses offered and received 
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The median number of days that weak opioids were administered in the previous 2 
weeks was 2 (IQR, 0, 13). For residents whose only prescribed analgesic was a weak 
opioid (n=20), the median number of days that it was administered was 1 (IQR, 0, 14). 
Across all three study visits, the mean number of residents who were offered a weak 
opioid at least once was 67.5% and the mean percentage of residents who were given 
a weak opioid at least once was 52.3%.  
8.1.2.3 Strong opioids 
At baseline there were 20 residents with 14 days’ worth of PRN dose records for 
strong opioids. In the previous 14 days: 12 (60.0%) residents were not offered any 
PRN strong opioids and 14 (70.0%) were not administered any (see Figure 18). At all 
study visits, there were no residents who were only prescribed PRN strong opioids. 
 
Figure 18. Flow diagram of number of residents prescribed, offered, and 
administered PRN strong opioids at baseline, plus median (and interquartile range) 
of doses offered and received 
At 4-months there were 18 residents with 14 days’ worth of PRN dose records. In the 
previous 14 days: 6 (33.3%) residents were not offered and 8 (44.4%) were not 
administered any PRN strong opioids (see Figure 19).  
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Figure 19. Flow diagram of number of residents prescribed, offered, and 
administered PRN strong opioids at 4-month study visit, plus median (and 
interquartile range) of doses offered and received 
At 12-months there were 17 residents with 14 days’ worth of PRN dose records. In 
the previous 14 days: 9 (52.9%) residents were not offered and 14 (82.4%) were not 
administered any PRN strong opioids (Figure 20 below). 
At all study visits, there were no residents who were only prescribed PRN strong 
opioids. Looking at all three study visits, the mean number of residents who were 
offered a strong opioid at least once was 51.3% and the mean percentage of residents 
who were given a strong opioid at least once was 34.4%.  
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Figure 20. Flow diagram of number of residents prescribed, offered, and 
administered PRN strong opioids at 12-month study visit, plus median (and 
interquartile range) of doses offered and received 
8.1.3 Key results from analgesic prescription and administration data, including 
care home factors 
These data show that the majority of care home residents in this sample were 
prescribed analgesics but this was mostly prescribed as PRN. More detailed study 
illustrates that many residents did not receive their prescribed PRN analgesics in the 
previous two weeks of each study visit, and in comparison to the total number of 
analgesic doses available, very little was given. Across all study visits, 41.9% residents 
did not receive any analgesic medication during the three 2-week periods of data 
collection.  
Paracetamol was the most commonly prescribed analgesic. Prescriptions of weak and 
strong opioids were even at baseline, and at the 4-month and 12-month visits, strong 
opioids were prescribed more frequently than weak opioids. A common prescribing 
error was that regular strong opioids were not accompanied by a prescription of PRN 
strong opioids (in case of breakthrough pain).  
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8.2 Secondary aims and objectives: analgesics 
8.2.1 The effects of care home factors on analgesic use 
8.2.1.1 Analgesic prescriptions  
Before running a clustered regression model exploring the association between care 
home factors and analgesic prescriptions, univariable analyses were conducted (also 
clustered at care home level) of potential predictor variables (age, gender, dementia 
diagnosis and severity, agitation, ethnicity, and first language) (Jensen-Dahm et al., 
2015, Sandvik et al., 2016, Kung et al., 1999, Horgas and Tsai, 1998, Closs et al., 2004). 
A mixed-effect univariate logistic regression analysis was run to explore the 
association between each potential predictor variable and whether or not the 
resident was prescribed an analgesic at baseline. The model accounted for clustering 
at the level of the care home. Table 15 displays the results of the analysis. 
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Table 15. Univariable analysis prior to investigation of the effect of care home factors 
on analgesic prescription 
 Regression coefficient (Coef.)  95% conf. intervals 
Age 0.00 -0.00, 0.01 
Baseline CDR 
Mild 
Moderate 
Severe 
 
Ref 
0.01 
0.67 
 
Ref 
-0.07, 0.08 
0.61, 0.74 
CMAI total 0.00 -0.00, 0.00 
 Chi-squared P value 
Gender 0.83 0.36 
Ethnicity (White or non-White) 0.35 0.55 
English as first language 0.59 0.96 
Dementia diagnosis 0.86 0.35 
Clinically significant CMAI 0.27 0.60 
 
The preliminary analysis identified dementia severity as a potential confounder 
(p<0.05): residents with severe dementia received more analgesic prescriptions than 
those with mild dementia. Thus dementia severity was included in the final model 
exploring care home factors as predictors of analgesic prescriptions (see Table 16).  
  
 113 
Table 16. Results of multi-level model exploring effect of care home factors on 
whether or not a resident received a prescription of analgesic medication 
 Odds ratio  95% conf. intervals 
Nursing home 1.23 -0.74, 2.04 
Ownership 
Private 
Charity 
Council/local authority 
 
Ref 
0.88 
2.27 
 
Ref 
0.47, 1.67 
0.58, 8.94 
Dementia registered 0.91 0.36, 2.35 
Dementia specialist 0.69 0.41, 1.16 
Number of beds 1.00 0.99, 1.02 
CQC rating 
Outstanding 
Good 
Requires improvement 
Inadequate 
 
Ref 
0.39 
0.26 
1.06 
 
Ref 
0.14, 1.05 
0.09, 0.92 
0.13, 7.89 
 
The only care home factor that significantly contributed to whether or not a resident 
was prescribed analgesics (at baseline) was if the care home was rated as ‘requires 
improvement’ by the CQC. The coefficient indicates that residents from these homes 
were 1.2 times less likely to receive a prescription for analgesics compared to 
residents in a home rated ‘outstanding’. It is worth noting that there are sizeable 
group differences in CQC ratings, with 69.4% of care homes in the sample rated as 
‘good’. It did not appear to make a difference if the care home was a nursing home 
or residential home, whether it was owned by a charity, council/local authority or 
private owner, whether it was dementia-registered or dementia specialist, or number 
of beds.  
To further explore the reasons why the majority of care home factors did not appear 
to influence analgesic prescribing, post-hoc tests of heterogeneity were run. A forest 
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plot identified that there was no difference between care homes and analgesic 
prescribing (I2=0.0%). The homogeneity in the sample explains why no differences 
were highlighted in the regression models. 
8.2.1.2 Analgesic administration 
As before, univariable analyses were conducted to identify clinically relevant 
potential covariates before running a multi-level regression model. The dependent 
variable was whether or not the resident was administered a PRN analgesic at 
baseline. 
Table 17. Univariable analyses of demographic and individual factors to identify 
potential confounders regarding baseline analgesic administration 
 Coef.  95% conf. intervals 
Age -0.01 -0.01, -0.00 
Baseline CDR 
Mild 
Moderate 
Severe 
 
Ref 
-0.07 
-0.13 
 
Ref 
-0.19, 0.06 
-0.26, -0.00 
CMAI total 0.00 -0.00, 0.00 
 Chi-squared p-value 
Gender 0.42 0.52 
Ethnicity (White or non-White) 4.90 0.03 
English as first language 3.31 0.07 
Dementia diagnosis 0.41 0.52 
Clinically significant CMAI 0.37 0.54 
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Univariable analyses (clustered at care home level) identified these baseline 
demographic variables as potential confounders (see Table 17):  
 age (older residents were administered fewer PRN analgesics) 
 dementia severity (those with severe dementia were administered fewer 
PRN analgesics) 
 ethnicity (non-White residents were administered more PRN analgesics) 
These variables were therefore included in the final model exploring the effects of 
care home factors on baseline analgesic administration (as a binary variable). 
Table 18. Multi-level regression model exploring the effect of care home factors on 
PRN analgesic administration at baseline 
 Odds ratio  95% conf. intervals 
Nursing home 0.86 0.36, 1.94 
Ownership 
Private 
Charity 
Council/local authority 
 
Ref 
1.46 
2.46 
 
Ref 
0.53, 4.05 
0.36, 16.75 
Dementia registered 0.74 0.15. 3.61 
Dementia specialist 0.70 0.32, 1.53 
Number of beds 1.00 0.98, 1.01 
CQC rating 
Outstanding 
Good 
Requires improvement 
Inadequate 
 
Ref 
1.06 
0.86 
2.80 
 
Ref 
0.30, 3.70 
0.19, 3.86 
0.10, 79.7 
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Table 18 shows that no care home factors (care provision; ownership; dementia 
registered; dementia specialist; number of beds; overall CQC rating) were significant; 
that is, there was no difference in analgesic administration when comparing different 
types of care homes. 
As before, post-hoc tests were run to explore whether the lack of effect of care home 
factors could be attributed to homogeneity between care homes. A forest plot 
showed that there was heterogeneity between all care homes, I2=56.7% (over 50% 
indicates that the difference may be caused by something other than chance), but 
these differences were not associated with the factors identified above. For example, 
by comparing the groups above it was found that there was heterogeneity between: 
care provision (nursing home, I2=56.3%, residential homes, I2=55.3%); ownership 
(private, I2=52.6%, charity, I2=70.4%, council/local authority n too low); CQC rating (I2 
ranged from 44.8%-82.1%), and dementia-registered and dementia-specialist tests 
returned I2 values>50%. This indicated that the differences between care homes 
cannot be defined by typical methods of classifying care homes but there were other 
factors involved.  
8.2.2 Differences in analgesic prescribing between groups 
Prior to investigating group differences in analgesic use, a sensitivity analysis was run 
that showed that age was the only demographic variable that significantly 
contributed to missingness resulting from death at any study visit (coef. = 0.01, 95% 
confidence interval (CI) = 0.01, 0.01, p<0.001). Therefore, where appropriate, age was 
included as a covariate in the final model. 
8.2.2.1 Do females receive more analgesics than males? 
Using a logistic regression clustered at the care home and study visit level, it was 
found that females received significantly more analgesic prescriptions than males 
(p=0.011), odds ratio (OR) = 1.27, therefore females were 27% more likely to be 
prescribed an analgesic compared to males. Females also received more 
prescriptions for regular analgesics compared to males (p=0.003, OR 1.33). There was 
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no difference in PRN prescriptions, nor a gender difference when considering PRN 
administration. 
Females received significantly more prescriptions for opioid drugs than males (OR 
1.39), including regular opioids (OR 1.67) so were 67% more likely to be prescribed a 
regular opioid. Females did not receive more PRN opioids than males. Table 19 
displays the results of the regression analyses. 
8.2.2.2 Is there an age difference in analgesic prescribing and administration, and 
do residents aged 81 years plus receive more analgesics than younger 
residents, aged 65-80 years? 
There were no age differences in analgesic prescriptions (see Table 19) however 
there was a difference in analgesic administration (p=0.004). In this sample, for every 
year increase in age, the probability that a PRN analgesic was administered in the 
previous 2 weeks decreased by 0.04.  
When analysing age group (65-80 years vs 81 years and over) age was not included 
as a covariate in the model, to avoid collinearity with the independent variable. Using 
a multi-level logistic regression, there was no significant difference in analgesic 
prescription (overall, regular, or PRN), or analgesic administration, when comparing 
residents aged 65-80 and residents aged 81 and above.  
Looking at analgesic classes, residents aged 81 years and over were prescribed 
significantly fewer regular non-opioids (OR 0.77) and less PRN opioids than younger 
residents (OR 0.76) (see Table 19). To investigate whether the significant association 
of age and analgesic administration was related to dementia severity or gender, a 
post-hoc test was run (controlling for CDR and gender). Coef. = -0.04 (95% CI, -0.07, -
0.01); thus age was independently associated with less administration of PRN 
analgesia. 
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8.2.2.3 Are residents with more severe dementia prescribed less analgesic 
medication than those with mild dementia? 
Residents with moderate or severe dementia were not prescribed fewer analgesics 
than residents with mild dementia. This also applied to regular and PRN analgesics. 
There was also no difference in prescribing prevalence when looking at non-opioids 
and opioids overall, but residents with severe dementia were 47% more likely to be 
prescribed regular opioids than residents with mild dementia (OR 1.47). See Table 20 
for details. 
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Table 19. Gender differences and age differences in prescriptions of analgesics and 
classes 
 Gender (OR) 
(reference = female) 
Age  Age group (OR) 
(reference = 65-80 
years) 
Analgesics (Odds ratio [OR]/Coef. (95% conf. intervals)) 
Prescribed  1.27 (1.06, 1.53) 0.00 (-0.01, 0.01) 0.92 (0.76, 1.12) 
Prescribed regular 1.33 (1.10, 1.60) -0.01 (-0.02, 0.00) 0.84 (0.69, 1.01) 
Prescribed PRN 1.09 (0.92, 1.31) 0.00 (-0.00, 0.01) 0.98 (0.82, 1.18) 
Administered PRN 0.82 (0.49, 1.37) -0.04 (-0.07, -0.01) 0.59 (0.33, 1.06) 
Non-opioids 
Prescribed  1.19 (0.99, 1.42) 0.00 (-0.01, 0.01) 0.87 (0.73, 1.06) 
Prescribed regular 1.20 (0.96, 1.49) -0.01 (-0.02, 0.00) 0.77 (0.62, 0.96) 
Prescribed PRN 1.08 (0.91, 1.29) 0.01 (-0.00, 0.02) 1.06 (0.88, 1.28) 
Opioids 
Prescribed 1.39 (1.14, 1.71) 0.00 (-0.01, 0.01) 0.96 (0.79, 1.18) 
Prescribed regular 1.67 (1.31, 2.15) 0.01 (-0.00, 0.02) 1.19 (0.92, 1.52) 
Prescribed PRN 1.09 (0.84, 1.42) -0.01 (-0.02, 0.01) 0.76 (0.59, 0.99) 
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Table 20. Relationship between dementia severity and analgesic use 
 Dementia severity (mild as reference) 
 Moderate Severe 
Analgesics (Odds ratios (95% conf. intervals)) 
Prescribed  1.05 (0.84, 1.31) 1.01 (0.81, 1.26) 
Prescribed regular 0.95 (0.76, 1.19) 1.21 (0.97, 1.50) 
Prescribed PRN 1.11 (0.90, 1.37) 0.95 (0.77, 1.16) 
Administered PRN 0.72 (0.39, 1.34) 0.50 (0.27, 0.93) 
Non-opioids 
Prescribed  0.96 (0.77, 1.19) 0.82 (0.66, 1.02) 
Prescribed regular 0.78 (0.60, 1.00) 0.83 (0.65, 1.06) 
Prescribed PRN 1.10 (0.89, 1.36) 0.93 (0.75, 1.14) 
Opioids 
Prescribed 1.14 (0.90, 1.45) 1.23 (0.98, 1.55) 
Prescribed regular 1.05 (0.79, 1.41) 1.47 (1.12, 1.93) 
Prescribed PRN 1.14 (0.83, 1.56) 0.98 (0.72, 1.35) 
 
8.2.2.4 Is severity of dementia negatively associated with the number of analgesic 
drugs administered? 
Residents with severe dementia were administered significantly fewer analgesics 
(p=0.03, OR 0.50) than those with mild dementia. Those with moderate dementia 
also received less analgesia but not at a significant level. Figure 21 displays the 
administration of analgesics by dementia severity and study visit. At the second study 
visit residents with moderate dementia were administered fewer analgesics than 
residents with mild or severe dementia, and fewer analgesics than residents with 
moderate dementia at other study visits. Residents with severe dementia 
consistently received fewer analgesics than those with mild dementia. For residents 
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with moderate dementia there is greater variance; at 4-months it appears that those 
with moderate dementia were administered less pain relief than residents with 
severe dementia. In addition, fewer analgesics were administered, and therefore all 
residents appear to receive less pain relief, as the study progressed. 
 
Figure 21. At each study visit, percentage of residents (of those prescribed analgesics) 
who were administered analgesics, by dementia severity 
8.2.3 Association between agitation and prescription of analgesic medication 
8.2.3.1 Is analgesic medication associated with different types of agitation (CMAI 
score)? 
These models controlled for gender and excluded CMAI factors as well as age. There 
was no association between CMAI score and analgesic prescribing (coef. = 0.00, 95% 
CI = -0.00, 0.01), nor whether residents had clinically significant agitation or not (coef.  
= 0.16, 95% CI = -0.07, 0.38). Residents with clinically significant agitation were 
prescribed more opioids (coef. = 0.23, 95% CI = 0.05, 0.40) but there was no 
association between clinically significant agitation and non-opioids (coef. = 0.14, 95% 
CI = -0.03, 0.31). See Table 21 for details regarding agitation subtypes. 
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Table 21. Analgesic and subtype prescribing by agitation behaviours  
 Aggressive 
 
Physically 
nonaggressive 
Verbally agitated Hiding/hoarding 
 (Odds ratio, (95% CI) 
Prescribed -
analgesics 
1.00  
(0.99, 1.01) 
1.00 
(0.99, 1.02) 
1.01 
(0.96, 1.03) 
0.94 
(0.90, 0.98) 
Prescribed 
regular analgesics 
1.01 
(1.00, 1.03) 
1.00 
(0.98, 1.01) 
1.00  
(0.99. 1.02) 
0.95 
(0.91, 0.99) 
Prescribed PRN 
analgesics 
0.99 
(0.98, 1.00) 
1.00 
(0.99, 1.02) 
1.01 
(1.00, 1.03) 
0.95  
(0.92, 0.99) 
Administered 
analgesics 
0.96 
(0.93, 0.99) 
1.05 
(1.01, 1.10) 
1.02 
(0.98, 1.07) 
1.03 
(0.90, 1.17) 
Prescribed - 
opioids 
1.01 
(1.00, 1.02) 
0.98 
(0.97, 1.00) 
1.04 
(1.03, 1.06) 
0.94 
(0.89, 0.98) 
Prescribed 
regular opioids 
1.02 
(1.01, 1.03) 
0.98 
(0.96, 1.00) 
1.03 
(1.00, 1.05) 
0.93 
(0.88, 0.99) 
Prescribed PRN 
opioids 
0.99 
(0.98, 1.01) 
1.00 
(0.98, 1.02) 
1.05 
(1.03, 1.08) 
0.94 
(0.88, 1.00) 
Prescribed – non 
opioids 
0.99 
(0.98, 1.00) 
1.01 
(1.00, 1.03) 
1.02 
(1.00, 1.03) 
0.96 
(0.92, 1.00) 
Prescribed 
regular non-
opioids 
1.00 
(0.99, 1.02) 
1.00 
(0.98, 1.02) 
1.01 
(0.99, 1.03) 
0.99 
(0.94, 1.04) 
Prescribed PRN 
non-opioids 
0.99 
(0.98, 1.00) 
1.01 
(0.99, 1.02) 
1.01 
(0.99, 1.03) 
0.96 
(0.92, 1.00) 
 
A multilevel regression model identified that there was a significant positive 
association between: 
 aggressive behaviours and regular analgesics including regular opioids  
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 physically non-aggressive behaviours and administered PRN analgesics  
 verbally agitated behaviours and opioids including regular and PRN opioids  
There was a negative association between: 
 aggressive behaviours and administered PRN analgesics 
 hiding/hoarding behaviours and prescribed analgesics (regular and PRN), 
opioids including regular opioids, non-opioids including PRN non-opioids 
8.2.4 Comparing analgesic prescribing prevalence in this cohort compared to 
international prescribing patterns 
 
Figure 22. Scatter plot of prescription prevalence over time, comparing regular 
analgesic prescribing in this cohort compared to systematic review studies 
Looking at Figure 22, prescriptions of regular analgesics in this cohort appear much 
lower than regular prescriptions in other countries. When incorporating PRN 
prescriptions, prescribing patterns of analgesics are similar to international 
prescribing prevalence (see Figure 23).  
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Figure 23. Scatter plot of prescription prevalence over time, comparing regular and 
PRN analgesic prescribing in this cohort compared to systematic review studies 
8.2.5 Key results of factors associated with analgesic prescription and 
administration 
Analyses of care home factors identified that care homes were homogeneous with 
regards to analgesic prescribing, and therefore no obvious categorisations of care 
homes (i.e. ownership, CQC rating, care provision, dementia-registration or 
dementia–specialism, number of beds) were predictive of higher prescription 
prevalence. However when looking at analgesic administration, care homes were 
heterogeneous to a level other than chance, and these differences appeared 
unrelated to aforementioned care home factors, indicating that there were ulterior 
factors contributing to analgesic administration. 
Individual factors also played a role in analgesic use. There were no gender 
differences for PRN prescriptions or administration, but females were prescribed 
significantly more regular analgesics, and based on the administration data that 
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showed that PRN analgesics were not given to their full prescription potential, it 
appears females received more pain relief than males.  
Residents with severe dementia were prescribed more regular opioids but were 
administered fewer PRN analgesics than residents with mild dementia (at a 
significant level) and moderate dementia, which was consistent across all study visits.  
Comparing analgesic prescribing prevalence in this cohort compared to the 
international studies included in the systematic review, it appears that English care 
homes prescribe fewer regular analgesics and are more reliant on PRN prescriptions 
than other countries.  
8.3 Secondary aims and objectives: psychotropics and analgesics 
8.3.1 Description of the prescription of psychotropic medication 
Psychotropic drugs were prescribed to 822 residents (57.7%) at baseline; prescribing 
levels were stable throughout the study (56.8% at 4-months, 57.4% at 12-months). 
Appendix 18 lists the prescribing prevalence of psychotropic drugs and drug classes 
at each study visit. The most commonly prescribed class of psychotropic drug was 
antidepressants, prescribed at baseline to 40.6% of residents, and 39.4% of residents 
at 12-months. Antidepressants were prescribed PRN to four residents, which is not 
common practice. In two cases, trazodone was prescribed with indications specified 
as anxiety and agitation, and in two cases amitriptyline was prescribed with no 
indication. 
Anxiolytics and hypnotics were prescribed to around 22% of residents. At baseline, 
18.4% of residents received regular prescriptions and 15.4% of residents were 
prescribed PRN anxiolytics/hypnotics. At 12-months, it was even: 12.6% were 
prescribed them regularly and 12.6% were prescribed them PRN. The most 
commonly prescribed drugs in this class were lorazepam (a benzodiazepine) and 
zopiclone (a hypnotic drug commonly used to treat insomnia). 
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Antipsychotic drugs were the least commonly prescribed class of psychotropics, 
prescribed to 17.3% of residents at baseline, rising to 18.5% at the 12-month study 
visit. The most commonly prescribed antipsychotic drug was risperidone (prescribed 
to 7.2% of residents at baseline). Antipsychotics were more likely to be prescribed 
regularly, not PRN (15.9% versus 1.9%, at baseline). Of the 246 residents prescribed 
antipsychotic medication, 232 residents were prescribed 1 antipsychotic (94.3% [95% 
CI, 90.6-96.6]), and 14 residents were prescribed 2 antipsychotics (5.7% [95% CI, 3.4-
9.4]).  
The median prescription duration (excluding residents who have withdrawn) of 
psychotropic drugs overall, and the three psychotropic classes, was three study visits 
i.e. at least one year.  
8.3.2 Secondary aim and objective: association between analgesics and 
psychotropics 
A multilevel Poisson regression model showed a significant positive relationship 
between number of analgesic prescriptions and number of psychotropic 
prescriptions (coef. = 0.07 [95% CI, 0.02, 0.11]) which means that residents who were 
prescribed a higher number of analgesic medications were also prescribed a higher 
number of psychotropic medications, compared to those who were prescribed fewer 
analgesics. This model included age and gender as possible confounding variables. 
An association was also found between antidepressants and analgesics. A multi-level 
regression, including age and gender as possible confounding variables, was run and 
the odds of being prescribed an analgesic was larger for those also prescribed an 
antidepressant (OR 1.24 [95% CI, 1.04-1.47]).  
A significant association was also found for anxiolytics/hypnotics (OR 1.33 [95% CI, 
1.07-1.64]).  
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There was no association found between having a prescription of analgesics and a 
prescription of antipsychotics. 
8.3.3 Key results from secondary aims and objectives: psychotropics and analgesics 
The majority of residents were prescribed psychotropics and the most prevalent class 
of psychotropic was antidepressants, prescribed to approximately 40% of residents.  
Residents in this cohort who were prescribed analgesics were more likely to also have 
been prescribed antidepressants and anxiolytic/hypnotics.  
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 Discussion 
9.1 Outline 
In this chapter I will describe the principal findings of the empirical study and draw 
comparisons with existing literature. I will discuss the strengths and limitations of the 
study, both inherent and in the context of other research. I will consider the possible 
explanations for the findings, and suggest clinical and policy implications. Finally I will 
propose avenues of future work that can build on this research.  
9.2 Principal findings 
This thesis describes how analgesic medication is used in English care homes. Across 
all study visits around 70% of residents were prescribed analgesics. The most 
commonly prescribed analgesic class was simple non-opioids, and paracetamol was 
the most widely used analgesic drug, prescribed to around 58% of residents. Non-
opioids were over twice as likely to be prescribed as PRN prescriptions compared to 
regular prescriptions. There was a low prevalence of NSAID prescribing in this cohort, 
with around 1% of residents prescribed these drugs at each study visit. Opioids were 
prescribed to approximately 23% of residents.  
There was little difference in prevalence between strong opioids and weak opioids at 
baseline (11.4% vs 11.5%) but by the final study visit more residents received strong 
opioids than weak opioids (14.1% vs 12.4%). Most strong opioids prescribed were 
transdermal patches, primarily buprenorphine. The median prescription duration 
(constrained by study duration of three study visits; one year) was two study visits 
(either at least 4 months, or at least 8 months) for strong opioids and three study 
visits (at least 1 year) for weak opioids.  
It was rare that residents were prescribed both regular and PRN opioids. At baseline, 
12.3% of residents prescribed a regular opioid were also prescribed a PRN opioid, at 
4-months, 15.5%, and at 12-months, 17.8%. This represents a prescribing error: it is 
recommended that those on a regular strong opioid are also prescribed a PRN dose 
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for breakthrough pain (National Institute for Health and Clinical Excellence, 2012b, 
Denison Davies et al., 2011). 
Care homes were homogeneous in terms of analgesic prescriptions but 
heterogeneous in administering PRN analgesics. Differences between care homes 
were not defined by the factors that were measured - and the factors that we may 
assume to influence administration - that is, care home quality, care provision, 
ownership, dementia- registration or dementia-specialism, or number of beds.  
PRN prescriptions for analgesics are used ubiquitously in care homes but little is 
currently known about typical usage. In this study, 67.9-70.6% of residents were 
prescribed analgesics but the majority (56.0-60.3%) of those residents were 
prescribed them PRN only. PRN analgesics were, on the whole, not offered as many 
times as they could have been, and were administered on even fewer occasions. 
There were 23.5% (n=227) of residents who were prescribed pain relief that was not 
administered at all during the three study visits. Overall, 41.9% of residents did not 
receive any pain relief (either no prescribed analgesia or PRN analgesia never 
administered). Typically the indication was not given on the MAR chart so it was not 
possible to make a judgement regarding the appropriateness of the decision to give 
or not give pain relief. As the study progressed fewer analgesics were administered.  
Individual differences were observed in both analgesic prescribing and 
administration. These differences were seen between age, gender, dementia 
severity, and type of agitation. 
When comparing dementia severity (and controlling for age), the only significant 
difference in prescribing prevalence was that residents with severe dementia were 
prescribed more regular opioids than residents with mild dementia. Residents with 
mild dementia were administered more PRN analgesics than those with moderate 
dementia, and significantly more than those with severe dementia. This was 
consistent across all three study visits. 
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Females were prescribed more regular opioids than males, but there was no 
difference between males and females in relation to PRN administration. Thus, it 
appears that overall female residents received more pain relief than male residents. 
Regarding age as a continuous variable there was no prescribing difference, but there 
was a negative association between age and administration of PRN medication 
(which was independent of both gender and dementia severity). Residents in the 81 
years and over age group were prescribed fewer regular non-opioids and more 
regular opioids than residents aged 65-80 years. 
Residents with more aggressive behaviours were prescribed more regular analgesics 
and regular opioids compared to other agitation types, but were administered fewer 
PRN analgesics. Residents with physically non-aggressive behaviours were 
administered more PRN analgesics. Residents with verbally agitated behaviours were 
prescribed more opioids. 
9.3 Differences in results in my study versus other studies 
Compared to the prescribing prevalence reported in the systematic review, regular 
analgesics are prescribed much less in England than in other countries. For example, 
approximately 30% of residents in this cohort were prescribed regular analgesics 
compared to 40-60% in other countries, and regular prescriptions of paracetamol 
were substantially lower than other countries: around 15% in this study versus 
around 50% in recent studies included in my review (La Frenais et al., 2017).  
Opioid prevalence has not changed much in English care homes since 2010 (22.8-
23.6% versus 22.4%) (Shah et al., 2012), but again, is lower than in other countries. 
International prescribing prevalence of regular opioids is around 20-30%, whereas in 
this cohort around 13% were prescribed regular opioids (La Frenais et al., 2017). The 
finding that strong opioids were increasingly prescribed over weak opioids, and 
patches were used more than oral opioids, is similar to other countries (Jensen-Dahm 
et al., 2015). A US study reported that nearly one quarter of long-term opioid users 
received transdermal prescriptions. The US prescriptions were primarily fentanyl 
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whereas in this study the most prevalent strong opioid was buprenorphine 
(Hunnicutt et al., 2018).  
The finding that 1.8-2.8% of the population were prescribed both regular and PRN 
opioids was low compared to other countries (O'Mahony et al., 2015). A US study of 
MDS data from 1998-2000 reported that only 1.7% of residents were prescribed both 
long- and short-acting opioids (Won et al., 2004) but in a recent study this had risen 
to 21.8% (Hunnicutt et al., 2018).  
In line with this study, previous research has also found that PRN medication is not 
often administered. One study looked at PRN use across the spectrum of drug classes 
and found that all types of PRN medications were infrequently administered, and 
only 9.0% of residents were administered at least one dose of PRN paracetamol 
(Stasinopoulos et al., 2017). Several studies have compared PRN analgesic use and 
pain, and there is evidence of under-treatment with PRN analgesics in care homes. 
Mezinskis et al. (2004) found that, in a study where the majority of cognitively 
impaired residents had a prescription for PRN analgesia, less than a third received 
any, despite the presence of chronic painful diagnoses. Lukas et al. (2013a) reported 
that nearly 21% of residents did not receive any analgesics despite significant pain. 
Few studies have explored care home factors at the organisation level (for example 
care provision, ownership, registration, or specialism) and analgesic use. One study 
from Norway did not observe any difference between care homes with regards to 
strong opioid prescribing (Griffioen et al., 2017a). However, intrinsic factors have 
previously been implicated in influencing pain management, and the findings 
presented in this thesis contribute to this evidence. A large European study identified 
heavy workload, staff shortages, team instability, staff turnover, and lack of time, as 
contributing to poor pain management (Lukas et al., 2013a). Person-centred care, 
pain awareness, training, consistency of care, confidence and responsibility, good 
communication between staff and family carers, and good internal communication 
are important for good pain management (Corbett et al., 2016).  
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Prior to a study conducted by Rigler et al. (2007), no association had been identified 
between opioid prescribing and age in the US. Rigler et al. (2007) found that long-
acting opioids were more likely to be prescribed to people aged 85 years and over 
(compared to those aged 60-75 years) and to people with dementia, instead of other 
non-transdermal opioids. The median age of the MARQUE population was 84.9 years 
at baseline, and all had dementia or probable dementia so the findings are 
comparable to this cohort. A more recent study found that in UK primary care 
between 2000 and 2010 the prescription of strong opioids had risen in people aged 
66-80 (Zin et al., 2014), and a study of the entire elderly Danish population found a 
strong association between age and opioid use (Jensen-Dahm et al., 2015). 
Unfortunately there is a dearth of studies exploring age and analgesic PRN use. Two 
Australian studies explored associations with PRN medications generally and did not 
find any association with age (Stasinopoulos et al., 2017, Stokes et al., 2004) but the 
residents’ ages in their populations were relatively homogenous. Thus, this study is 
the first to explore the specific relationship between PRN analgesic administration 
and age.  
The findings regarding gender difference are in line with previous evidence that 
female care home residents receive more analgesia than male residents (Jacob and 
Kostev, 2018, Lukas et al., 2013a, Sandvik et al., 2016). A large US care home study 
found a positive relationship between female gender and regular analgesics (Won et 
al., 2004). Furthermore, in this study female residents were prescribed more regular 
opioids, which is also seen in UK primary care (Zin et al., 2014). A review of Norwegian 
prescribing practice in care homes (Sandvik et al., 2016) found a positive relationship 
between regular paracetamol prescriptions and females but in this study there was 
no difference. Conversely several other care home studies have found no gender 
difference in analgesic prescribing or administration (Hemmingsson et al., 2017, 
Stokes et al., 2004, Rigler et al., 2007). Interestingly, in Sweden there was an increase 
from 2007 to 2013 in analgesic use in male residents who were in pain, which may 
indicate that under-treatment in males is decreasing (Hemmingsson et al., 2017). 
There is a limited body of research exploring gender differences and PRN analgesic 
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administration; an Australian study did not find a relationship between gender and 
PRN drug use (not specifically analgesics) (Stokes et al., 2004). 
In terms of dementia severity, existing data are mixed. In care homes (where there is 
a higher prevalence of dementia) there tends to be a higher prescribing prevalence 
of opioids compared to those who live in the community (Jensen-Dahm et al., 2015, 
Shah et al., 2012), and, as reported and discussed in my systematic review, use of 
opioids has increased in the care home population over time (La Frenais et al., 2017). 
These increases may be reflective of higher needs of the care home population 
(Pitkala et al., 2015). A Dutch study found no difference in prescriptions of analgesic 
class and dementia severity, but did report that despite receiving regular analgesics 
a significant number of residents were still in moderate to severe pain (van Kooten 
et al., 2017). A US care home study (Hunnicutt et al., 2018) reported that strong 
opioid use was lower in those with moderate to severe dementia, which is opposite 
to the findings in this study. Regarding PRN use, most studies appear to agree that 
residents with more severe dementia are administered these less (Closs et al., 2004, 
Mezinskis et al., 2004, Bauer et al., 2016).  
A number of studies have explored the effect of analgesia on agitation, but there are 
few studies that report analgesic prescriptions and types of agitation. Hendriks et al. 
(2015) found no association between pain and agitation in a longitudinal care home 
study from admission to death, however they did not do any subgroup analyses on 
different agitation behaviours (Ahn and Horgas, 2013). Verbally agitated behaviour 
has been found to decrease following increased analgesia, as have physically non-
aggressive behaviours, but no response was seen in aggressive behaviours (Husebø 
et al., 2014b).  
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9.4 Strengths and weaknesses 
9.4.1 Strengths 
This study presents new information. Many researchers have expressed the need for 
data regarding PRN use (Achterberg, 2016, Dörks et al., 2016, Hoffmann and 
Schmiemann, 2016, Bauer et al., 2016). It is the largest study to describe PRN 
medication use in care homes and presents the most comprehensive assessment of 
analgesic administration in care homes. Given that PRN prescriptions were 
infrequently administered, it appears that (at least in English care homes) the 
presence of a PRN prescription of analgesia is not an accurate measure of pain 
treatment and future studies reporting medication use in care homes should consider 
this. 
Many studies have compared analgesic use in people with and without dementia, but 
the comparison between different dementia severities is an important aspect of this 
research as it includes potentially at-risk groups that may be missed in a broader 
population. The two weeks’ worth of PRN administration data coincides with the 
CMAI data. As a result it is possible to compare PRN administration with agitated 
behaviours that have occurred over the same time period. Furthermore, the CMAI is 
described in terms of its factors, which has more clinical relevance than the global 
score.  
The heterogeneity identified between care homes is a valuable addition to an 
ongoing discourse in the literature around analgesic prescribing and administration 
in care homes, and about identifying areas for improvement in pain assessment and 
management. Recent studies have also observed that factors associated with the 
care home team (for example, internal communication, training, high staff turnover, 
team culture, and leadership) appear to play a larger role than factors external to the 
team (such as care home size, GP, or ownership) (Kaasalainen et al., 2010, Bowers et 
al., 2003, Stokes et al., 2004, Griffioen et al., 2017b, Lukas et al., 2013a). These factors 
will be discussed in more detail in the context of clinical and policy implications.  
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This study is representative of the population that it aims to describe. The care homes 
were geographically diverse within England, and in terms of number of residents, the 
study is the largest prospective care home study to date. A large sample size is 
important because the needs of care home residents are so varied. As dementia is 
underdiagnosed in the care home population, using the NPC to identify those with 
probable dementia was a strength as it led to the inclusion of residents who would 
have been excluded if a clinical dementia diagnosis was a criterion (Gordon et al., 
2013, Lukas et al., 2013b). Other than lack of cognitive impairment there were no 
other eligibility criteria, which increases external validity, and all eligible cognitively 
impaired residents (or next of kin) were contacted, thus reducing selection bias.  
This study has reported prescribing patterns in terms of residents and not number of 
prescriptions. Quantifying medication use in this way is valuable because it accounts 
for multiple prescriptions for one individual, and it is easier to observe prescribing 
errors, such as a lack of PRN opioid prescriptions accompanying regular prescriptions 
for opioids.  
The longitudinal nature of the study means that medication use could be observed 
over time. Care home residents can experience significant changes (such as increased 
cognitive impairment and agitation) over relatively short periods of time, and 
individuals can experience these changes at different rates. Longitudinal data allows 
us to capture medication prescribing and administration in relation to an individual 
resident’s current status. These data have identified a prescribing dominance shift 
from weak opioids to strong opioids that in cross-sectional data may not have been 
observed.  
Analyses controlled for clustering at the care home level thus accounting for 
unobserved variables that may result from this shared context. Clustering controls 
for the confounding effect of care homes for both independent and dependent 
variables, and thus increases the validity of the differences identified. As such, 
findings can be generalised with some confidence to the wider population and can 
also provide a good comparison of prescribing patterns in relation to other studies.  
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This study provides reliable data. Trained researchers conducted proxy interviews 
with raters who were familiar with the residents. Many large studies utilise 
databases, for example MDS data, where efforts may not be made to ensure 
familiarity and so documentation may be completed by a MDS coordinator who does 
not provide direct care to the resident (Won et al., 2004). MARQUE researchers 
collected prescription data directly from source data (i.e. MAR charts). Transcriptions 
from hard copy data to database were audited for every resident at all three study 
visits. These steps contribute to ensuring that data was reliable and therefore an 
accurate representation of current clinical practice. 
9.4.2 Limitations 
It is impossible to assess the appropriateness of prescriptions without pain data. 
Ideally study findings would include and triangulate prescription data, individual 
factors, and level of pain, to determine whether pain relief was appropriate. For 
example, the residents who were prescribed PRN pain relief and did not receive any 
may not have been in any pain during the study visits. Unfortunately given the scope 
of the research, principally the time limits and high recruitment target, pain 
assessments were not included. Conversely, observational pain assessments are a 
snapshot in time, and even if these data were collected they may not have presented 
a valid picture of the previous two weeks, because pain is likely to fluctuate 
(Rajkumar et al., 2017). As the medication forms did not routinely include the 
indications for the prescriptions, nor identify palliative drugs or adjuvants such as 
amitriptyline or pregabalin for pain, these data also could not have been utilised. This 
limitation (the omission of indication) is often found in larger scale studies and 
database studies. Therefore the findings presented in this thesis cannot directly 
contribute to the ongoing exploration of groups at risk of untreated or undertreated 
pain.  
The sample lacks external validity to some groups of care home residents. Within the 
sociodemographic data typically one group was far more dominant. For example, 
87.8% of residents were white British versus the next largest group, 3.2% white other, 
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or 53.7% widowed versus the next largest group, 23.2% married. While 
representative of the English care home population, the groups were likely 
underpowered for subgroup analyses. As a result differences in prescribing between 
groups, and consequently at-risk groups, were not identified. Furthermore, for the 
purposes of analysis, questionable dementia and mild dementia (according to the 
CDR) were merged as one group and so comparisons from these data and other 
studies reporting data regarding mild dementia cannot be directly compared. 
However there were only a few residents who were rated as having questionable 
dementia and so it is unlikely that this has affected the findings. The mean age of this 
population was 84.9 years (SD = 8.6) at baseline so relatively homogeneous and 
potentially less comparable to other studies. 
Data were only collected in England versus other larger studies like SHELTER that 
reported from countries across Europe (Lukas et al., 2013b). National policies, social 
care provision, funding, and medical input vary considerably between countries and 
therefore these data may not be generalisable outside of England. The population 
oversampled dementia-registered and dementia-specialist homes, nursing homes, 
and better quality care homes (CQC ratings of ‘outstanding’ or ‘good’). While most 
homes that were approached agreed to participate in the study, there may be 
selection bias: care homes that allow access to researchers and are open to research 
may be more confident about additional scrutiny (Livingston et al., 2017), be better 
placed to accommodate the extra burden of research participation, have more 
external healthcare support, or have a more proactive management team who may 
apply this approach to care improvement as well. These homes may also be less 
reliant on pharmacological management of BPSD (Sawan et al., 2016, Walsh et al., 
2017).  
There are limitations to the reliability of the data. The CMAI and the modified Clinical 
Dementia Rating scale are observational ratings. While every effort was made to 
ensure that proxy raters were sufficiently familiar with the resident and had not been 
on leave during the assessment period, it is not guaranteed that this was always the 
case. Therefore data may not be consistently reliable. It was also not possible to 
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ensure the same rater at each follow-up due to staff turnover, shift patterns, and 
competing priorities. However both measures have previously shown good inter-
rater reliability (Zuidema et al., 2011, Cedarbaum et al., 2013). A further possible 
limitation of the CMAI is that more disruptive behaviours may be reported more 
frequently than less disruptive behaviours. Care home staff are busy and may not be 
as aware of behaviours that attract less attention, such as a resident who is restless 
in their bedroom. Furthermore, because interviews took place during the day, night-
time behaviours may not have been recorded, or been recorded at a lower frequency. 
Hence, agitation may have been more prevalent than the data suggests. 
It was difficult to record accurate data about whether PRN medication was actually 
offered or not, often due to indecipherable MAR charts. PRN analgesics were deemed 
to be offered if the relevant box on the MAR chart had a code entered. The codes 
typically represented ‘PRN offered but not required’ or occasionally reasons why it 
was not appropriate to give medication such as if the resident was unwell or sleeping. 
More unusually, there was a code that was not in the key; it was tentatively presumed 
that this was written by an agency nurse who was familiar with a different set of MAR 
chart codes. However ‘PRN offered but not required’ does not necessarily describe a 
situation where medication was actually offered to the resident and declined. Instead 
the decision may have been made by the nurse without any communication with the 
resident. It seemed that some care homes required every box on the MAR chart to 
be completed whereas other homes were content with empty boxes for PRN 
medication. If the care home policy requires a box to be filled, then codes for 
medication decisions may be entered by nurses ‘automatically’ without an 
assessment of need. As a result inferences could not be made about the rigour with 
which pain assessments were undertaken in care homes, as there may not have been 
any clinical difference in homes that ‘offered’ medications according to their MAR 
chart, and those that did not.  
There are no data regarding GP input for each care home, or whether care home 
pharmacists were involved in medicines management. As prescribers, GPs and 
pharmacists can influence how analgesics are administered. For example in care 
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homes where PRN prescribing is more personalised (and where perhaps blanket PRN 
prescriptions are used less frequently), administration rates for PRN pain relief may 
be expected to be higher. Information regarding support arrangements between 
homes could have helped to explain some of the observed variation, and thus its 
omission limits our interpretation of these data.  
The prescription duration data assume that three study visits equals one year of 
continuous prescription, however prescriptions may have been stopped and started 
between study visits. Therefore drug durations may be shorter than reported.  
Finally, there is also no information on non-pharmacological treatments that may be 
used to manage pain. However it has been reported that in England non-
pharmacological treatment is not part of normal practice (Corbett et al., 2016). 
9.5 Meaning and possible explanations 
In this section I will consider existing research and my own theories to explain the 
findings in terms of the following four themes. First, why prescribing levels of 
analgesics are lower in English care homes compared to other countries. Second, the 
increasing prevalence of strong opioid use. Third, the role that resident factors 
contribute to analgesic prescription and PRN administration. Fourth, the differences 
observed between care homes and PRN administration. 
9.5.1 Prescribing levels in English care homes compared to other countries 
Analgesic prescribing is lower in English care homes compared to other countries in 
Europe, for both regular and PRN medications (Lukas et al., 2013a, La Frenais et al., 
2017). Comparing recent studies (data collected post-2010) reported in the 
systematic review, regular analgesic prescribing levels are considerably lower than in 
countries such as Australia (62.8-75.2%), Austria (52.0%), and Norway (57.6%), some 
of which have similar healthcare systems to the UK. As discussed in my review, 
authors who reported low analgesic use often also described a culture where pain 
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assessment was not a priority (Boerlage et al., 2013, Neumann-Podczaska et al., 2016, 
Onder et al., 2014, Lukas et al., 2013a). 
Looking at 2010 UK prescribing data reported by Shah et al. (2012), paracetamol 
prescribing was almost twice as high in care homes as in the community (37.6% vs 
20.4) and was considerably lower than in this cohort (56.7-59.4%). High levels of PRN 
paracetamol prescriptions may be a result of clinicians prescribing PRN analgesics in 
case of incidences of pain for residents who do not need a regular prescription, in 
order to limit unnecessary contact and delays in pain relief (Stasinopoulos et al., 
2017, Carder, 2011). Opioid prescribing levels between care homes and the 
community were more similar in the 2010 data (22.4% vs 20.1%) (Shah et al., 2012), 
and in this cohort, prevalence was only slightly higher (22.8-23.6%). Therefore lower 
prescribing levels of opioids observed in English care homes compared to 
international levels appear to reflect the national healthcare system. It has been 
suggested that, following the murders by Harold Shipman, a GP who killed patients 
with lethal diamorphine doses, clinicians are more reserved in their prescribing of 
opioids and may avoid or minimise their use (BMA, 2017), which may translate to 
under-prescribing or low dose prescriptions.  
It is important to note that the distinction between weak and strong opioids is 
somewhat arbitrary. For instance, a low dose of buprenorphine has a lower potency 
compared to a high dose of codeine. In this study, buprenorphine patches were the 
most commonly prescribed strong opioid, and the median dose was 21.4mg of 
morphine, equivalent to a buprenorphine dose between 5mcg/hour and 
10mcg/hour, the two lowest available doses of transdermal buprenorphine. This may 
be indicative of misinterpretation of the ‘start low, go slow’ guidance as ‘start low, 
stay low’ (Hanlon et al., 2009), and residents may still be in pain despite regular 
analgesics (van Kooten et al., 2017).  
A concern is that residents’ pain may be undertreated. Without pain data it is 
impossible to infer appropriateness of medication use in this cohort, however 
existing data are a useful source of comparison. In the SHELTER study it was reported 
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that in English care homes 54.5% of residents experienced pain; specifically, 8.1% of 
all residents reported being in constant pain and 57.4% experienced intermittent 
pain (Lukas et al., 2013b). Overall, pain prevalence was similar to other countries but 
constant pain was lower in England. The WHELD study, which was conducted in and 
near London (UK), used an observational scale and found that 35.3% of residents had 
clinically relevant pain, predominantly mild chronic pain (Rajkumar et al., 2017). 
Given that around 20% of the residents in the MARQUE study were prescribed regular 
analgesics, and PRN analgesia was not given often (on average non-opioids were 
given 8 times a week and opioids were given 7 times a week, based on median 
prescribed doses), it appears that some residents may have untreated pain. The 
studies cited above reported similar findings. The SHELTER study identified that 
25.6% of residents who were in pain were not prescribed pain medication and 16.3% 
of residents in pain were prescribed analgesia PRN only (Lukas et al., 2013a). The 
WHELD study found that 41.9% of residents in pain were not prescribed regular 
analgesics (Rajkumar et al., 2017).  
Residents can be reticent to report their own pain for a number of reasons including 
the belief that pain is a normal part of ageing, reluctance to recognise or signpost 
their own frailty or dependence, stoicism, not wanting to bother staff or be seen as 
a ‘complainer’, or a lack of confidence in either their own value or hope for effective 
treatment (de Souto Barreto et al., 2013, Vaismoradi et al., 2016, Achterberg, 2016, 
Mentes et al., 2004, Kaasalainen et al., 2010). GPs and care home staff may not have 
the time or training to complete detailed assessments or regular reviews for complex 
residents with multiple morbidities including dementia. It is rare that other 
specialisms (such as physiotherapy) are involved (Gordon, 2015, Robbins et al., 2013, 
Sampson et al., 2018). As a result, care home residents may not receive adequate 
pain assessments.  
Furthermore, there are no guidelines specific to this population. There are several 
guidelines that could be applied to this population, for example, STOPP/START 
criteria, British Geriatrics Society/British Pain Society guidelines for older people 
(O'Mahony et al., 2015, Abdulla et al., 2013), national palliative care guidelines 
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(National Institute for Health and Clinical Excellence, 2012b), or guidelines written for 
NHS trusts (Denison Davies et al., 2011). However there are none explicitly for care 
home residents and as a result clinicians working with this population may not refer 
to existing guidelines. It appears that care home residents and their pain are excluded 
as a result, either slipping through the gaps or viewed differently to those in hospitals 
or the community. This may in part explain the commonly observed prescribing error 
where regular opioid prescriptions were not accompanied by a PRN opioid 
prescription. The omission of a PRN opioid alongside a regular prescription could lead 
to undertreated chronic severe pain or untreated breakthrough pain (Hanlon et al., 
2010).  
9.5.2 Increasing prevalence of strong opioid use 
Although opioid prescribing levels are lower than in other countries (La Frenais et al., 
2017) there appear to be a global rise in the use of strong opioids, and inappropriate 
use or overuse of opioids is another concern. A study conducted in South London 
homes found that, following paracetamol, care home staff were most familiar with 
buprenorphine patches as the next treatment approach (Corbett et al., 2016). 
Pimentel et al. (2016) reported that many care home residents were opioid-naïve 
prior to their prescription of transdermal opioids. In the WHELD study, moderate pain 
was more prevalent than severe pain (Rajkumar et al., 2017). More than 90% of 
residents prescribed transdermal fentanyl did not have chronic pain (Fain et al., 
2017). Potentially inappropriate use of strong opioids may be due to a number of 
reasons. First, use of patches has been attributed to ease of administration (Griffioen 
et al., 2017b). Second, as NSAID use has decreased, so has use of weak opioids (to a 
lesser extent) whereas strong opioid use has increased in people with and without 
dementia (Sandvik et al., 2016). It may be that strong opioids have replaced NSAIDs. 
Third, it has been suggested that strong opioids may be used for their sedative effects 
(Jensen-Dahm et al., 2015). Looking at antipsychotic use, and comparing this to 
worldwide data, perhaps the scrutiny of antipsychotics (Banerjee, 2009) has led to 
increases in other drugs compensating, such as strong opioids or other psychotropics.  
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Antipsychotic prescribing prevalence is lower compared to other countries; a 
systematic review of antipsychotic use in people with dementia in Europe, US, and 
Canada found a pooled prevalence of 27.5% (95% CI, 25.7-29.3%) (Kirkham et al., 
2017). In this study lorazepam, a benzodiazepine commonly used in the management 
of BPSD, was prescribed to 8.4-9.3% of residents in this study, mostly PRN. 
Antidepressants can also be used to treat agitation. A Cochrane review saw a modest 
reduction in BPSD when comparing citalopram and sertraline to placebo, and 
antidepressants have been suggested as a safer alternative to antipsychotics (Seitz et 
al., 2011, Porsteinsson et al., 2014). Both citalopram and sertraline have a similar 
efficacy and safety profile, however sertraline does not have the additional caution 
regarding QT-interval prolongation (National Institute for Health and Care Excellence, 
2018a). In a study published in 2011, sertraline was reported to be the most 
commonly prescribed antidepressant in the UK, in line with NICE guidelines (Banerjee 
et al., 2011, National Institute for Health and Care Excellence, 2018a), but citalopram 
appears to be the most prevalent antidepressant in care homes (Bergh et al., 2012, 
Bourgeois et al., 2012, Karkare et al., 2011). In this study citalopram (the most 
commonly prescribed antidepressant) was prescribed over twice as much as 
sertraline (13.7-15.2% vs 5.7-7.5%). 
9.5.3 The associations between resident factors and analgesic use 
Resident factors such as gender, dementia severity, and agitation behaviours, are 
associated with pain management. Even considering that pain has been found to be 
more prevalent in females compared to males (Fillingim et al., 2009), under-
treatment of pain in males has also been identified by Won et al. (2004) and 
Hunnicutt et al. (2017), two care home studies from the US. Females may be 
prescribed more regular medication because they are more likely to report pain 
compared to males (including higher intensity pain levels, higher frequency pain, and 
an increased number of painful body areas) (Lukas et al., 2013a, Racine et al., 2012). 
A qualitative study in assisted-living residences found that resident request made it 
easier for carers to know when to administer PRN medication (Carder, 2011). In this 
study females were also prescribed more antidepressants, and there was a positive 
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association between antidepressants and analgesics. Chronic pain can cause 
depression, including in care home residents with dementia (Lukas et al., 2013b, Erdal 
et al., 2017).  
Existing literature supports the idea that pain is of equal or increased prevalence in 
more severe dementia (Closs et al., 2004, Rajkumar et al., 2017). In terms of less 
administration of PRN analgesia for residents with severe dementia and older age, 
these residents may be administered fewer PRN drugs because their pain is better 
controlled by regular stronger drugs. Residents with severe dementia may be 
prescribed more regular opioids because they are perceived as more ‘end of life’. A 
longitudinal Dutch study found that paracetamol was the primary treatment for pain, 
and reported that analgesic treatment was typically only stepped up towards end of 
life. The authors queried whether there was new or increased pain at this time, or 
whether clinicians were more accepting of side effects like sedation when patients 
were considered palliative (Hendriks et al., 2015).  
There may still be under-treated pain in residents with severe dementia, in residents 
who are not prescribed any regular analgesia, or those who are prescribed a regular 
opioid but no PRN. Cognitive impairment and inability to verbalise pain has been 
shown to be strongly associated with untreated pain (Hunnicutt et al., 2017, Ahn et 
al., 2015). Underestimation of pain in dementia patients may be caused by an atypical 
presentation of pain, for example agitation or posture (Neumann-Podczaska et al., 
2016). Carers may not notice a slow decline in impairment or realise that residents 
who were previously able to communicate their pain are now unable to do so, instead 
believing that cessation of pain complaints represents a lack of pain. Even if a resident 
is assessed to be in pain, there are institutional barriers that demote the likelihood 
that a positive assessment of pain will lead to increased analgesia, which have been 
discussed on page 25. 
Aggressive and verbally agitated residents were prescribed more analgesics. Verbally 
agitated behaviour has been found to decrease following pain interventions (Husebø 
et al., 2014b). Additionally, verbally agitated behaviour may be perceived as a 
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symptom of pain because the behaviours, like crying or shouting, are similar to how 
people without dementia behave when they are in pain, which may be why verbally 
agitated residents were prescribed more opioids. Previous studies exploring an 
association between pain and aggression have produced mixed results. Resistance to 
care has been associated with pain previously (Hunnicutt et al., 2017) but in a trial of 
stepped pain management, there was no difference in prevalence of aggressive 
behaviours following increased analgesia (Husebø et al., 2014b). Residents with more 
aggressive behaviours may be administered fewer PRN analgesics (and possibly less 
PRN medication overall) because staff find it more difficult to administer these drugs 
to aggressive residents (where residents are resistive, or staff are fearful) and either 
fail to do so or do not attempt to do so (Barber et al., 2009). This idea is supported 
by the fact that residents with more physically aggressive agitation were prescribed 
more regular opioids, which were typically patches and thus easier to administer. 
Residents with physically non-aggressive behaviours may not encounter this problem 
because there may not be any issues regarding medication administration or staff 
avoidance, or because their behaviour may be more disruptive (such as wandering or 
trying to leave) and receive more attention from the care team and consequently 
more PRN medication. However, increased pain has been found to have a negative 
association with behaviours that require movement (as movement may be 
compromised by pain) (Ahn and Horgas, 2013, Tosato et al., 2012). In some of these 
cases, staff may be falsely identifying pain (Jordan et al., 2010).  
9.5.4 Differences observed between care homes and PRN administration 
The heterogeneity between care homes regarding PRN administration suggests 
internal factors. Even if a pain assessment is undertaken it does not necessarily result 
in administered pain relief; the process is non-sequential (Dowding et al., 2016). It is 
inevitable that there will be variability between care homes, as some will be better 
at translating a positive pain assessment to effective pain management, and there 
will be different reasons for this. A study conducted in Norway by Lövheim et al. 
(2006) found that carers overestimated how many residents were being treated for 
their pain. It seems logical that in these cases carers would be less likely to escalate 
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concerns about pain management. This study also posited that carers appeared to 
have a good understanding of pain and that poor communication was more relevant 
in under-treatment of pain. Fragmented lines of communication can result from 
processes inherent to care homes, such as multiple care staff working with an 
individual resident over a short period of time, shift work, and poor documentation 
practices (Lichtner et al., 2016, Dowding et al., 2016). 
9.6 Clinical implications 
Currently, care home residents in the UK receive limited external healthcare (and 
therefore multidisciplinary) support. In contrast to other countries, for example the 
Netherlands where there are on-site nursing home physicians, the majority of care 
home residents in the UK are only seen sporadically by their GPs (Sampson et al., 
2018), and it is unclear how aware GPs are of each resident’s pain status (de Souto 
Barreto et al., 2013). GPs have limited time and so support is needed both inside and 
outside the care home. A Canadian trial found that implementing an on-site pain 
team improved team collaboration and communication, increased autonomy in staff, 
and resulted in better pain management including individualised plans for residents. 
Barriers included lack of pain education, maintaining frequent meetings, lines of 
communication, and competing priorities for team members, so support from the 
care home management to provide protected time for meetings and related tasks is 
imperative (Kaasalainen et al., 2016). Pain management training could be provided 
to a care home staff member who can cascade this knowledge and create an in-house 
pain team comprising different disciplines. Alternatively, or additionally, care homes 
and clinicians could better utilise community pharmacists, care home liaison nurses, 
geriatricians, or enhanced care teams (Alsaeed et al., 2016, Sampson et al., 2018). In 
March 2018 the Royal Pharmaceutical Company stated that pharmacists should work 
with GPs to regularly review medicines in care homes and NHS England announced 
plans to start recruiting more pharmacists to meet this need (NHS England, 2018, 
Royal Pharmaceutical Company, 2018).  
Prescribers such as GPs and pharmacists have a duty to provide residents with 
personalised schedules and ensure they write sufficiently detailed prescriptions.  An 
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English study intervened with pain management strategies for 13 residents with 
severe dementia, and each resident received a different treatment plan. These 
ranged from pharmacological including regular paracetamol, topical NSAIDs, and 
changing the time of administration, to non-pharmacological including massage, 
dental treatment, and reduced time sitting on hard surfaces, and pain assessment 
scores were reduced one month later (Jordan et al., 2010). There is no one-size–fits-
all approach to managing pain in this population, but careful assessment and 
reassessment is key. If there are barriers to administration then clinicians and nurses 
should work together to ameliorate this, such as de-prescribing other drugs or 
changing the route, for example an oral solution for residents averse to swallowing 
pills. Prescribers should ensure that they write the indication on the MAR to advise 
and remind nurses of the reason for the prescription, which could lead to more 
appropriate use of PRN analgesics. 
There may be residents who are not in pain who are prescribed round-the-clock 
transdermal opioids. Potentially inappropriate use of strong opioids due to ease of 
administration or sedative effects is unethical because strong opioids can have 
negative side effects (Abdulla et al., 2013). A further ethical consideration is the lack 
of ongoing consent or assent given in the administration of transdermal opioids 
(Jensen-Dahm et al., 2015). Residents are typically not involved in their treatment 
plans and this further reinforces their lack of autonomy in these decisions. Patches 
are not recommended where oral opioids are suitable, and opioids should be 
prescribed on a trial basis with defined treatment goals. As such, weak opioids should 
usually be used prior to strong opioids. Clinicians and care home staff should monitor 
regular opioid use including adherence (residents may now be willing to take oral 
medications where previously they were not), effectiveness, and side effects. 
It is important for GPs to understand and consider communication difficulties and 
potential biases within the care home team (and themselves) when prescribing PRN 
medication, and should review MAR charts retrospectively to find out whether 
analgesics are administered as intended. Family members are valuable sources of 
information regarding past pain behaviours such as stoicism and non-verbal cues that 
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would be useful for paid carers when assessing residents who are unable to 
communicate their own pain. Including families in these discussions will require more 
time as relatives often have concerns about the adverse effects of analgesic use 
(Kaasalainen et al., 2010). Furthermore family reports of behavioural response may 
not be accurate (Weiner et al., 1999) so it is best to supplement pain assessments 
with knowledge of diagnosed painful conditions and observational tools. This may, 
for example, decrease potential under-treatment of males who may verbalise their 
pain less. GPs should think very carefully before prescribing analgesics as PRN; these 
data show that these drugs may only rarely be administered to their patient. 
There appears to be a gap between pain assessment and pain management and 
potentially a need for an algorithm to accompany assessments and trigger an action 
by the care team. There are existing examples of pragmatic pain pathway tools that 
could be adapted from NHS care to care homes (South Worcestershire Clinical 
Commissioning Group, 2017, Herefordshire Clinical Commissioning Group, 2015). 
Adaptation has been shown to be feasible in a care home setting (Petyaeva et al., 
2018). Tools need to be simple so they can be used by new and junior care staff, as 
well as minimising the time burden (Kaasalainen et al., 2010).  
Communication between CAs and nurses has been found to mostly be unidirectional, 
where CAs report pain to nurses but receive limited feedback in return (Corbett et 
al., 2016). A lack, or perceived lack, of response to reporting pain may lead to CAs not 
taking ownership of pain management, feeling dismissed or less motivated, or being 
less proactive in the future (Kaasalainen et al., 2010, Corbett et al., 2016, Mentes et 
al., 2004). CAs should be empowered within this pathway. First, by enabling CAs to 
report pain in a standardised manner that is consistent. Second, by ensuring that the 
‘conversation’ does not end at the point that CAs report pain to nurses; the pathway 
should include feedback from nurses to CAs about action taken as a result 
(Kaasalainen et al., 2010). Third, a request for ongoing monitoring and supporting 
documentation regarding the effectiveness of the pain management plan for which 
CAs are responsible. A French study found that 72.8% of residents in pain were not 
receiving regular pain evaluations (de Souto Barreto et al., 2013). 
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Further efforts to improve communication include dedicated reporting between 
shifts to promote consistency of care (for example, the continuity of PRN 
administration if a resident is in pain that day), or encouragement from nurses for 
CAs to communicate expected episodes of pain (such as personal care or dressing 
changes) so that pain can be diminished by pre-emptive analgesia (Mentes et al., 
2004, Kaasalainen et al., 2010). Efforts to improve communication can be low-cost 
but valuable (Lövheim et al., 2006). 
9.6.1 Key points for clinicians  
 Clinicians and care home staff need to better utilise community support, for 
example, pharmacists, geriatricians, or enhanced care teams. 
 Pain management schedules should be personalised for each resident 
(including non-pharmacological treatments) with better documentation 
including indications. 
 GPs need to mediate the risk that PRN analgesics may not be administered, 
and think carefully before deciding not to prescribe analgesia regularly. 
 Clear and simple pain management algorithms should be used to trigger an 
action following pain assessment, including a further assessment of 
effectiveness. 
 Communication between nurses and CAs should be bi-directional, continue 
throughout the day, and be used to empower junior staff. 
9.7 Policy implications 
This work has demonstrated that care home residents, and particularly certain 
groups, are at risk of untreated pain. Care for residents is provided by both health 
and social care, and therefore policies that can improve outcomes for this population 
need to be addressed by both sectors. For health care, improvements via policy can 
be provided by NICE. For social care, which is a mixed-economy sector with many 
providers, these improvements need to be driven by the regulators, CQC. 
Stakeholders such as the Alzheimer’s Society, can also be influential in driving 
towards better standards in pain management. 
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There is a need for pain management guidelines to be written specifically for care 
home residents. They should be accessible and practical for non-specialists including 
care staff (Rajkumar et al., 2017, Kaasalainen et al., 2010), and have explicit and 
specific guidance for different stages of cognitive impairment, and residents with 
communication difficulties. The CQC reported that in 40% of care homes they found 
limited staff knowledge and use of available guidance, which translated into variable 
or poor care (Care Quality Commission UK, 2014). A comparison of prescribing 
patterns and recommendations by the American Geriatrics Society for prescribing for 
older adults in chronic pain identified that analgesic choices were mostly inconsistent 
with recommendations (Won et al., 2004) and specific guidelines may increase 
adherence. Where policies advocate for reduced use of a drug class, they should also 
attempt to predict substitutions and provide guidance for their use too (Maust et al., 
2018, Soumerai et al., 1993). For example, reducing use of antipsychotics may have 
led to increased use of opioids, benzodiazepines, and antidepressants, but these 
drugs have side effects and risks as well. Increasingly, care homes are moving to 
electronic notes systems. These systems could be used to flag prescriptions that do 
not adhere to guidelines, such as regular opioid prescriptions without a prescription 
of a PRN opioid.  
NICE have published a quality standard for care in people with dementia that stated 
that every patient in later stages of dementia should have an assessment from a 
palliative care service, including a review of pain (National Institute for Health and 
Clinical Excellence, 2010). However following admission to a care home residents 
may not undergo regular assessments of dementia severity, the term ‘later stages’ 
could be seen as vague, and as a consequence of these factors, and service capacity, 
uptake of this guidance is likely to be low. A multidisciplinary approach to 
medications management can work towards ensuring appropriate medication use 
(Walsh et al., 2017). Fortunately this sentiment has been echoed elsewhere and 
action has been taken to introduce more pharmacy support into care homes (Royal 
Pharmaceutical Company, 2018, NHS England, 2018). Commissioners and health care 
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providers need to ensure that gaps including care planning, and access to primary 
and specialist care services, are filled (Carter, 2011). 
The CQC should include pain management in their assessments, and check MAR 
charts including PRN administration to ensure better documentation. In the US, 
where prescribing levels are often higher than other countries, pain assessment is 
part of the quality assessment procedure (La Frenais et al., 2017, Morris et al., 1990). 
Using pain assessment as a quality indicator has been explored in the Netherlands 
and found to be feasible (Zwakhalen et al., 2012, Boerlage et al., 2013). Despite 
availability of a number of pain assessment tools including the PAINAD and Abbey 
Pain Scale (Warden et al., 2003, Abbey et al., 2004) they are rarely consistently 
implemented in care home practice (Griffioen et al., 2017b) and policy changes could 
promote use. To support this, the CQC could include medication reviews as part of 
its quality standards, enforcing the need for clear documentation regarding decisions 
to commence, continue, or de-prescribe, and promoting family carer and CA 
involvement.  
Finally, the financial implications of low administration rates and potential medicines 
waste can be vast. It is estimated that care homes discard £24 million worth of 
unused medicines each year, and a contributing factor is repeat dispensing of PRN 
medicines that are prescribed but not used (Trueman et al., 2010). Analgesics are one 
of the most prevalent PRN medications in care homes (Stasinopoulos et al., 2017). 
Reducing this unnecessary cost with more appropriate prescribing and dispensing 
can only be beneficial for our care system. An alternative to ‘just in case’ PRN 
prescriptions could be increased use of ‘home remedies’ where care home staff can 
offer over-the-counter products such as paracetamol to residents without a 
prescription.  
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9.7.1 Key points for policy makers 
 It is imperative that guidelines are written that are specific for care home 
residents, and these should explicitly address cognitive and communication 
impairments. 
 Pain assessment could be included as a CQC quality indicator, and used to 
promote regular use of pain assessment tools. 
 Commissioners and health care providers need to ensure that care home 
residents are able to access primary and secondary care services. 
 Money can be saved by avoiding routine dispensing of PRN drugs that are 
not administered and instead using ‘home remedies’. 
9.8 Future research 
Pain assessment does not necessarily lead to pain management interventions 
(Zwakhalen et al., 2012) and there is a need for more research to understand this 
process within the care home context. Care homes are unique in their disciplinary 
isolation and hierarchical structure and studies from other settings may not be 
relevant (Wilson et al., 2012, Lichtner et al., 2016, Goodman et al., 2016). There is a 
need for qualitative work to understand the gap between personal beliefs and 
attitudes about the identified factors (such as age, and types of agitation) and how 
this impacts the pathway to analgesic prescription and PRN administration. In this 
study poor documentation was a limitation; a better way to assess whether or not 
PRN drugs are being offered may be to adopt a non-participant observation of 
practice. Additionally, mixed-methods research could explore whether increasing 
continuity of care (that is, ensuring that where possible the same CAs provide care 
for the same residents) can enhance pain management through increased knowledge 
of individual pain behaviours, increased familiarity with predictable pain episodes, 
and allowing CAs to be more empowered in the process of assessment, escalation, 
and reassessment. 
Building on current efforts to produce a superior pain assessment tool for people 
with cognitive impairment (van der Steen et al., 2015), there needs to be a study that 
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ties in pain assessment, pain conditions experienced by the resident, type of 
dementia (for there is some evidence that this has an effect on the experience of 
pain), and the type, dosage, and administration of analgesics (Gagliese et al., 2017). 
As the population is so heterogeneous, future studies need to find a good balance of 
sampling a large population from many care homes but also collecting detailed data 
regarding (potentially painful) comorbidities and pain assessments (there are several 
well-validated observational measures). Where pain assessments may not be 
feasible, another option would be to collect data from residents’ notes about 
diagnosed painful conditions, or a medication-based comorbidity index (for example 
the Rx-Risk model (Von Korff et al., 1992) or Medication-Based Disease Burden Index 
(George et al., 2006)). Where possible, indications should account for adjuvants to 
give a better picture of analgesic prescribing. That way, researchers can compare 
neuropathic pain prevalence and analgesic prescribing to ensure that residents who 
suffer this type of pain are not at risk of under-treatment. 
Care home residents are very different from typical drug trial participants, with 
multiple morbidities and polypharmacy. More clinical trials are needed to explore the 
safety and efficacy of drugs that are commonly used in this population. This is 
particularly important for drugs used off-label such as antipsychotics and 
benzodiazepines for agitation, for longer durations than recommended such as 
zopiclone, or medications at risk of over-use like strong opioid patches.  
With a population at increased risk of adverse effects from medication, further 
research into non-drug treatments, and how to ensure appropriate and consistent 
use, is necessary. It has been reported that in England non-pharmacological 
treatment is not seen as part of normal practice and family carers are more likely to 
suggest non-drug treatments than care staff (despite care staff recognising their 
value) (Corbett et al., 2016), however they can be an effective, and cheaper, 
alternative (Jordan et al., 2010).  
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9.8.1 Key points for researchers 
 Qualitative work is needed to 1) compensate for care home documentation 
that may not be reliable, and 2) understand how personal beliefs and 
attitudes of clinicians and carers may influence analgesic prescribing and 
administration. 
 Future research proposals should aim to collect data that can triangulate 
resident pain, care staff assessment of pain, and analgesic treatment. 
 Long-term clinical trials are needed to explore the safety and efficacy of 
potentially risky drugs in the care home population. 
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 Conclusion 
This thesis achieved its aims to describe how analgesic medication was prescribed 
and administered in English care homes and additionally, to explore resident and care 
home factors that may be related to analgesic use. This work has increased 
knowledge about current analgesic prescribing, and added new knowledge about 
PRN administration and factors associated with analgesic use. Prior to this thesis, 
little was known about how analgesics were used in English care homes, and thus it 
is a significant contribution to the field.  
The three main findings from this research are 1) there is generally lower prescribing 
of regular analgesics in England compared to other countries, 2) care homes rely 
largely on PRN prescriptions of paracetamol that are not often administered, and 3) 
there is heterogeneity between care homes regarding PRN administration but this is 
not associated with care home quality.  
It appears that, while overall analgesic prescribing is similar to other countries, 
clinicians in England are more reliant on prescribing PRN analgesics than other 
countries where regular pain relief is more commonly used. It is not possible to 
speculate on the appropriateness of prescriptions but assuming that care home 
populations in other countries are broadly similar, it appears English care home 
residents are receiving less pain relief than their international counterparts. Clinicians 
may be unaware of how often prescribed PRN analgesics are administered. There are 
disparities between care homes regarding PRN administration, implying that internal 
factors are influential in the administration of PRN analgesics. Prescribing clinicians 
may be delegating too much responsibility to a workforce that may not have the 
skills, time, experience, or internal culture to facilitate good and consistent pain 
management.  
Policymakers may be interested in the financial implications of unused PRN 
medications, but should also consider how policy can influence good pain 
management. PRN administration data and resident factors associated with analgesic 
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use should be accounted for when creating pain management guidelines aimed at 
care home residents with dementia. There are examples from other countries about 
how quality indicators are used to improve pain management, and these could also 
be used to ensure better medication documentation. Clinicians and researchers 
should understand that a prescription for a PRN analgesic does not necessarily 
equate to adequate pain relief, and it is vital to collect PRN administration data in 
clinical practice and in future studies. 
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 Other academic achievements 
11.1 Published papers 
LA FRENAIS, F., STONE, P., SAMPSON, EL. 2016. Analgesic prescribing in care home 
residents: how epidemiological studies may inform clinical practice. Pain 
Management. (Appendix 19) 
LA FRENAIS, F. L., BEDDER, R., VICKERSTAFF, V., STONE, P. & SAMPSON, E. L. 2017. 
Temporal Trends in Analgesic Use in Long‐Term Care Facilities: A Systematic 
Review of International Prescribing. Journal of the American Geriatrics 
Society. (Appendix 1) 
 
LIVINGSTON, G., BARBER, J., MARSTON, L., RAPAPORT, P., LIVINGSTON, D., COUSINS, 
S., ROBERTSON, S., LA FRENAIS, F. & COOPER, C. 2017. Prevalence of and 
associations with agitation in residents with dementia living in care homes: 
MARQUE cross-sectional study. British Journal of Psychiatry Open, 3, 171-178. 
(Appendix 20) 
 
LAYBOURNE, A., LIVINGSTON, G., COUSINS, S., RAPAPORT, P., LAMBE, K., LA FRENAIS, 
F., SAVAGE, H., MANELA, M., STRINGER, A., MARSTON, L., BARBER, J. & 
COOPER, C. 2018. Carer coping and resident agitation as predictors of quality 
of life in care home residents living with dementia: Managing Agitation and 
Raising Quality of Life (MARQUE) English national care home prospective 
cohort study. International journal of geriatric psychiatry. (Appendix 21) 
 
11.2 Presentations 
LA FRENAIS, F. (2017, June). Are care home residents with undiagnosed dementia 
more at risk of antipsychotic overuse? Oral presentation at the Alzheimer’s 
Association International Conference, London.  
LA FRENAIS, F., LIVINGSTON, G., COOPER, C., MARSTON, L., BARBER, J., VICKERSTAFF, 
V., STONE, P., SAMPSON, EL. (2017, May). Use of analgesic and psychotropic 
medication in UK care home residents living with dementia. Poster session presented 
at the European Association of Palliative Care, Madrid.  
LA FRENAIS, F., BEDDER, R., STONE, P., SAMPSON, EL. (2016, October). Systematic 
review of prescribing patterns of analgesic medications for older people living in care 
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homes over time. Poster session presented at the Annual Palliative Care Research 
Conference for Marie Curie.  
 
11.3 Other 
Podcast ‘Discussing the MARQUE Study – Managing Agitation in Dementia’, for NIHR 
Dementia Researcher website - March, 2018. 
Training school of the COST Action TD 1005 (Pain assessment in patients with 
impaired cognition, especially dementia) in Gent (Belgium) – March, 2015. 
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Appendix 2 – Systematic review search terms 
PubMed/Medline/International Pharmaceutical Abstracts 
1. exp home for the aged/ or exp elderly care/ or exp institutional care/  
2. home for the aged.mp. or exp home for the aged/  
3. residential facilities.mp. or exp residential home/  
4. ("care home" or "care homes").mp. [mp=title, abstract, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
 
5. ("long term care" or "long-term care" or "longterm care").mp. [mp=title, abstract, 
heading word, drug trade name, original title, device manufacturer, drug manufacturer, 
device trade name, keyword] 
 
6. ("aged care" or "aged-care").mp. [mp=title, abstract, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
 
7. ("residential home" or "residential homes").mp. [mp=title, abstract, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword] 
 
8. "assisted living".mp. or exp assisted living facility/  
9. (convalescent or elderly or geriatric or aged or nursing or residential or care or 
healthcare).mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword] 
 
10. (home or facility or centre or center or facilities).mp. [mp=title, abstract, heading word, 
drug trade name, original title, device manufacturer, drug manufacturer, device trade 
name, keyword] 
 
11. ((convalescent or elderly or geriatric or aged or nursing or residential or care or 
healthcare) adj (home or facility or centre or center or facilities)).mp. 
 
12. analgesic.mp. or exp analgesic agent/  
13. pain management.mp. or exp analgesia/  
14. 12 or 13  
15. ("nursing home" or "nursing homes").mp. [mp=title, abstract, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
 
16. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 11 or 15 
17. 14 and 16 
 
 
Embase 
1. exp home for the aged/ or exp elderly care/ or exp institutional care/  
2. home for the aged.mp. or exp home for the aged/  
3. residential facilities.mp. or exp residential home/  
4. ("aged care" or "aged-care").mp. [mp=title, abstract, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
 
5. "assisted living".mp. or exp assisted living facility/  
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6. (convalescent or elderly or geriatric or aged or nursing or residential or care or 
healthcare).mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword] 
 
7. analgesic.mp. or exp analgesic agent/  
8. pain management.mp. or exp analgesia/  
9. 7 or 8  
10. (home or homes or facility or centre or center or facilities).mp. [mp=title, abstract, 
heading word, drug trade name, original title, device manufacturer, drug manufacturer, 
device trade name, keyword] 
 
11. ((convalescent or elderly or geriatric or aged or nursing or residential or care or 
healthcare) adj (home or homes or facility or centre or center or facilities)).mp. 
 
12. 1 or 2 or 3 or 4 or 5 or 11 
13. 9 and 12 
 
 
PsycINFO 
1. nursing homes/ or exp residential care institutions/  
2. residential care institutions/ or exp nursing homes/  
3. institutional care.mp.  
4. long term care.mp.  
5. home for the aged.mp.  
6. care home.mp.  
7. (convalescent or elderly or geriatric or aged or nursing or residential).mp. [mp=title, 
abstract, heading word, table of contents, key concepts, original title, tests & measures] 
 
8. (home or homes or facility or facilities or centre or center).mp. [mp=title, abstract, heading 
word, table of contents, key concepts, original title, tests & measures] 
 
9. ((convalescent or elderly or geriatric or aged or nursing or residential) adj (home or homes 
or facility or facilities or centre or center)).mp. 
 
10. 1 or 2 or 3 or 4 or 5 or 6 or 9  
11. exp analgesic drugs/  
12. exp pain management/  
13. exp prescription drugs/  
14. 11 or 12 or 13  
15. 10 and 14 
Cochrane 
1. MeSH descriptor: [Analgesics] explode all trees 
2. MeSH descriptor: [Pain Management] explode all trees 
3. MeSH descriptor: [Prescription Drugs] explode all trees 
4. #1 or #2 or #3  
5. MeSH descriptor: [Homes for the Aged] explode all trees 
6. MeSH descriptor: [Nursing Homes] explode all trees 
7. MeSH descriptor: [Long-Term Care] explode all trees 
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8. MeSH descriptor: [Residential Facilities] explode all trees 
9. "care home" or "care homes"  
10. "longterm care" or "long term care"  
11. "aged care" or "aged-care"  
12. #12 "nursing home"  
13. #13 "residential home" or "residential homes"  
14. #14 "assisted living"  
15. #15 convalescent or elderly or geriatric or aged or nursing or residential or care 
or healthcare  
16. #16 home or facility or centre or center or facilities  
17. #17 #15 adj #16  
18. #18 #17 or #14 or #13 or #12 or #11 or #10 or #9 or #8 or #7 or #6 or #5  
19. #19 #18 and #4 
Web of Science 
1. TOPIC: ("home for the aged" or "institutional care" or "care home") OR  
2. TOPIC: ((convalescent or elderly or geriatric or aged or nursing or residential) AND 
(home or homes or facility or facilities)) AND  
3. TOPIC: (analges* or "analgesic agent" or "pain management" or analgesic) AND  
4. TOPIC: (resident) 
CINAHL 
1. MH nursing homes or residential care 
2. nursing home  
3. nursing homes or long-term facilities  
4. MH nursing homes or nursing home patients  
5. nursing homes or housing for the elderly or long term care  
6. (MH "Nursing Homes+") OR (MH "Nursing Home Patients")  
7. (MH "Long Term Care")  
8. "home for the aged"  
9. (MH "Institutionalization") OR "institutional care"  
10. "aged-care"  
11. convalescent or elderly or geriatric or aged or nursing or residential  
12. "care home" or "care homes"  
13. home or homes or facility or facilities or centre or center  
14. S11 adj S13  
15. S1 OR S2 OR S3 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S12 OR S14  
16. (MH "Analgesics+")  
17. "analgesic agent"  
18. "pain management"  
19. (MH "Drugs, Prescription")  
20. (MH "Prescriptions, Drug")  
21. S17 OR S18 OR S19 OR S20  
22. S15 AND S21  
Google Scholar  
(prescription* or prescribing or drug* or medicine* or medication* or pharma* or 
polypharmacy) and (residential or care home* or care facilit* or nursing home*)  
 193 
Appendix 3 – Systematic review quality scale 
STUDY:   
1) Representativeness of the target cohort 
a) truly representative of the average care home resident / CH resident with dementia  
b) somewhat representative of the average care home resident / CH resident with dementia  
 c) selected group of users e.g. nurses, volunteers 
 d) no description of the derivation of the cohort 
2) Is the case definition adequate? (cognitively impaired vs non-cognitively impaired) 
 a) yes, with independent validation  
Requires some independent validation (e.g. >1 person/record/time/process to extract 
information, or reference to primary record source such medical/hospital records) or (valid 
and reliable) cognitive assessment (conducted by study team or completed <3 months prior) 
b) yes, e.g. record linkage or reports or (unvalidated or unreliable) cognitive assessment 
(e.g. ICD codes in database) or nurse or self report with no reference to primary record, or 
cognitive assessment completed >3 months prior  
  c) no description 
  d) not applicable 
 
3) Were data collection tools adequate? (analgesic prescription information) 
 a) Yes – medical records, insurance data 
 b) No – nurse or self report 
 c) Can’t tell 
 
4) Were data collection tools standardised? (case definition and analgesic prescription information) 
 a) Yes  
 b) No 
 c) Can’t tell 
 
5) What percentage of selected individuals agreed to participate? 
 a) 60-100% agreement   
 b) Less than 60% agreement 
 c) Can’t tell 
6) Were special features of the sampling design accounted for in the analysis?  
  a) Yes/not applicable 
 b) No  
 
7) Conflict of interest 
 a) No clear conflict of interest 
 b) Conflict of interest acknowledged 
 
STRONG: 1 = a and 2 = a/d and 3 = a and 4 = a and 5 = a and 6 = a 
MODERATE: 1 = a/b; and 2 = a/b/d; and 3 = a; and 5 = c/d; or 4 = b/c and 6 = a/b 
WEAK: 1 = c/d; or 2 = c; or 3 = b/c or 4 = c and 6 = a/b 
RATER 1:     RATER 2: 
Is there a discrepancy?                Yes No   FINAL RATING:  
If yes, why? Differences in interpretation of criteria   Oversight 
  Differences in interpretation of study  Other 
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Appendix 4 – ATC codes according to WHO 
N02 General analgesics and antipyretics 
N02A Opioids 
N02B Other analgesics and antipyretics 
N02BE01 Acetaminophen 
M01 Anti-inflammatory and anti-rheumatic products  
M01A Anti-inflammatory and anti-rheumatic products, non-steroids 
M02A Topical products for joint and muscular pain 
B01AC06 Acetylsalicylic acid (aspirin) 
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Appendix 5 – Systematic review included study characteristics and quality ratings 
Included cohorts –  
Author and year of publication Country 
Year data 
collection 
ended n 
Number of 
care homes 
Quality 
rating 
Regular 
prescriptions only, 
or regular + PRN 
Atramont et al. (2018)a France 2013 11687 nk na both 
Bauer et al. (2016) Austria 2012 425 12 weak both 
Bauer et al. (2016) Austria 2012 425 12 weak regular 
Bergman et al. (2007) Sweden 2003 7904 nk moderate both 
Blytt et al. (2018)a Norway 2011 1825 64 na both 
Boerlage et al. (2013) Netherlands 2008 201 1 strong both 
Carey et al. (2008) UK 2005 2864 nk moderate both 
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Included cohorts –  
Author and year of publication Country 
Year data 
collection 
ended n 
Number of 
care homes 
Quality 
rating 
Regular 
prescriptions only, 
or regular + PRN 
Decker et al. (2009) US 2003 215 13 weak regular 
Elseviers et al. (2010) Belgium 2005 2510 76 weak both 
Erdal et al. (2017)a Norway 2015 931 65 na regular 
Ferrell et al. (1990) US 1990 92 1 moderate both 
Hatton (1990) England 1987 449 25 weak both 
Hoffmann and Schmiemann (2016) Germany 2015 852 21 strong regular 
Hoffmann and Schmiemann (2016) Germany 2015 852 21 strong both 
Hunnicutt et al. (2017)a US 2012 1,387,405 nk na regular 
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Included cohorts –  
Author and year of publication Country 
Year data 
collection 
ended n 
Number of 
care homes 
Quality 
rating 
Regular 
prescriptions only, 
or regular + PRN 
Jervis et al. (2007) US 2002 45 1 moderate both 
Jyrkka et al. (2006) Finland 1998 13 nk moderate both 
Kaasalainen et al. (1998) Canada 1996 83 1 moderate both 
Kaasalainen et al. (2016) Canada 2012 345 6 weak both 
King (2003) Australia 1994 998 15 moderate both 
King (2003) Australia 1997 414 11 weak both 
Kölzsch et al. (2012) Germany 2010 560 40 weak regular 
Krüger et al. (2012) Norway 2008 513 7 moderate regular 
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Included cohorts –  
Author and year of publication Country 
Year data 
collection 
ended n 
Number of 
care homes 
Quality 
rating 
Regular 
prescriptions only, 
or regular + PRN 
Hemmingsson et al. (2017) Sweden 2013 1849 nk weak both 
Hemmingsson et al. (2017) Sweden 2007 2764 nk weak both 
Lövheim et al. (2008) Sweden, Finland 2006 236 nk weak regular 
Neutel et al. (2002) Canada 1996 227 1 strong both 
Nolan and O'Malley (1989) Ireland 1987 301 11 moderate both 
Nygaard and Naik (1999) Norway 1996 347 15 weak regular 
Nygaard et al. (2003) Norway 1997 1042 15 moderate regular 
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Included cohorts –  
Author and year of publication Country 
Year data 
collection 
ended n 
Number of 
care homes 
Quality 
rating 
Regular 
prescriptions only, 
or regular + PRN 
O'Grady and Weedle (1997) Ireland 1997 115 1 weak both 
Onder et al. (2014) Italy 2013 3179 nk weak both 
Onder et al. (2014) 
Europe not including 
Italy 
2013 3608 nk weak both 
Passmore et al. (1995) N. Ireland 1989 595 nk moderate both 
Primrose et al. (1987) Scotland 1984 400 18 weak both 
Reynolds et al. (2008) US 2004 551 6 weak both 
Reynolds et al. (2008) US 2004 551 6 weak regular 
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Included cohorts –  
Author and year of publication Country 
Year data 
collection 
ended n 
Number of 
care homes 
Quality 
rating 
Regular 
prescriptions only, 
or regular + PRN 
Roughead et al. (2008) Australia 2005 16126 nk weak both 
Sandvik et al. (2016) Norway 2004 1163 26 strong regular 
Sandvik et al. (2016) Norway 2011 1858 64 strong regular 
Sandvik et al. (2016) Norway 2000 1926 251 weak regular 
Smalbrugge et al. (2007) Netherlands 2001 290 14 weak regular 
Smalbrugge et al. (2007) Netherlands 2001 290 14 weak both 
Snowdon et al. (2006) Australia 2003 3054 50 moderate both 
Stafford et al. (2011) Australia 2007 2345 41 moderate both 
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Included cohorts –  
Author and year of publication Country 
Year data 
collection 
ended n 
Number of 
care homes 
Quality 
rating 
Regular 
prescriptions only, 
or regular + PRN 
Tan et al. (2015) Australia 2014 383 6 moderate regular 
Taxis et al. (2016) 
Australia, Netherlands 
2009 3597 32 moderate both 
Torvik et al. (2009). Norway 2006 214 7 moderate both 
van Dijk et al. (2000) Netherlands 1995 2355 6 moderate both 
Vander Stichele et al. (1992) Belgium 1990 198 20 weak both 
Veal et al. (2014) Australia 2012 7309 nk moderate both 
Veal et al. (2014) Australia 2012 7309 nk moderate regular 
Williams et al. (1999) US 1990 818 61 weak both 
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Included cohorts –  
Author and year of publication Country 
Year data 
collection 
ended n 
Number of 
care homes 
Quality 
rating 
Regular 
prescriptions only, 
or regular + PRN 
Yakabowich et al. (1994) Canada 1987 6848 88 moderate Both 
a2017- 2018 update
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Appendix 6 – Medication instructions 
 Medication 
 All medications prescribed in the last 4 weeks should be noted on the 
MARQUE medication data capture form.  
 For all medications (as prescribed and PRN/as required), the left 
hand side columns should be completed.  
 For PRN/as required medications only, please complete the ride 
hand side columns giving details for the last 2 weeks.  
 Care home MAR (Medication Administration Record) should be sent 
with approx. 10% of the residents. Please anonymise and attach to 
the (completed) MARQUE medication data capture form 
 
1. Common MACRO issues 
 If a medication is given in liquid form/oral suspension, e.g. Paracetamol 
250mg/5ml, please put strength on the hard copy and in the medication 
name box on MACRO (i.e. 250mg/5ml) but put the mg dosage (i.e. 250mg) 
in the Prescribed Dosage section on MACRO. 
Please note. i) If you only put the ‘ml’ or do not put a strength then we cannot tell 
how much of the drug the resident is being prescribed. ii) Please always put the full 
dose i.e. if it is ‘up to 20ml’ of the above drug, you should record it as 1000mg 
 
 Please also record other strengths e.g. Codeine 8/500. If it is one tablet per 
dosage, put 508mg on MACRO, if 2, put 1016mg on MACRO 
 
 Alendronic acid 70mg weekly should be recorded as: Alendronic acid – 
prescribed dosage -  70 –mg - How many times over 4 months* - 4 – 
(duration) 
 
 Buprenorphine patch 5mcg/hour please record as: Buprenorphine patch 
5mcg/hour – prescribed dosage – 1 – 777 – How many times over 4 months* 
- 4 – (duration) 
 
 For any medications given less than daily, use the How many times over 4 
months* frequency and then put the number of times per month.  
 
 Dosages for creams etc should be put as Dose: 7777.77 Units of dose: 777 
*this actually means How many times over 1 month, but we are unable to change it. 
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2. PRN specific comments 
 PRN is indicated by ‘p.r.n’ or ‘as required’ or ‘up to’ 
 
 On MACRO this should be recorded as Dosage type: As required 
 
 As directed is not PRN, and should be recorded as a Prescribed dosage on 
MACRO 
 
 MARQUE medication data capture form: Do not put PRN in the Prescribed 
frequency column, always put the maximum frequency specified on the 
MAR chart (e.g. ‘up to twice a day’), on the data capture form and on 
MACRO. We will know it is PRN if there is a ‘Yes’ in the ‘PRN?’ column 
 
 If no frequency is specified, put NA in the Prescribed frequency column/777 
on MACRO 
 
 If a PRN medication is never given to the resident, still put the maximum 
frequency on the data capture form and on MACRO, and then put zeros on 
the right hand side (the PRN section) of the data capture form. 
 
 If frequency is not indicated sometimes medication charts will have 
dots/asterisks by the times on the MAR charts which indicates that it should 
be given/offered at that time – please check with care home staff if this is 
unclear 
 
 Please try and get the full 14 days of PRN medication data, as it 
corresponds to the agitation inventory. Do not put days outside of the last 
14 days as they do not correspond to the agitation inventory. 
 
PRN column definitions on Medication Data Capture Form 
 
 PRN? If yes please complete boxes to the right: please put yes or no, if on 
the MAR chart it says any of these: ‘p.r.n’ or ‘as required’ or ‘up to’. Columns 
to the right of this only need to be completed for PRN medication 
 Route of administration: tablet/caplet/oral suspension/soluble 
tablet/cream/injection/etc 
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 Total number of doses offered: In the last 14 days (ending on the day before 
the proxy) how many times did the nurse think about giving the resident 
medication – basically how many boxes have either initials or a letter in 
them? 
 Total number of doses refused: Of the boxes with a letter or initial in, how 
many of those doses were refused? Either by the nurse or the resident, for 
whatever reason, including social leave and asleep. 
 No. of days medication given: Out of the 14 days, on how many days did the 
resident actually ingest the medication?  
 Indication: if it gives any reason on the MAR chart for why this drug is 
prescribed. If possible please ask a nurse, and put (verbal) after the reason. 
 
If you are not sure about any medication, please anonymise the MAR chart and 
scan and send directly with your questions to Frankie, f.lafrenais@ucl.ac.uk or 
f.lafrenais@nhs.net (if you do not get a response on the nhs.net email please email 
my UCL account to let Frankie know). 
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Appendix 7 – MARQUE Stream 2 (WS2) ethical approval letter 
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 211 
Appendix 8 – Noticeable Problems Checklist (NPC) 
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Appendix 9 - MARQUE WS2 information sheet for residents  
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 Appendix 10 - MARQUE WS2 resident consent form  
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Appendix 11 – MARQUE WS2 consultee information sheet 
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Appendix 12 – MARQUE WS2 consultee declaration form 
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Appendix 13 – Home census 
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Appendix 14 – Medication CRF 
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Appendix 15 – Relevant drugs 
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Appendix 16 – Cohen-Mansfield Agitation Inventory (CMAI) 
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Appendix 17 – Clinical Dementia Rating (CDR) 
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 Appendix 18 - Table describing prescribing prevalence of psychotropic classes and drugs at each study visit, and mean daily dose 
 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
Psychotropics Baseline 822 (57.7%) 
[55.1-60.2] 
655 (46.0%) 
[43.4-48.6] 
64 (4.5%) 
[3.5-5.7] 
102 (7.2%) 
[5.9-8.6] 
na 
4-month 690 (56.8%) 
[54.0-59.6] 
540 (44.4%) 
[41.7-47.3] 
47 (3.9%) 
[2.9-5.1] 
103 (8.5%) 
[7.0-10.2] 
na 
12-month 491 (57.4%) 
[54.0-60.6] 
371 (43.3%) 
[40.0-46.7] 
46 (5.4%) 
[4.0-7.1] 
74 (8.6%) 
[6.9-10.7] 
na 
 Median (IQR) study visits that drug is prescribed: 2 (2, 3) (inc. withdrawn residents), 3 (2, 3) (exc. withdrawn residents) 
Anxiolytics and 
hypnotics 
Baseline 310 (21.8%) 
[19.7-24.0] 
160 (11.2%) 
[9.7-13.0] 
118 (8.3%) 
[7.0-9.8] 
31 (2.2%) 
[5.9-8.6] 
na 
4-month 276 (22.7%) 
[20.4-25.2] 
139 (11.4%) 
[9.8-13.4] 
109 (9.0%) 
[7.5-10.7] 
28 (2.3%) 
[1.6-3.3) 
na 
12-month 195 (22.8%) 
[20.1-25.7] 
87 (10.2%) 
[8.3-12.4] 
87 (10.2%) 
[8.3-12.4] 
21 (2.5%) 
[1.6-3.7] 
na 
 Median (IQR) study visits that drug is prescribed: 3 (2, 3) (inc. withdrawn residents), 3 (2, 3) (exc. withdrawn residents) 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
Buspirone Baseline 3 (0.2%) 
[0.1-0.7] 
2 (0.1%) 
[0.0-0.6] 
1 (0.1%) 
[0.0-0.5] 
0 (0%) 11.7 (5.8) 
5-15 
 4-month 2 (0.2%) 
[0.0-0.6] 
2 (0.2%) 
[0.0-0.6] 
0 (0%) 0 (0%) 10.0 (7.1) 
5-15 
 12-month 1 (0.1%) 
[0.0-0.8] 
1 (0.1%) 
[0.0-0.8] 
0 (0%) 0 (0%) 5.0 (0.0) 
 Median (IQR) study visits that drug is prescribed: 3 (2, 3) (inc. withdrawn residents), 3 (3, 3) (exc. withdrawn residents) 
Clobazam Baseline 1 (0.1%) 
[0.0-0.5] 
0 (0%) 1 (0.1%) 
[0.0-0.5] 
0 (0%) 10 (0) 
4-month 0 (0%) 0 (0%) 0 (0%) 0 (0%) na 
12-month 0 (0%) 0 (0%) 0 (0%) 0 (0%) na 
 Median (IQR) study visits that drug is prescribed: 1 (N/A) (inc. withdrawn residents), 1 (N/A) (exc. withdrawn residents) 
Clonazepam Baseline 21 (1.5%) 
[1.0-2.3] 
17 (1.2%) 
[0.7-1.9] 
4 (0.3%) 
[0.1-0.8] 
0 (0%) 0.7 (0.4) 
0.25-1.5 
4-month 15 (1.2%) 
[0.7-2.0] 
14 (1.2%) 
[0.7-1.9] 
1 (0.1%) 
[0.0-0.6] 
0 (0%) 0.8 (0.5) 
0.25-2 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
12-month 14 (1.6%) 
[1.0-2.7] 
12 (1.4%) 
[0.8-2.5] 
2 (0.2%) 
[0.1-0.9] 
0 (0%) 1.0 (0.7) 
0.25-2.7 
 Median (IQR) study visits that drug is prescribed: 3 (1, 3) (inc. withdrawn residents), 3 (2, 3) (exc. withdrawn residents) 
Diazepam Baseline 46 (3.2%) 
[2.4-4.3] 
17 (1.2%) 
[0.7-1.9] 
27 (1.9%) 
[1.3-2.8] 
2 (0.1%) 
[0.0-0.6] 
5.2 (3.9) 
0.5-20 
4-month 43 (3.5%) 
[2.6-4.7] 
13 (1.1%) 
[0.6-1.8] 
28 (2.3%) 
[1.6-3.3] 
2 (0.2%) 
[0.0-0.7] 
4.6 (2.7) 
2-12 
12-month 26 (3.0%) 
[2.1-4.4] 
8 (0.9%) 
[0.5-1.9] 
18 (2.1%) 
[1.3-3.3] 
0 (0%) 6.2 (5.3) 
1-20 
 Median (IQR) study visits that drug is prescribed: 3 (2, 3) (inc. withdrawn residents), 3 (2, 3) (exc. withdrawn residents) 
Lorazepam Baseline 120 (8.4%) 
[7.1-10.0] 
38 (2.7%) 
[1.9-3.6] 
80 (5.6%) 
[4.5-6.9] 
2 (0.1%) 
[0.0-0.6] 
1.5 (0.9) 
0.5-4 
4-month 112 (9.2%) 
[7.7-11.0] 
39 (3.2%) 
[2.4-4.4] 
69 (5.7%) 
[4.5-7.1] 
4 (0.3%) 
[0.1-0.9) 
1.5 (1.2) 
0.5-9 
12-month 80 (9.3%) 
[7.6-11.5] 
22 (2.6%) 
[1.7-3.9] 
56 (6.5%) 
[5.1-8.4] 
2 (0.2%) 
[0.1-0.9] 
1.5 (0.8) 
0.5-4 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
 Median (IQR) study visits that drug is prescribed: 3 (2, 3) (inc. withdrawn residents), 3 (2.5, 3) (exc. withdrawn residents) 
Lormetazepam Baseline 1 (0.1%) 
[0.0-0.5] 
1 (0.1%) 
[0.0-0.5] 
0 (0%) 0 (0%) 1.0 (0) 
4-month 1 (0.1%) 
[0.0-0.6] 
1 (0.1%) 
[0.0-0.6] 
0 (0%) 0 (0%) 1.0 (0) 
12-month 1 (0.1%) 
[0.0-0.6] 
1 (0.1%) 
[0.0-0.6] 
0 (0%) 0 (0%) 1.0 (0) 
 Median (IQR) study visits that drug is prescribed: 3 (N/A) (inc. withdrawn residents), 3 (N/A) (exc. withdrawn residents) 
Midazolam Baseline 23 (1.6%) 
[1.1-2.4] 
0 (0%) 22 (1.5%) 
[1.0-2.3] 
0 (0%) 34.5 (22.2) 
2.5-60 
 4-month 25 (2.1%) 
[1.4-3.0] 
1 (0.1%) 
[0.0-0.5] 
24 (1.7%) 
[1.1-2.5] 
0 (0%) 78.8 (63.5) 
20-240 
 12-month 23 (2.7%) 
[1.8-4.0] 
4 (0.5%) 
[0.1-1.2] 
19 (2.2%) 
[1.3-3.4] 
0 (0%) 43.0 (26.3) 
20-120 
 Median (IQR) study visits that drug is prescribed: 3 (3, 3) (inc. withdrawn residents), 3 (1, 3) (exc. withdrawn residents) 
Nitrazepam Baseline 4 (0.3%) 4 (0.3%) 0 (0%) 0 (0%) 5.9 (1.2) 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
[0.1-0.7] [0.1-0.7] 5-7.5 
4-month 5 (0.4%) 
[0.2-1.0] 
5 (0.4%) 
[0.2-1.0] 
0 (0%) 0 (0%) 5.0 (1.8) 
2.5-7.5 
12-month 4 (0.4%) 
[0.1-1.2] 
4 (0.4%) 
[0.1-1.2] 
0 (0%) 0 (0%) 5.6 (1.3) 
5-7.5 
 Median (IQR) study visits that drug is prescribed: 2 (1, 3) (inc. withdrawn residents), 2.5 (1.5, 3) (exc. withdrawn residents) 
Oxazepam Baseline 5 (0.4%) 
[0.1-0.8] 
1 (0.1%) 
[0.0-0.5] 
3 (0.2%) 
[0.1-0.7] 
1 (0.1%) 
[0.0-0.5] 
17.5 (9.6) 
10-30 
4-month 4 (0.3%) 
[0.1-0.9] 
1 (0.1%) 
[0.0-0.6] 
3 (0.2%) 
[0.1-0.8] 
0 (0%) 20 (0.0) 
12-month 3 (0.4%) 
[0.1-1.1] 
1 (0.1%) 
[0.0-0.8] 
2 (0.2%) 
[0.1-0.9] 
0 (0%) 15.0 (7.1) 
10-20 
 Median (IQR) study visits that drug is prescribed: 3 (3, 3) (inc. withdrawn residents), 3 (2.5, 3) (exc. withdrawn residents) 
Temazepam Baseline 14 (1.0%) 
[0.6-1.7] 
13 (0.9%) 
[0.5-1.6] 
1 (0.1%) 
[0.0-0.5] 
0 (0%) 12.1 (6.4)  
5-20 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
4-month 11 (0.9%) 
[0.5-1.6] 
11 (0.9%) 
[0.5-1.6] 
0 (0%) 0 (0%) 12.3 (6.5) 
5-20 
12-month 6 (0.7%) 
[0.3-1.6] 
6 (0.7%) 
[0.3-1.6] 
0 (0%) 0 (0%) 10.8 (4.9) 
5-20 
 Median (IQR) study visits that drug is prescribed: 2.5 (2, 3) (inc. withdrawn residents), 3 (3, 3) (exc. withdrawn residents) 
Zolpidem Baseline 5 (0.4%) 
[0.1-0.8] 
5 (0.4%) 
[0.1-0.8] 
0 (0%) 0 (0%) 5 (0) 
 
4-month 5 (0.4%) 
[0.2-1.0] 
5 (0.4%) 
[0.2-1.0] 
0 (0%) 0 (0%) 5 (0) 
12-month 4 (0.5%) 
[0.1-1.2] 
3 (0.4%) 
[0.1-1.0] 
1 (0.1%) 
[0.0-0.6] 
0 (0%) 5.0 (0.0) 
 Median (IQR) study visits that drug is prescribed: 2 (2, 3) (inc. withdrawn residents), 2 (2, 3) (exc. withdrawn residents) 
Zopiclone Baseline 119 (8.4%) 
[7.0-9.9] 
100 (7.0%) 
[5.8-8.5] 
18 (1.3%) 
[0.8-2.0] 
1 (0.1%) 
[0.0-0.5] 
5.2 (2.0) 
3.5-15 
4-month 98 (8.1%) 
[6.7-9.7] 
82 (6.7%) 
[5.5-8.3] 
15 (1.2%) 
[0.7-2.0] 
1 (0.1%) 
[0.0-0.5] 
4.9 (1.7) 
3.75-7.5 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
12-month 68 (7.9%) 
[6.3-10.0] 
50 (5.8%) 
[4.5-7.6] 
18 (2.1%) 
[1.3-3.3] 
0 (0%) 5.0 (1.8) 
3.75-7.5 
 Median (IQR) study visits that drug is prescribed: 2 (1, 3) (inc. withdrawn residents), 2.5 (2, 3) (exc. withdrawn residents) 
Antidepressants Baseline 578 (40.6%) 
[38.0-43.1] 
573 (40.2%) 
[37.7-42.8] 
3 (0.2%) 
[0.1-0.6] 
1 (0.1%) 
[0.0-0.4] 
na 
4-month 485 (40.0%) 
[37.2-42.7] 
482 (39.7) 
[37.0-42.5] 
2 (0.2%) 
[0.0-0.7] 
1 (0.1%) 
[0.0-0.6] 
na 
12-month 337 (39.4%) 
[36.1-42.7] 
335 (39.1%) 
[35.9-42.5] 
2 (0.2%) 
[0.1-0.9] 
0 (0%) na 
 Median (IQR) study visits that drug is prescribed: 2 (1.5, 3) (inc. withdrawn residents), 3 (2, 3) (exc. withdrawn residents) 
Amitriptyline Baseline 33 (2.3%) 
[0.7-2.3] 
31 (2.2%) 
[1.5-3.1] 
2 (0.1%) 
[0.0-0.5] 
0 (0%) 18.0 (18.3) 
5-100 
4-month 30 (2.5%) 
[1.7-3.5] 
30 (2.5%) 
[1.7-3.5] 
0 (0%) 0 (0%) 19.0 (20.0) 
5-100 
12-month 17 (2.0%) 
[1.2-3.2] 
17 (2.0%) 
[1.2-3.2] 
0 (0%) 0 (0%) 25.0 (25.7) 
5-100 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
 Median (IQR) study visits that drug is prescribed: 2 (2, 3) (inc. withdrawn residents), 3 (2, 3) (exc. withdrawn residents) 
Citalopram Baseline 217 (15.2%) 
13.5-17.2] 
217 (15.2%) 
13.5-17.2] 
0 (0%) 0 (0%) 17.3 (9.1) 
5-100 
4-month 172 (14.2%) 
[12.2-16.2] 
172 (14.2%) 
[12.2-16.2] 
0 (0%) 0 (0%) 17.6 (13.1) 
5-160 
12-month 117 (13.7%) 
[11.4-16.2] 
117 (13.7%) 
[11.4-16.2] 
0 (0%) 0 (0%) 17.8 (9.6) 
10-80 
 Median (IQR) study visits that drug is prescribed: 2 (1, 3) (inc. withdrawn residents), 3 (2, 3) (exc. withdrawn residents) 
Duloxetine Baseline 9 (0.6%) 
[0.3-1.2] 
9 (0.6%) 
[0.3-1.2] 
0 (0%) 0 (0%) 45.0 (16.0) 
30-60 
4-month 8 (0.7%) 
[0.3-1.3] 
8 (0.7%) 
[0.3-1.3] 
0 (0%) 0 (0%) 43.1 (18.7) 
15-60 
12-month 6 (0.7%) 
[0.3-1.5] 
6 (0.7%) 
[0.3-1.5] 
0 (0%) 0 (0%) 48.3 (13.3) 
30-60 
 Median (IQR) study visits that drug is prescribed: 2 (1, 3) (inc. withdrawn residents), 2.5 (1, 3) (exc. withdrawn residents) 
Fluoxetine Baseline 31 (2.2%) 31 (2.2%) 0 (0%) 0 (0%) 23.0 (7.9) 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
[1.5-3.1] [1.5-3.1] 10-40 
4-month 26 (2.1%) 
[1.4-3.1] 
26 (2.1%) 
[1.4-3.1] 
0 (0%) 0 (0%) 25.8 (13.9) 
10-80 
12-month 13 (1.5%) 
[0.8-2.6] 
13 (1.5%) 
[0.8-2.6] 
0 (0%) 0 (0%) 21.5 (5.5) 
20-40 
 Median (IQR) study visits that drug is prescribed: 2 (2, 3) (inc. withdrawn residents), 3 (2, 3) (exc. withdrawn residents) 
Lofepramine Baseline 6 (0.7%) 
[0.3-1.5] 
6 (0.7%) 
[0.3-1.5] 
0 (0%) 0 (0%) 122.5 (75.9) 
35-210 
4-month 5 (0.4%) 
[0.1-1.0] 
5 (0.4%) 
[0.1-1.0] 
0 (0%) 0 (0%) 70.0 (0.0) 
12-month 2 (0.2%) 
[0.0-0.8] 
2 (0.2%) 
[0.0-0.8] 
0 (0%) 0 (0%) 140.0 (99.0) 
70-210 
 Median (IQR) study visits that drug is prescribed: 1 (1, 1) (inc. withdrawn residents), 1 (1, 1) (exc. withdrawn residents) 
Mirtazapine Baseline 159 (11.2%) 
[9.6-12.9] 
159 (11.2%) 
[9.6-12.9] 
0 (0%) 0 (0%) 28.0 (11.3) 
7.5-45 
4-month 136 (11.2%) 136 (11.2%) 0 (0%) 0 (0%) 27.5 (12.1) 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
[8.5-13.1] [8.5-13.1] 5-75 
12-month 94 (11.0%) 
[8.9-13.3] 
94 (11.0%) 
[8.9-13.3] 
0 (0%) 0 (0%) 28.9 (11.1) 
7.5-45 
 Median (IQR) study visits that drug is prescribed: 2 (1, 3) (inc. withdrawn residents), 3 (2, 3) (exc. withdrawn residents) 
Paroxetine Baseline 12 (0.8%) 
[0.5-1.5] 
12 (0.8%) 
[0.5-1.5] 
0 (0%) 0 (0%) 22.5 (6.2) 
10-30 
4-month 10 (0.8%) 
[0.4-1.5] 
10 (0.8%) 
[0.4-1.5] 
0 (0%) 0 (0%) 23.3 (5.0) 
20-30 
12-month 9 (1.1%) 
[0.5-2.0] 
9 (1.1%) 
[0.5-2.0] 
0 (0%) 0 (0%) 22.2 (6.7) 
10-30 
 Median (IQR) study visits that drug is prescribed: 3 (2.5, 3) (inc. withdrawn residents), 3 (3, 3) (exc. withdrawn residents) 
Phenelzine Baseline 1 (0.1%) 
[0.0-0.5] 
1 (0.1%) 
[0.0-0.5] 
0 (0%) 0 (0%) 30.0 (0.0) 
4-month 1 (0.1%) 
[0.0-0.5] 
1 (0.1%) 
[0.0-0.5] 
0 (0%) 0 (0%) 30.0 (0.0) 
12-month 0 (0%) 0 (0%) 0 (0%) 0 (0%) na 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
 Median (IQR) study visits that drug is prescribed: 2 (2, 2) (inc. withdrawn residents), 2 (2, 2) (exc. withdrawn residents) 
Sertraline Baseline 81 (5.7%) 
[4.6-7.0] 
80 (5.6) 
[4.5-6.9] 
0 (0%) 0 (0%) 85.6 (67.8) 
25-500 
4-month 75 (6.2%) 
[4.9-7.7] 
75 (6.2%) 
[4.9-7.7] 
0 (0%) 0 (0%) 77.8 (42.6) 
[25-200] 
12-month 64 (7.5%) 
[5.8-9.4] 
64 (7.5%) 
[5.8-9.4] 
0 (0%) 0 (0%) 75.0 (42.0) 
25-200 
 Median (IQR) study visits that drug is prescribed: 2 (1, 3) (inc. withdrawn residents), 3 (2, 3) (exc. withdrawn residents) 
Trazodone Baseline 62 (4.4%) 
[3.4-5.5] 
60 (4.2%) 
[3.3-5.4] 
2 (0.1%) 
[0.0-0.6] 
0 (0%) 92.8 (53.6) 
25-250 
 4-month 47 (3.9%) 
[2.9-5.1] 
44 3.6%) 
[2.7-4.8] 
2 (0.2%) 
[0.0-0.7] 
1 (0.1%) 
[0.0-0.5] 
92.1 (45.8) 
10-200 
 12-month 30 (3.5%) 
P2.5-5.0] 
28 (3.3%) 
[2.3-4.7] 
2 (0.2%) 
[0.1-0.9] 
0 (0%) 91.7 (47.9) 
25-200 
 Median (IQR) study visits that drug is prescribed: 2 (1, 3) (inc. withdrawn residents), 3 (1, 3) (exc. withdrawn residents) 
Venlafaxine Baseline 17 (1.2%) 17 (1.2%) 0 (0%) 0 (0%) 113.8 (53.7) 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
[0.7-1.9] [0.7-1.9] 22-225 
 4-month 16 (1.3%) 
[0.8-2.1] 
16 (1.3%) 
[0.8-2.1] 
0 (0%) 0 (0%) 124.2 (56.0) 
37.5-225 
 12-month 14 (1.6%) 
[0.9-2.7] 
14 (1.6%) 
[0.9-2.7] 
0 (0%) 0 (0%) 133.9 (52.4) 
75-225 
 Median (IQR) study visits that drug is prescribed: 3 (2, 3) (inc. withdrawn residents), 3 (2, 3) (exc. withdrawn residents) 
Antipsychotics Baseline 246 (17.3%) 
[15.4-19.3] 
219 (15.4%) 
[13.6-17.3] 
19 (1.3%) 
[0.9-2.1] 
8 (0.6%) 
[0.3-1.1] 
na 
 4-month 209 (17.2%) 
[15.2-19.4] 
189 (15.6%) 
13.6-17.7] 
14 (1.2%) 
[0.6-1.9] 
6 (0.5%) 
[0.2-1.1] 
na 
 12-month 158 (18.5%) 
[16.0-21.2] 
136 (15.9%) 
[13.6-18.5] 
14 (1.6%) 
[1.0 -2.7] 
8 (0.9) 
[0.5-1.9] 
na 
 Median (IQR) study visits that drug is prescribed: 2 (2, 3) (inc. withdrawn residents), 3 (2, 3) (exc. withdrawn residents) 
Amisulpride Baseline 16 (1.1%) 
[0.7-1.8] 
16 (1.1%) 
[0.7-1.8] 
0 (0%) 0 (0%) 98.4 (97.7) 
25-400 
 4-month 11 (0.9%) 10 (0.8%) 0 (0%) 1 (0.1%) 87.5 (66.9) 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
[0.5-1.6] [0.4-1.5] [0.0-0.5] 25-200 
 12-month 9 (1.1%) 
[0.5-2.0] 
9 (1.1%) 
[0.5-2.0] 
0 (0%) 0 (0%) 133.3 (136.4) 
25-400  
 Median (IQR) study visits that drug is prescribed: 2 (1, 3) (inc. withdrawn residents), 3 (2, 3) (exc. withdrawn residents) 
Aripiprazole Baseline 6 (0.4%) 
[0.2-0.9] 
6 (0.4%) 
[0.2-0.9] 
0 (0%) 0 (0%) 12.1 (7.5) 
2.5-20 
 4-month 5 (0.4%) 
[0.1-1.0] 
5 (0.4%) 
[0.1-1.0] 
0 (0%) 0 (0%) 14 (6.5) 
5-20 
 12-month 5 (0.6%) 
[0.2-1.4] 
5 (0.6%) 
[0.2-1.4] 
0 (0%) 0 (0%) 9.0 (4.2) 
5-15 
 Median (IQR) study visits that drug is prescribed: 2 (1, 3) (inc. withdrawn residents), 2.5 (1, 3) (exc. withdrawn residents) 
Chlorpromazine Baseline 1 (0.1) 
[0.0-0.5] 
1 (0.1) 
[0.0-0.5] 
0 (0%) 0 (0%) 179.0 (0.0) 
 4-month 1 (0.1%) 
[0.0-0.5] 
1 (0.1%) 
[0.0-0.5] 
0 (0%) 0 (0%) 175.0 (0.0) 
 12-month 0 (0%) 0 (0%) 0 (0%) 0 (0%) na 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
 Median (IQR) study visits that drug is prescribed: 2 (2, 2) (inc. withdrawn residents), 2 (2, 2) (exc. withdrawn residents) 
Clozapine Baseline 2.0 (0.1%) 
[0.0-0.6] 
2.0 (0.1%) 
[0.0-0.6] 
0 (0%) 0 (0%) 275.0 (35.4) 
250-300 
 4-month 2 (0.2%) 
[0.0-0.6] 
2 (0.2%) 
[0.0-0.6] 
0 (0%) 0 (0%) 275.0 (35.4) 
250-300 
 12-month 1 (0.1%) 
[0.0-0.6] 
1 (0.1%) 
[0.0-0.6] 
0 (0%) 0 (0%) 250.0 (0.0) 
 Median (IQR) study visits that drug is prescribed: 2.5 (2, 3) (inc. withdrawn residents), 3 (3, 3) (exc. withdrawn residents) 
Flupentixol Baseline 4 (0.3%) 
[0.1-0.7] 
4 (0.3%) 
[0.1-0.7] 
0 (0%) 0 (0%) 2.0 (1.4) 
1-3.6 
 4-month 4 (0.3%) 
[0.1-0.8] 
4 (0.3%) 
[0.1-0.8] 
0 (0%) 0 (0%) 1.0 (0.3) 
0.7-1.3 
 12-month 3 (0.4%) 
[0.1-1.0] 
3 (0.4%) 
[0.1-1.0] 
0 (0%) 0 (0%) 1.1 (0.6) 
0.7-1.5 
 Median (IQR) study visits that drug is prescribed: 2 (2, 3) (inc. withdrawn residents), 2.5 (1.5, 3) (exc. withdrawn residents) 
Haloperidol Baseline 16 (1.1%) 7 (0.5%) 9 (0.6%) 0 (0%) 4.3 (4.2) 
 251 
 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
[0.7-1.8] [0.2-1.0] [0.3-1.2] 1-15 
 4-month 16 (1.3%) 
[0.8-2.1] 
9 (0.7%) 
[0.4-1.4] 
7 (0.6%) 
[0.3-1.2] 
0 (0%) 6.0 (8.9) 
1-30 
 12-month 13 (1.5%) 
[0.8-2.6] 
6 (0.7%) 
[0.3-1.6] 
7 (0.8%) 
[0.4-1.7] 
0 (0%) 2.9 (3.3) 
[1-11.5] 
 Median (IQR) study visits that drug is prescribed: 3 (1, 3) (inc. withdrawn residents), 3 (2, 3) (exc. withdrawn residents) 
Levomepromazine Baseline 4 (0.3%) 
[0.1-0.7] 
0 (0%) 4 (0.3%) 
[0.1-0.7] 
0 (0%) 137.5 (147.4) 
12.5-300 
 4-month 2 (0.2%) 
[0.0-0.6] 
0 (0%) 2 (0.2%) 
[0.0-0.6] 
0 (0%) 81.3 (97.2) 
12.5-150 
 12-month 3 (0.4%) 
[0.1-1.0] 
1 (0.1%) 
[0.0-0.6] 
2 (0.2%) 
[0.0-0.8] 
0 (0%) 25.0 (0.0) 
 Median (IQR) study visits that drug is prescribed: 3 (3, 3) (inc. withdrawn residents), 1 (1, 1) (exc. withdrawn residents) 
Olanzapine Baseline 23 (1.6%) 
[1.1-2.4] 
23 (1.6%) 
[1.1-2.4] 
0 (0%) 0 (0%) 6.7 (5.9) 
2.5-20 
 4-month 19 (1.6%) 19 (1.6%) 0 (0%) 0 (0%) 6.7 (6.3) 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
[0.9-2.4] [0.9-2.4] 2.5-20 
 12-month 17 (2.0%) 
[1.2-3.2] 
17 (2.0%) 
[1.2-3.2] 
0 (0%) 0 (0%) 6.9 (6.0) 
2.5-20 
 Median (IQR) study visits that drug is prescribed: 3 (2, 3) (inc. withdrawn residents), 3 (2, 3) (exc. withdrawn residents) 
Promazine Baseline 14 (1.0%) 
[0.6-1.7] 
6 (0.4%) 
[0.2-0.9] 
7 (0.5%) 
[0.2-1.0] 
1 (0.1%) 
[0.0-0.5] 
63.2 (47.9) 
10-200 
 4-month 9 (0.7%) 
[0.4-1.4] 
5 (0.4%) 
[0.2-1.0] 
2 (0.2%) 
[0.0-0.7] 
2 (0.2%) 
[0.0-0.7] 
53.9 (58.2) 
10-200 
 12-month 5 (0.6%) 
[0.2-1.4] 
3 (0.4%) 
[0.1-1.1] 
2 (0.2%) 
[0.1-0.9] 
0 (0%) 85.0 (69.8) 
25-200 
 Median (IQR) study visits that drug is prescribed: 2.5 (2, 3) (inc. withdrawn residents), 3 (2, 3) (exc. withdrawn residents) 
Quetiapine Baseline 58 (4.1%) 
[3.2-5.2] 
55 (3.9%) 
[3.0-5.0] 
1 (0.1%) 
[0.0-0.5] 
2 (0.1%) 
[0.0-0.6] 
69.6 (61.3) 
10-300 
 4-month 54 (4.4%) 
[3.4-5.8] 
52 (4.3%) 
[3.3-5.6] 
1 (0.1%) 
[0.0-0.6] 
1 (0.1%) 
[0.0-0.6] 
75.2 (76.2) 
12.5-400 
 12-month 39 (4.6%) 38 (4.4%) 0 (0%) 1 (0.1%) 68.9 (81.5) 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
[3.3-6.2] [3.2-6.0] [0.0-0.6] 12.5-400 
 Median (IQR) study visits that drug is prescribed: 2 (2, 3) (inc. withdrawn residents), 3 (2, 3) (exc. withdrawn residents) 
Risperidone Baseline 106 (7.4%) 
[6.2-8.9] 
103 (7.2%) 
[6.0-8.7] 
3 (0.2%) 
[0.1-0.7] 
0 (0%) 0.9 (0.8) 
0.25-6 
 4-month 86 (7.1%) 
[5.8-8.7] 
81 (6.7%) 
[5.4-8.2] 
3 (0.2%) 
[0.1-0.8] 
2 (0.2%) 
[0.0-0.7] 
1.0 (0.9) 
0.25-6 
 12-month 65 (7.6%) 
[6.0-9.6] 
57 (6.7%) 
[5.2-8.5] 
4 (0.5%) 
[0.2-1.2] 
4 (0.5%) 
[0.2-1.2] 
1.2 (1.1) 
0.25-6.25 
 Median (IQR) study visits that drug is prescribed: 2 (1, 3) (inc. withdrawn residents), 3 (2, 3) (exc. withdrawn residents) 
Sulpiride Baseline 5 (0.4%) 
[0.1-0.8] 
5 (0.4%) 
[0.1-0.8] 
0 (0%) 0 (0%) 140 (54.8) 
100-200 
 4-month 5 (0.4%) 
[0.2-1.0] 
5 (0.4%) 
[0.2-1.0] 
0 (0%) 0 (0%) 108.0 (57.6) 
40-200 
 12-month 3 (0.4%) 
[0.1-1.1] 
3 (0.4%) 
[0.1-1.1] 
0 (0%) 0 (0%) 180.0 (192.9) 
40-400 
 Median (IQR) study visits that drug is prescribed: 2.5 (1, 3) (inc. withdrawn residents), 3 (2, 3) (exc. withdrawn residents) 
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 Study visit Total 
N (%)  
[95% CI] 
Regular only 
N (%)  
[95% CI] 
PRN only 
N (%)  
[95% CI] 
Both regular + PRN 
N (%)  
[95% CI] 
Daily dose (mg) 
Mean (SD) 
range 
Trifluoperazine Baseline 2 (0.1%) 
[0.0-0.6] 
2 (0.1%) 
[0.0-0.6] 
0 (0%) 0 (0%) 6.5 (4.9) 
3-10 
 4-month 2 (0.2%) 
[0.0-0.7] 
2 (0.2%) 
[0.0-0.7] 
0 (0%) 0 (0%) 6.5 (4.9) 
3-10 
 12-month 1 (0.1%) 
[0.0-0.6] 
1 (0.1%) 
[0.0-0.6] 
0 (0%) 0 (0%) 5.0 (0.0) 
 Median (IQR) study visits that drug is prescribed: 2.5 (2, 3) (inc. withdrawn residents), 3 (3, 3) (exc. withdrawn residents) 
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